metformin has been researched along with Benign Neoplasms in 469 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metformin has anti-inflammatory effects through multiple routes, which provides potential therapeutic targets for certain inflammatory diseases, such as neuroinflammation and rheumatoid arthritis." | 9.41 | Role of metformin in inflammation. ( Feng, YY; Pang, H; Wang, Z, 2023) |
| "Cancer survivors with overweight or obesity were randomized to (1) self-directed weight loss (comparison), (2) coach-directed weight loss, or (3) metformin treatment." | 9.41 | Effects of Behavioral Weight Loss and Metformin on IGFs in Cancer Survivors: A Randomized Trial. ( Appel, LJ; Carducci, MA; Charleston, J; Dalcin, AT; Durkin, N; Hassoon, A; Jerome, GJ; Juraschek, SP; Kanarek, NF; Lansey, DG; Maruthur, NM; Miller, ER; Mueller, NT; Tseng, E; Wang, NY; White, K; Yeh, HC, 2021) |
| " Metformin, which is widely prescribed for type 2 diabetes mellitus (T2DM) patients, regulates blood sugar by inhibiting hepatic gluconeogenesis and promoting insulin sensitivity to facilitate glucose uptake by cells." | 9.12 | New Insight into the Effects of Metformin on Diabetic Retinopathy, Aging and Cancer: Nonapoptotic Cell Death, Immunosuppression, and Effects beyond the AMPK Pathway. ( Cheng, KC; Chiu, CC; Hsu, SK; Lin, YH; Mgbeahuruike, MO; Sheu, SJ; Wang, HD; Wu, CY; Yen, CH, 2021) |
| "The aim of this study was to review TZD and metformin as pharmacological treatments for insulin resistance associated with obesity and cancer." | 9.05 | Pharmacological Strategies for Insulin Sensitivity in Obesity and Cancer: Thiazolidinediones and Metformin. ( Biondo, LA; de O S Ferreira, KC; Neto, JCR; Teixeira, AAS, 2020) |
| "To discussing metformin effects on rheumatoid arthritis complications." | 9.01 | Metformin one in a Million Efficient Medicines for Rheumatoid Arthritis Complications: Inflammation, Osteoblastogenesis, Cardiovascular Disease, Malignancies. ( Haybar, H; Mowla, K; Rajaei, E; Zayeri, ZD, 2019) |
| "Metformin is not currently used for weight loss or diabetes prevention because it lacks an FDA indication for obesity and/or pre-diabetes treatment." | 8.93 | Metformin: an Old Therapy that Deserves a New Indication for the Treatment of Obesity. ( Apovian, CM; Aronne, LJ; Igel, LI; Saunders, KH; Sinha, A; Vojta, D, 2016) |
| "Metformin, an oral anti-diabetic drug, is being considered increasingly for treatment and prevention of cancer, obesity as well as for the extension of healthy lifespan." | 8.88 | Metformin in obesity, cancer and aging: addressing controversies. ( Berstein, LM, 2012) |
| "Metformin is widely used for treating patients with type 2 diabetes mellitus." | 8.86 | [New clinical data with metformin therapy in patients with diabetes mellitus]. ( Jermendy, G, 2010) |
| "Activated CD8 T cells were exposed to hypoxia and metformin and analyzed by fluorescence-activated cell sorting for cell proliferation, apoptosis and phenotype." | 8.31 | Metformin improves cancer immunotherapy by directly rescuing tumor-infiltrating CD8 T lymphocytes from hypoxia-induced immunosuppression. ( Dvorakova, T; Finisguerra, V; Formenti, M; Gallez, B; Mignion, L; Van den Eynde, BJ; Van Meerbeeck, P, 2023) |
| "To explore the therapeutic potential and the underlying mechanism of metformin, an adenosine monophosphate-activated kinase (AMPK) activator, in ocular melanoma." | 8.12 | Metformin promotes histone deacetylation of optineurin and suppresses tumour growth through autophagy inhibition in ocular melanoma. ( Chai, P; Fan, X; Ge, S; Jia, R; Jia, S; Ruan, J; Shi, W; Wang, S; Xu, X; Yu, J; Zhou, Y; Zhuang, A; Zuo, S, 2022) |
| "We identified 196 incident bladder cancers in the metformin cohort and 66 cancers in the SU cohort." | 7.80 | Incidence of bladder cancer in patients with type 2 diabetes treated with metformin or sulfonylureas. ( Finkelman, BS; Haas, NB; Haynes, K; Keefe, SM; Lewis, JD; Mamtani, R; Pfanzelter, N; Vaughn, DJ; Wang, X, 2014) |
| " The chronic treatment of inbred 129/Sv mice with metformin (100 mg/kg in drinking water) slightly modified the food consumption but failed to influence the dynamics of body weight, decreased by 13." | 7.76 | Gender differences in metformin effect on aging, life span and spontaneous tumorigenesis in 129/Sv mice. ( Anisimov, VN; Berstein, LM; Egormin, PA; Kovalenko, IG; Piskunova, TS; Popovich, IG; Poroshina, TE; Rosenfeld, SV; Semenchenko, AV; Tyndyk, ML; Yurova, MV; Zabezhinski, MA, 2010) |
| " Here we show the chronic treatment of female outbred SHR mice with metformin (100 mg/kg in drinking water) slightly modified the food consumption but decreased the body weight after the age of 20 months, slowed down the age-related switch-off of estrous function, increased mean life span by 37." | 7.74 | Metformin slows down aging and extends life span of female SHR mice. ( Anisimov, VN; Berstein, LM; Egormin, PA; Kovalenko, IG; Piskunova, TS; Popovich, IG; Poroshina, TE; Semenchenko, AV; Tyndyk, ML; Yurova, MV; Zabezhinski, MA, 2008) |
| "Metformin has a molecular weight of 129 Daltons and therefore readily crosses the placenta." | 6.55 | Metformin, the aspirin of the 21st century: its role in gestational diabetes mellitus, prevention of preeclampsia and cancer, and the promotion of longevity. ( Conde-Agudelo, A; Erez, O; Grossman, LI; Hüttemann, M; Maymon, E; Pacora, P; Panaitescu, B; Romero, R; Yoon, BH, 2017) |
| "Furthermore metformin seems to decrease cancer risk in diabetic patients." | 6.46 | Metformin for aging and cancer prevention. ( Anisimov, VN, 2010) |
| "Multiple cancers have been reported to be associated with angiogenesis and are sensitive to anti-angiogenic therapies." | 5.91 | Metformin and simvastatin synergistically suppress endothelin 1-induced hypoxia and angiogenesis in multiple cancer types. ( Chen, H; Gao, X; Li, J; Li, Y; Liu, J; Liu, P; Ren, Y; Song, S; Wang, B; Wang, H; Wang, R; Wang, Y; Zhang, M, 2023) |
| "Metformin may offer benefits to certain cancer populations experiencing metabolic abnormalities." | 5.72 | Metformin Mitigated Obesity-Driven Cancer Aggressiveness in Tumor-Bearing Mice. ( Chang, CY; Chen, CJ; Chen, WY; Li, JR; Liao, SL; Ou, YC; Wang, JD; Wu, CC, 2022) |
| "Metformin is a first-line antidiabetic drug for the treatment of type 2 diabetes mellitus (DM2); its molecular target is AMP-activated protein kinase (AMPK), which is involved in many metabolic processes." | 5.72 | [Metformin and malignant neoplasms: a possible mechanism of antitumor action and prospects for use in practice]. ( Frolova, YS; Gaimakova, DV; Galimova, AM; Islamgulov, AH; Karimova, AR; Kuznetsov, KO; Nazmieva, KA; Oganesyan, IY; Rizvanova, EV; Sadertdinova, AG; Safina, ER, 2022) |
| "Abnormal glucose metabolism in cancer cells causes generation and secretion of excess lactate, which results in acidification of the extracellular microenvironment." | 5.62 | Metformin induced lactic acidosis impaired response of cancer cells towards paclitaxel and doxorubicin: Role of monocarboxylate transporter. ( Bhat, MK; Chaube, B; Deb, A; Malvi, P; Mayengbam, SS; Mohammad, N; Singh, A; Singh, SV, 2021) |
| "Type 2 diabetes (T2D) and cancer have been shown to be part of the DM1 phenotype." | 5.56 | Diabetes, metformin and cancer risk in myotonic dystrophy type I. ( Alsaggaf, R; Amr, S; Gadalla, SM; Greene, MH; Pfeiffer, RM; St George, DMM; Wagner, KR; Wang, Y; Zhan, M, 2020) |
| "Metformin therapy was prescribed in 190 (81%) patients." | 5.46 | Metformin use associated with lower risk of cancer in patients with diabetes mellitus type 2. ( Gušić, E; Kulo Ćesić, A; Kusturica, J; Maleškić, S; Rakanović-Todić, M; Šečić, D, 2017) |
| "Metformin has anti-inflammatory effects through multiple routes, which provides potential therapeutic targets for certain inflammatory diseases, such as neuroinflammation and rheumatoid arthritis." | 5.41 | Role of metformin in inflammation. ( Feng, YY; Pang, H; Wang, Z, 2023) |
| "The potential application of metformin contains three directions: Firstly, improvement of metabolic factors associated with treatment effects, such as insulin resistance and peripheral neuropathy." | 5.41 | Current status and frontier tracking of clinical trials on Metformin for cancer treatment. ( Wang, W; Wei, L; Wu, Z; Zhu, S, 2023) |
| "Cancer survivors with overweight or obesity were randomized to (1) self-directed weight loss (comparison), (2) coach-directed weight loss, or (3) metformin treatment." | 5.41 | Effects of Behavioral Weight Loss and Metformin on IGFs in Cancer Survivors: A Randomized Trial. ( Appel, LJ; Carducci, MA; Charleston, J; Dalcin, AT; Durkin, N; Hassoon, A; Jerome, GJ; Juraschek, SP; Kanarek, NF; Lansey, DG; Maruthur, NM; Miller, ER; Mueller, NT; Tseng, E; Wang, NY; White, K; Yeh, HC, 2021) |
| "Addition of rosiglitazone to glucose-lowering therapy in people with type 2 diabetes is confirmed to increase the risk of heart failure and of some fractures, mainly in women." | 5.14 | Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. ( Beck-Nielsen, H; Curtis, PS; Gomis, R; Hanefeld, M; Home, PD; Jones, NP; Komajda, M; McMurray, JJ; Pocock, SJ, 2009) |
| " Metformin, which is widely prescribed for type 2 diabetes mellitus (T2DM) patients, regulates blood sugar by inhibiting hepatic gluconeogenesis and promoting insulin sensitivity to facilitate glucose uptake by cells." | 5.12 | New Insight into the Effects of Metformin on Diabetic Retinopathy, Aging and Cancer: Nonapoptotic Cell Death, Immunosuppression, and Effects beyond the AMPK Pathway. ( Cheng, KC; Chiu, CC; Hsu, SK; Lin, YH; Mgbeahuruike, MO; Sheu, SJ; Wang, HD; Wu, CY; Yen, CH, 2021) |
| " Clinical trials investigating metformin effects on the evaluation of homeostatic models of insulin resistance (HOMA-IR), Ki-67, body mass index (BMI), fasting blood sugar (FBS), and insulin were selected for further analysis." | 5.12 | Impact of Metformin on Cancer Biomarkers in Non-Diabetic Cancer Patients: A Systematic Review and Meta-Analysis of Clinical Trials. ( Amirabadizadeh, A; Aramjoo, H; Farkhondeh, T; Llorens, S; Roshanravan, B; Saeedi, F; Samarghandian, S; Shakibaei, M; Talebi, M, 2021) |
| "The aim of this study was to review TZD and metformin as pharmacological treatments for insulin resistance associated with obesity and cancer." | 5.05 | Pharmacological Strategies for Insulin Sensitivity in Obesity and Cancer: Thiazolidinediones and Metformin. ( Biondo, LA; de O S Ferreira, KC; Neto, JCR; Teixeira, AAS, 2020) |
| "To discussing metformin effects on rheumatoid arthritis complications." | 5.01 | Metformin one in a Million Efficient Medicines for Rheumatoid Arthritis Complications: Inflammation, Osteoblastogenesis, Cardiovascular Disease, Malignancies. ( Haybar, H; Mowla, K; Rajaei, E; Zayeri, ZD, 2019) |
| "Metformin is the most widely prescribed treatment of hyperglycemia and type II diabetes since 1970s." | 5.01 | Mitochondrial targets of metformin-Are they physiologically relevant? ( Brázdová, A; Drahota, Z; Houštěk, J; Mráček, T; Pecinová, A, 2019) |
| "Metformin, a primary treatment for diabetes mellitus (DM) patients, is associated with improved outcomes for diabetic cancer patients fuelling further investigation on its mechanisms of action." | 4.95 | Metformin and improved treatment outcomes in radiation therapy - A review. ( Leech, M; Marignol, L; Samsuri, NAB, 2017) |
| "Metformin is not currently used for weight loss or diabetes prevention because it lacks an FDA indication for obesity and/or pre-diabetes treatment." | 4.93 | Metformin: an Old Therapy that Deserves a New Indication for the Treatment of Obesity. ( Apovian, CM; Aronne, LJ; Igel, LI; Saunders, KH; Sinha, A; Vojta, D, 2016) |
| "Metformin is the most commonly prescibed drug for type 2 diabetes mellitus as it is inexpensive, safe, and efficient in ameliorating hyperglycemia and hyperinsulinemia." | 4.91 | [Advances of the anti-tumor research of metformin]. ( Liu, KX; Xue, CJ, 2015) |
| " Metformin emerges as a choice candidate as it acts both on reducing gluconeogenesis and improving insulin sensitivity, and has demonstrated tumour suppressor properties in multiple cancer types." | 4.90 | Cancer cachexia and diabetes: similarities in metabolic alterations and possible treatment. ( Chevalier, S; Farsijani, S, 2014) |
| "Metformin, an oral anti-diabetic drug, is being considered increasingly for treatment and prevention of cancer, obesity as well as for the extension of healthy lifespan." | 4.88 | Metformin in obesity, cancer and aging: addressing controversies. ( Berstein, LM, 2012) |
| "Metformin is widely used in the treatment of diabetes mellitus type 2 where it reduces insulin resistance and diabetes-related morbidity and mortality." | 4.86 | Metformin: taking away the candy for cancer? ( de Jong, S; de Vries, EG; Gans, RO; Gietema, JA; Jalving, M; Lefrandt, JD; Reyners, AK, 2010) |
| "Metformin is widely used for treating patients with type 2 diabetes mellitus." | 4.86 | [New clinical data with metformin therapy in patients with diabetes mellitus]. ( Jermendy, G, 2010) |
| "Activated CD8 T cells were exposed to hypoxia and metformin and analyzed by fluorescence-activated cell sorting for cell proliferation, apoptosis and phenotype." | 4.31 | Metformin improves cancer immunotherapy by directly rescuing tumor-infiltrating CD8 T lymphocytes from hypoxia-induced immunosuppression. ( Dvorakova, T; Finisguerra, V; Formenti, M; Gallez, B; Mignion, L; Van den Eynde, BJ; Van Meerbeeck, P, 2023) |
| "To explore the therapeutic potential and the underlying mechanism of metformin, an adenosine monophosphate-activated kinase (AMPK) activator, in ocular melanoma." | 4.12 | Metformin promotes histone deacetylation of optineurin and suppresses tumour growth through autophagy inhibition in ocular melanoma. ( Chai, P; Fan, X; Ge, S; Jia, R; Jia, S; Ruan, J; Shi, W; Wang, S; Xu, X; Yu, J; Zhou, Y; Zhuang, A; Zuo, S, 2022) |
| " The mothers of the cases/controls and their diagnoses of diabetes (DM) before/during pregnancy as well as their insulin/metformin prescriptions during pregnancy were identified." | 3.96 | Maternal diabetes and risk of childhood cancer in the offspring. ( Hirvonen, E; Leinonen, MK; Madanat-Harjuoja, LM; Pitkäniemi, J; Seppälä, LK; Vettenranta, K, 2020) |
| "To identify distinct temporal likelihoods of age-related comorbidity (ARC) diagnoses: cardiovascular diseases (CVD), cancer, depression, dementia, and frailty-related diseases (FRD) in older men with type 2 diabetes (T2D) but ARC naïve initially, and assess the heterogeneous effects of metformin on ARCs and mortality." | 3.85 | Differential effects of metformin on age related comorbidities in older men with type 2 diabetes. ( Espinoza, SE; Habib, SL; Jo, B; Lorenzo, C; Wang, CP, 2017) |
| "We identified 196 incident bladder cancers in the metformin cohort and 66 cancers in the SU cohort." | 3.80 | Incidence of bladder cancer in patients with type 2 diabetes treated with metformin or sulfonylureas. ( Finkelman, BS; Haas, NB; Haynes, K; Keefe, SM; Lewis, JD; Mamtani, R; Pfanzelter, N; Vaughn, DJ; Wang, X, 2014) |
| "Chronic metformin treatment improved the glycemic homeostasis in pre-diabetic MSG-rats, glucose intolerance, tissue insulin resistance, hyperinsulinemia and decreased the fat tissue accretion." | 3.80 | Protective effect of metformin against walker 256 tumor growth is not dependent on metabolism improvement. ( Agostinho, AR; Barella, LF; Beraldi, EJ; de Castro Prado, MA; de Oliveira, JC; de Sant'Anna, JR; de Souza, CO; de Souza, HM; Franco, CC; Gravena, C; Malta, A; Mathias, PC; Miranda, RA; Prates, KV; Tófolo, LP; Torrezan, R; Trombini, AB, 2014) |
| "Metformin, the first-line drug for treating diabetes, selectively kills the chemotherapy resistant subpopulation of cancer stem cells (CSC) in genetically distinct types of breast cancer cell lines." | 3.77 | Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. ( Hirsch, HA; Iliopoulos, D; Struhl, K, 2011) |
| " The chronic treatment of inbred 129/Sv mice with metformin (100 mg/kg in drinking water) slightly modified the food consumption but failed to influence the dynamics of body weight, decreased by 13." | 3.76 | Gender differences in metformin effect on aging, life span and spontaneous tumorigenesis in 129/Sv mice. ( Anisimov, VN; Berstein, LM; Egormin, PA; Kovalenko, IG; Piskunova, TS; Popovich, IG; Poroshina, TE; Rosenfeld, SV; Semenchenko, AV; Tyndyk, ML; Yurova, MV; Zabezhinski, MA, 2010) |
| "In this issue of Cell Cycle, a new paper shows that metformin, an oral antidiabetic drug that activates AMP-activated protein kinase, prolongs both mean and maximal life span and prevents reproductive aging of female mice." | 3.74 | Cancer and aging: more puzzles, more promises? ( Blagosklonny, MV; Campisi, J, 2008) |
| " Here we show the chronic treatment of female outbred SHR mice with metformin (100 mg/kg in drinking water) slightly modified the food consumption but decreased the body weight after the age of 20 months, slowed down the age-related switch-off of estrous function, increased mean life span by 37." | 3.74 | Metformin slows down aging and extends life span of female SHR mice. ( Anisimov, VN; Berstein, LM; Egormin, PA; Kovalenko, IG; Piskunova, TS; Popovich, IG; Poroshina, TE; Semenchenko, AV; Tyndyk, ML; Yurova, MV; Zabezhinski, MA, 2008) |
| "Metformin shows preclinical anti-cancer activity through multiple pathways." | 3.30 | A phase I trial of metformin in combination with vincristine, irinotecan, and temozolomide in children with relapsed or refractory solid and central nervous system tumors: A report from the national pediatric cancer foundation. ( Badgett, T; Crimella, J; Fridley, BL; Gill, J; Gorlick, R; Llosa, N; Metts, JL; Reed, D; Sandler, E; Sansil, S; Smith, T; Thapa, R; Thompson, P; Trucco, M; Weiser, DA, 2023) |
| "Metformin was associated with a reduced cancer incidence risk (adjusted hazard ratio [HR] = 0." | 3.30 | Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes. ( Broder, JC; Ernst, ME; Espinoza, S; Gibbs, P; Lockery, JE; Loomans-Kropp, HA; Orchard, SG; Polekhina, G; Wolfe, R; Woods, RL; Zoungas, S, 2023) |
| "Undiagnosed Type 2 diabetes (T2D) has been associated with advanced stage cancer at diagnosis, higher mortality, and lower long-term all-cause survival." | 3.30 | A nurse-led intervention in patients with newly diagnosed cancer and Type 2 diabetes: A pilot randomized controlled trial feasibility study. ( Burgos Melendez, JM; Cabassa, JS; Chatzkel, JA; George, TJ; Huggins, S; Jo, A; Legaspi, AB; Markham, MJ; McClaren, MJ; Munoz-Pena, JM; Murphy, MC; Nelson, T; O'Neal, LJ; Rogers, S; Scarton, L; Yao, Y, 2023) |
| "Metformin is a widely used drug in patients with type 2 diabetes mellitus." | 3.01 | Metformin: A Promising Antidiabetic Medication for Cancer Treatment. ( Feng, Y; Jiang, Y; Liang, G; Mu, W; Qu, F, 2023) |
| "Metformin is a biguanide, evolved as one of the most widely used medicines." | 3.01 | Metformin: new applications for an old drug. ( Daneshvar, S; Gholipour-Khalili, E; Hamzehzadeh, S; Hosseini, MS; Majidazar, R; Naseri, A; Rezazadeh-Gavgani, E; Sanaie, S; Seraji, P; Seyedi-Sahebari, S, 2023) |
| "Metformin has been a long-standing prescribed drug for treatment of type 2 diabetes (T2D) and its beneficial effects on virus infection, autoimmune diseases, aging and cancers are also recognized." | 3.01 | Metformin and Its Immune-Mediated Effects in Various Diseases. ( Nojima, I; Wada, J, 2023) |
| "Metformin has been used clinically for more than 60 years." | 3.01 | The function, mechanisms, and clinical applications of metformin: potential drug, unlimited potentials. ( Deng, D; Liu, J; Zhang, M; Zhu, X, 2023) |
| "Metformin is a well-known anti-diabetic drug that has been repurposed for several emerging applications, including as an anti-cancer agent." | 3.01 | Metformin and cancer hallmarks: shedding new lights on therapeutic repurposing. ( Ge, S; Hua, Y; Jia, R; Yao, Y; Zheng, Y; Zhuang, A, 2023) |
| "The promising combination for cancer treatment is with immunotherapy." | 3.01 | Metformin as a booster of cancer immunotherapy. ( Panaampon, J; Saengboonmee, C; Zhou, Y, 2023) |
| "Metformin has been designated as one of the most crucial first-line therapeutic agents in the management of type 2 diabetes mellitus." | 3.01 | Metformin: A Review of Potential Mechanism and Therapeutic Utility Beyond Diabetes. ( Bansal, S; Dutta, S; Dutta, SB; Haque, M; Shah, RB; Singhal, S; Sinha, S, 2023) |
| "Post-metformin increase in AMPK phosphorylation may potentially explain lack of disease progression in nearly half of our patients." | 2.90 | A phase I delayed-start, randomized and pharmacodynamic study of metformin and chemotherapy in patients with solid tumors. ( Caplain, J; Das, M; Grimm, E; Martell, R; Rajagopal, S; Saif, MW; Serebrennikova, O; Tsichlis, PN, 2019) |
| "The primary end point was total cancer incidence." | 2.87 | Effect of Aspirin on Cancer Chemoprevention in Japanese Patients With Type 2 Diabetes: 10-Year Observational Follow-up of a Randomized Controlled Trial. ( Doi, N; Jinnouchi, H; Masuda, I; Matsumoto, C; Morimoto, T; Nakayama, M; Ogawa, H; Okada, S; Saito, Y; Sakuma, M; Soejima, H; Waki, M, 2018) |
| "Sirolimus is a mammalian target of rapamycin (mTOR) inhibitor." | 2.87 | A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors. ( Bissonnette, MB; Cohen, EEW; Fleming, GF; Gajewski, TF; Janisch, L; Karrison, T; Maitland, M; Pinto, N; Polite, BN; Ratain, MJ; Salgia, R; Sehdev, A; Sharma, MR; Turcich, M; Zha, Y, 2018) |
| "Metformin can suppress gluconeogenesis and reduce blood sugar by activating adenosine monophosphate-activated protein kinase (AMPK) and inducing small heterodimer partner (SHP) expression in the liver cells." | 2.82 | The role of AMPK-dependent pathways in cellular and molecular mechanisms of metformin: a new perspective for treatment and prevention of diseases. ( Hasanvand, A, 2022) |
| "Metformin is a first-line oral antidiabetic agent that results in clear benefits in relation to glucose metabolism and diabetes-related complications." | 2.82 | The role of MicroRNA networks in tissue-specific direct and indirect effects of metformin and its application. ( Fang, D; Gao, X; Liang, Y; Luo, M; Wang, G; Wang, L; Wu, J; Yang, Q; Zeng, M, 2022) |
| "Given its role in cancer, therapeutic interventions that target and inhibit this pathway's key components are under intense investigation." | 2.82 | Molecular inhibition of RAS signalling to target ageing and age-related health. ( Laskovs, M; Partridge, L; Slack, C, 2022) |
| "Metformin treatment was not associated with cancer-related mortality in adults compared with placebo or no treatment." | 2.82 | Efficacy of metformin therapy in patients with cancer: a meta-analysis of 22 randomised controlled trials. ( Chen, Y; Cheng, Q; Huang, J; Liu, F; Liu, J; Liu, Z; Mao, X; Wen, J; Ye, W; Yi, Z; Zeng, Y; Zhang, L, 2022) |
| " We conducted an open-label phase I dose escalation trial of this drug combination in patients with advanced/refractory cancers." | 2.82 | Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers. ( Fu, S; Hong, D; Janku, F; Karp, D; Khawaja, MR; Lu, KH; Madhusudanannair, V; McQuinn, LM; Meric-Bernstam, F; Naing, A; Ng, CS; Nick, AM; Piha-Paul, SA; Subbiah, V; Tsimberidou, A, 2016) |
| "More patients reported bone fractures in the rosiglitazone group (238, 10." | 2.80 | Cancer and bone fractures in observational follow-up of the RECORD study. ( Curtis, PS; Home, PD; Jones, NP, 2015) |
| "We compared cancer risk among the subjects who had no diabetes, had type 2 diabetes but were not on diabetes drugs, used metformin only, used antidiabetic drugs other than metformin, or used metformin in combination with other antidiabetic drugs." | 2.79 | Effects of metformin dose on cancer risk reduction in patients with type 2 diabetes mellitus: a 6-year follow-up study. ( Cheng, HW; Kachingwe, BH; Lin, HC; Lin, HL; Uang, YS; Wang, LH, 2014) |
| "The primary outcome measure (cancer substudy) was the occurrence of any new or recurrent adjudicated cancer." | 2.79 | The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia. ( Birkeland, KI; Bordeleau, L; Bosch, J; Chang Yu, P; Dagenais, GR; Gerstein, HC; Keltai, M; Marin-Neto, JA; Pirags, V; Probstfield, J; Ratner, RE; Riddle, MC; Rosenstock, J; Ryden, LE; Spinas, GA; Yakubovich, N; Yusuf, S, 2014) |
| "One patient with head and neck cancer experienced a partial response." | 2.77 | A phase I study of temsirolimus and metformin in advanced solid tumours. ( Ernst, S; Johnson, C; MacKenzie, MJ; Winquist, E, 2012) |
| "Metformin was associated with a lower mortality rate (HR 0." | 2.76 | Prognostic implications of glucose-lowering treatment in patients with acute myocardial infarction and diabetes: experiences from an extended follow-up of the Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) 2 Study. ( Malmberg, K; Mellbin, LG; Norhammar, A; Rydén, L; Wedel, H, 2011) |
| "Type 2 diabetes has been associated with an increased risk of cancer." | 2.76 | Intensive glucose control and risk of cancer in patients with type 2 diabetes. ( Chalmers, J; De Bruin, ML; Grobbee, DE; Kengne, AP; Knol, MJ; Leufkens, HG; Patel, A; Stefansdottir, G; Woodward, M; Zoungas, S, 2011) |
| "Xanthenes are a special class of oxygen-incorporating tricyclic compounds." | 2.72 | Xanthenes in Medicinal Chemistry - Synthetic strategies and biological activities. ( Durães, F; Maia, M; Pinto, MMM; Resende, DISP; Sousa, E, 2021) |
| "Metformin has gained interest as an antitumor agent." | 2.72 | Mitochondrial Inhibition: a Treatment Strategy in Cancer? ( Bueno, MJ; Quintela-Fandino, M; Ruiz-Sepulveda, JL, 2021) |
| "Metformin (MTF) is a widely used drug for the treatment of diabetes mellitus type 2 (DM2) and frequently used as an adjuvant therapy for polycystic ovarian syndrome, metabolic syndrome, and in some cases also tuberculosis." | 2.72 | The role of AMPK/mTOR signaling pathway in anticancer activity of metformin. ( Adamickova, A; Chomanicova, N; Gazova, A; Kyselovic, J; Valaskova, S, 2021) |
| " These anticancer properties appear to synergize with existing chemotherapeutics, which allows a reduction in drug dosage without losing potency while minimizing adverse effects." | 2.72 | Repurposing of Metformin for Cancer Therapy: Updated Patent and Literature Review. ( Abdullah, Y; Ahmed, RSI; Ahmed, ZSO; Dou, QP; Golovoy, M, 2021) |
| "The biguanide seems to directly impair cancer energy asset, with the consequent phosphorylation of AMP-activated protein kinase (AMPK) inhibiting cell proliferation and tumor growth." | 2.72 | Metformin and Cancer Glucose Metabolism: At the Bench or at the Bedside? ( Bauckneht, M; Bruno, S; Cossu, V; Lanfranchi, F; Marini, C; Orengo, AM; Raffa, S; Ravera, S; Sambuceti, G, 2021) |
| "Immunotherapy-based cancer treatment has revolutionized the era of cancer patients recuperation and it has brought a strong hope to treatment of some types of cancers." | 2.66 | Immune-mediated anti-tumor effects of metformin; targeting metabolic reprogramming of T cells as a new possible mechanism for anti-cancer effects of metformin. ( Bahrambeigi, S; Shafiei-Irannejad, V, 2020) |
| "Metformin is used for the treatment of type 2 diabetes mellitus and has shown therapeutic effects in preclinical models of other pathologies, such as cancer and autoimmune diseases." | 2.66 | Context-Dependent Pharmacological Effects of Metformin on the Immune System. ( Caserta, CA; Lefoulon, F; Marcucci, F; Romeo, E; Rumio, C, 2020) |
| "Metformin is a biguanide that in the context of type 2 diabetes primarily targets the liver." | 2.66 | Metformin in Oncology - How Far Is Its Repurposing as an Anticancer Drug? ( Kaňková, K; Pácal, L, 2020) |
| "Metformin has been used for a long time as an antidiabetic medication for type 2 diabetes." | 2.66 | Metformin: A Possible Option in Cancer Chemotherapy. ( Ezeokpo, BC; Ogamba, OJ; Onyenekwe, BM; Ugwueze, CV; Young, EE, 2020) |
| "Metformin is a widely used biguanide drug due to its safety and low cost." | 2.66 | Metformin and Its Benefits for Various Diseases. ( Guo, Y; Lv, Z, 2020) |
| "T-cell-based cancer immunotherapies, such as immune checkpoint blockers (ICBs) and chimeric antigen receptor (CAR)-Tcells, have significant anti-tumor effects against certain types of cancer, providing a new paradigm for cancer treatment." | 2.66 | A new aspect of an old friend: the beneficial effect of metformin on anti-tumor immunity. ( Cha, JH; Jung, YS; Kim, K; Yang, WH, 2020) |
| "Over the past decade, cancer therapy has rapidly evolved from traditional approaches, such as surgery, chemotherapy, and radiotherapy, to revolutionary new treatment options with immunotherapy." | 2.66 | Metformin and cancer immunity. ( Ma, R; Riker, AI; Xi, Y; Yi, B, 2020) |
| "Cancer is an important threat to public health because of its high morbidity and mortality." | 2.66 | Pleiotropic Effects of Metformin on the Antitumor Efficiency of Immune Checkpoint Inhibitors. ( Liu, M; Liu, W; Luo, J; Luo, Z; Wang, Y, 2020) |
| "The efficacy of metformin in treating cancer has been extensively investigated since epidemiologic studies associated this anti-diabetic drug with a lower risk of cancer incidence." | 2.66 | The multifaceted effects of metformin on tumor microenvironment. ( Gasparre, G; Iorio, M; Kurelac, I; Porcelli, AM; Umesh Ganesh, N, 2020) |
| "Since Warburg's observation that most cancers exhibit elevated glycolysis, decades of research have attempted to reduce tumor glucose utilization as a therapeutic approach." | 2.61 | A Tumor Agnostic Therapeutic Strategy for Hexokinase 1-Null/Hexokinase 2-Positive Cancers. ( Herschman, HR; Xu, S, 2019) |
| "It is thought that it exerts its anti-cancer effect through the inhibition of the mammalian target of rapamycin (mTOR) signalling pathway." | 2.61 | The journey of metformin from glycaemic control to mTOR inhibition and the suppression of tumour growth. ( Amin, S; Lux, A; O'Callaghan, F, 2019) |
| "Metformin is a natural agent that is well known as an antidiabetic drug." | 2.61 | Metformin as a Radiation Modifier; Implications to Normal Tissue Protection and Tumor Sensitization. ( Farhood, B; Mortezaee, K; Musa, AE; Najafi, M; Shabeeb, D, 2019) |
| "To uncover the anti-cancer mechanisms of metformin, preclinical studies determined that metformin impairs cellular metabolism and suppresses oncogenic signaling pathways, including receptor tyrosine kinase, PI3K/Akt, and mTOR pathways." | 2.58 | Metformin as an anti-cancer agent: actions and mechanisms targeting cancer stem cells. ( Saini, N; Yang, X, 2018) |
| "Metformin has also been reported to decrease expression of multiple histone methyltransferases, to increase the activity of the class III HDAC SIRT1 and to decrease the influence of DNMT inhibitors." | 2.58 | Epigenetic effects of metformin: From molecular mechanisms to clinical implications. ( Bridgeman, SC; Ellison, GC; Mamotte, CDS; Melton, PE; Newsholme, P, 2018) |
| "Metformin is a lipophilic biguanide which inhibits hepatic gluconeogenesis and improves peripheral utilization of glucose." | 2.58 | Metformin in cancer. ( Chowdhury, TA; Mallik, R, 2018) |
| "Metformin has been a frontline therapy for type 2 diabetes (T2D) for many years." | 2.58 | Metformin as an Anticancer Agent. ( Bhagwat, M; Bu, P; Vancura, A; Vancurova, I; Zeng, J, 2018) |
| "Metformin is a biguanide drug that has been used to treat type 2 diabetes mellitus for more than 60 years." | 2.58 | Metformin: An Old Drug with New Applications. ( Li, L; Massey, S; Story, D; Zhou, J, 2018) |
| "Metformin, a first-line medication for type 2 diabetes mellitus, arouses growing concerns on its anti-cancer effect." | 2.55 | Enemies or weapons in hands: investigational anti-diabetic drug glibenclamide and cancer risk. ( Gao, R; Xu, W; Yang, T, 2017) |
| "Metformin has a molecular weight of 129 Daltons and therefore readily crosses the placenta." | 2.55 | Metformin, the aspirin of the 21st century: its role in gestational diabetes mellitus, prevention of preeclampsia and cancer, and the promotion of longevity. ( Conde-Agudelo, A; Erez, O; Grossman, LI; Hüttemann, M; Maymon, E; Pacora, P; Panaitescu, B; Romero, R; Yoon, BH, 2017) |
| "While there was evidence that type 2 diabetes is associated with an increased risk of cancer, existing studies seemed insufficient to definitively demonstrate a link between cancer risk and use of specific anti-hyperglycemic therapies." | 2.55 | Cancer risks of anti-hyperglycemic drugs for type 2 diabetes treatment - a clinical appraisal. ( Kosiborod, M; Leiter, LA; Poulter, NR; Rajagopalan, S; Ray, K; Vora, J, 2017) |
| "Metformin has been known for its antidiabetic effects for decades and is used as a first line therapy in type 2 diabetes." | 2.55 | Metformin: Insights into its anticancer potential with special reference to AMPK dependent and independent pathways. ( Ahmad, M; Ikhlas, S, 2017) |
| "Metformin users also had reduced cancer compared to non-diabetics (rate ratio=0." | 2.55 | Metformin reduces all-cause mortality and diseases of ageing independent of its effect on diabetes control: A systematic review and meta-analysis. ( Bellman, SM; Campbell, JM; Lisy, K; Stephenson, MD, 2017) |
| "The increased risk of type 2 diabetes and cardiovascular disease in PCOS is closely associated with BMI." | 2.55 | Medical comorbidity in polycystic ovary syndrome with special focus on cardiometabolic, autoimmune, hepatic and cancer diseases: an updated review. ( Andersen, M; Glintborg, D, 2017) |
| "Metformin has been used to treat type 2 diabetes for over 50 years." | 2.55 | Anti-tumor activity of metformin: from metabolic and epigenetic perspectives. ( Li, S; Liu, M; Ma, L; Mao, W; Tong, C; Yu, X; Zhai, Y, 2017) |
| "Metformin has also been reported to reverse resistance to epidermal growth factor receptor (EGFR)-inhibiting tyrosine kinase inhibitors." | 2.55 | Hyperglycaemia Induced by Novel Anticancer Agents: An Undesirable Complication or a Potential Therapeutic Opportunity? ( Shah, RR, 2017) |
| "Observational studies on metformin and cancer varied in design, and the majority were at risk of a range of biases." | 2.55 | Metformin and cancer in type 2 diabetes: a systematic review and comprehensive bias evaluation. ( Bhaskaran, K; Chaturvedi, N; Farmer, RE; Forbes, HJ; Ford, D; Kaplan, R; Smeeth, L, 2017) |
| "Metformin has been widely used for over 5 decades." | 2.55 | Metformin: New Preparations and Nonglycemic Benefits. ( Fujita, Y; Inagaki, N, 2017) |
| "In addition, cutting-edge targeting of cancer stem cells by metformin is summarized." | 2.55 | Metformin targets multiple signaling pathways in cancer. ( Keller, ET; Lei, Y; Liu, X; Liu, Y; Lu, Y; Qian, CN; Yi, Y; Zhang, J, 2017) |
| "The substantial burden of cancer and diabetes and the association between the two conditions has been a motivation for researchers to look for targeted strategies that can simultaneously affect both diseases and reduce their overlapping burden." | 2.53 | Does Metformin Reduce Cancer Risks? Methodologic Considerations. ( Golozar, A; Lin, JA; Liu, S; Peairs, K; Yeh, HC, 2016) |
| "Metformin has been used for nearly a century to treat type 2 diabetes mellitus." | 2.53 | The expanding role of metformin in cancer: an update on antitumor mechanisms and clinical development. ( Gong, J; Kaur, S; Kelekar, G; Mita, M; Shen, J, 2016) |
| "Development of agents for cancer prevention has been particularly challenging for two main reasons." | 2.53 | Repurposing Drugs for Cancer Prevention. ( Lee, DK; Szabo, E, 2016) |
| "Clinical trials in pre-surgical endometrial cancer patients exhibited a significant decrease in Ki67 with metformin monotherapy." | 2.53 | Repurposing metformin for cancer treatment: current clinical studies. ( Altman, JK; Arya, A; Carneiro, B; Chae, YK; Chandra, S; Giles, F; Kalyan, A; Kaplan, J; Malecek, MK; Platanias, L; Shin, DS, 2016) |
| "Metformin has an interesting potential to treat vascular dysfunction and tumor angiogenesis in conditions beyond diabetes." | 2.53 | Metformin and Angiogenesis in Cancer - Revisited. ( Alkharabsheh, O; Dimitrov, NV; Kannarkatt, J; Tokala, H, 2016) |
| "Metformin use has been associated with a reduced risk of developing cancer and an improvement in overall cancer survival rates in meta-analyses, but, to date, evidence to support the use of metformin as an adjuvant therapy in individual cancer types has not been presented." | 2.53 | Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis. ( Cafferty, FH; Coyle, C; Langley, RE; Vale, C, 2016) |
| "The many anticancer actions of metformin lead to a cytostatic effect." | 2.53 | Metformin: An anti-diabetic drug to fight cancer. ( Boudy, V; d'Hayer, B; Daugan, M; Dufaÿ Wojcicki, A, 2016) |
| "Metformin is a well-established, effective agent for the management of type 2 diabetes mellitus." | 2.52 | Metformin in cancer treatment and prevention. ( Morales, DR; Morris, AD, 2015) |
| "The different types of cancer, heterogeneity of populations and presence of comorbidity make it difficult to determine the benefits of metformin in cancer prevention and treatment." | 2.52 | Metformin: risk-benefit profile with a focus on cancer. ( Cazzaniga, M; DeCensi, A; Dunn, BK; Gorlero, F; Lazzeroni, M; Provinciali, N, 2015) |
| "Obesity is associated with a range of health outcomes that are of clinical and public health significance, including cancer." | 2.52 | Obesity and cancer: mechanistic insights from transdisciplinary studies. ( Allott, EH; Hursting, SD, 2015) |
| "The anticancer activity of metformin is mediated through a direct regulation of miRNAs, which further modulates several downstream genes in metabolic or preoncogenic pathways." | 2.52 | A New Role for an Old Drug: Metformin Targets MicroRNAs in Treating Diabetes and Cancer. ( Li, L; Xu, B; Zhou, JY, 2015) |
| "The biomolecular characteristics of tumors, such as appropriate expression of organic cation transporters or genetic alterations including p53, K-ras, LKB1, and PI3K may impact metformin's anticancer efficiency." | 2.50 | Repositioning metformin in cancer: genetics, drug targets, and new ways of delivery. ( Aldea, M; Berindan-Neagoe, I; Craciun, L; Crivii, C; Florian, IS; Kacso, G; Tomuleasa, C, 2014) |
| "There is increasing evidence that cancer cells show specific alterations in different aspects of lipid metabolism." | 2.50 | Managing lipid metabolism in proliferating cells: new perspective for metformin usage in cancer therapy. ( Ciriolo, MR; Desideri, E; Lettieri Barbato, D; Vegliante, R, 2014) |
| "Metformin is a commonly utilized antidiabetic agent, which has been associated with improved clinical outcomes in cancer patients." | 2.50 | Use of biguanides to improve response to chemotherapy. ( Sandulache, VC; Skinner, HD; Yang, L, 2014) |
| "Given that diabetes and cancer each account for 8% and 13% of global deaths and there is a substantial financial burden incurred by both disorders, developing diabetes therapies that are safe, efficacious and cost-effective has never been more desirable." | 2.50 | Cancer risks from diabetes therapies: evaluating the evidence. ( Kong, D; Li, C, 2014) |
| "Finally, associations across all cancers may differ from those in specific cancer types." | 2.50 | Hype versus hope: metformin and vitamin D as anticancer agents. ( Goodwin, PJ; Lohmann, AE, 2014) |
| "The literature has long recognised that type 2 diabetes (T2D) is associated with an increased incident risk of several cancer types, independent of the mutual risk factor, obesity." | 2.50 | Diabetes and cancer: 5 years into the recent controversy. ( Badrick, E; Renehan, AG, 2014) |
| "Overall cancer incidence was reduced by 31% [summary relative risk (SRR), 0." | 2.50 | Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders. ( DeCensi, A; Dunn, BK; Ford, L; Gandini, S; Heckman-Stoddard, BM; Puntoni, M; Szabo, E, 2014) |
| "Metformin was associated with a reduction in all-cause mortality [HR, 0." | 2.50 | The effect of metformin on mortality following cancer among patients with diabetes. ( Beyene, J; Lega, IC; Lipscombe, LL; Margel, D; Rochon, PA; Shah, PS, 2014) |
| "However, among cancer patients, the literature is conflicting about the real impact of metformin on survival and outcomes of cancer treatments." | 2.50 | Exploring the role of metformin in anticancer treatments: a systematic review. ( Barroso-Sousa, R; Glasberg, J; Miranda, VC; Riechelmann, RP, 2014) |
| "Metformin, a biguanide, is a commonly administered drug for the management of type 2 diabetes mellitus." | 2.50 | Anti-diabetic drug metformin: challenges and perspectives for cancer therapy. ( Cherian, AM; Lakshmanan, VK; Nair, SV; Pillai, P; Snima, KS, 2014) |
| "Metformin is a widely prescribed antidiabetic drug with an established efficacy coupled with a favorable safety profile and low cost." | 2.49 | Metformin and cancer. ( Elisaf, MS; Rizos, CV, 2013) |
| "Metformin was not associated with the risk of: breast cancer, lung cancer, ovarian cancer, uterus cancer, prostate cancer, bladder cancer, kidney cancer, and melanoma." | 2.49 | Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. ( Franciosi, M; Lapice, E; Lucisano, G; Nicolucci, A; Pellegrini, F; Strippoli, GF, 2013) |
| "More over, the prognosis of diabetic cancer patients on metformin therapy seems be better, than in diabetics without metformin treatment." | 2.49 | [Metformin: the overlap of diabetology and oncology]. ( Anděl, M; Skrha, P; Trnka, J, 2013) |
| "The effects of antidiabetic drugs on cancer risk have been described and discussed in several studies suggesting opposite effects of the biguanide metformin and sulfonylureas on cancer incidence and mortality." | 2.49 | Effects of sulfonylureas on tumor growth: a review of the literature. ( Conte, P; Favaretto, A; Pasello, G; Urso, L, 2013) |
| "Metformin may exert its anti-cancer activity by a direct effect (insulin) and an indirect effect (AMPK and mTOR)." | 2.49 | [Metformin, an antidiabetic molecule with anti-cancer properties]. ( Beck, E; Scheen, AJ, 2013) |
| "Patients with type 2 diabetes have increased cancer risk and cancer-related mortality, which can be reduced by metformin treatment." | 2.49 | Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: a systematic review and meta-analysis. ( Gorak, EJ; Quddus, F; Yin, M; Zhou, J, 2013) |
| "Cancer cells in solid tumors are generally subjected to such harsh conditions; however, they manage to efficiently survive and proliferate." | 2.49 | The multifaceted activities of AMPK in tumor progression--why the "one size fits all" definition does not fit at all? ( Bonini, MG; Gantner, BN, 2013) |
| "Metformin's anti-cancerous properties have been demonstrated in various cancer cells in vitro, such as lung, pancreatic, colon, ovarian, breast, prostate, renal cancer cells, melanoma, and even in acute lymphoblastic leukemia cells." | 2.49 | Metformin and cancer. ( Evangelopoulos, A; Kazazis, C; Vallianou, NG, 2013) |
| "Cancer is now recognized to be a disease arising from both genetic and metabolic abnormalities." | 2.49 | Cancer metabolism as a therapeutic target. ( Adekola, KU; Batra, S; Rosen, ST; Shanmugam, M, 2013) |
| "Understanding the complexity of cancer and of the underlying regulatory networks provides a new paradigm that tackles cancer development and treatment through a system biology approach, contemporarily acting on various intersecting pathways." | 2.49 | Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multi-faceted effects. ( Berrino, F; Gariboldi, M; Melani, C; Mogavero, A; Negri, T; Pasanisi, P; Pierotti, MA; Pilotti, S, 2013) |
| "Metformin is a biguanide derivative which is widely prescribed as an oral drug for diabetes mellitus type 2." | 2.49 | Metformin: a rising star to fight the epithelial mesenchymal transition in oncology. ( Barrière, G; Rigaud, M; Tartary, M, 2013) |
| "Metformin is a biguanide derivative used in the treatment of type II diabetes (T2D) and one of the world's most widely prescribed drugs." | 2.49 | Metformin and cancer: from the old medicine cabinet to pharmacological pitfalls and prospects. ( Emami Riedmaier, A; Fisel, P; Nies, AT; Schaeffeler, E; Schwab, M, 2013) |
| "Therefore, targeting LKB1 in cancer is now mainly focusing on the activation of AMPK and inactivation of mTOR." | 2.49 | Targeting LKB1 signaling in cancer. ( Korsse, SE; Peppelenbosch, MP; van Veelen, W, 2013) |
| "No beneficial effect on prostate cancer incidence was found for meformin intake in the meta-analysis." | 2.49 | Association of metformin use with cancer incidence and mortality: a meta-analysis. ( Chen, L; Li, H; Tan, X; Wang, S; Zhang, P, 2013) |
| "Metformin has been shown to exert anti-neoplastic and chemopreventive activities in epidemiological and animal studies." | 2.48 | Metformin and neoplasia: implications and indications. ( Aljada, A; Mousa, SA, 2012) |
| "The risks of cancer among metformin users were significantly lower than those among non-metformin users: the pooled RRs (95% confidence interval) were 0." | 2.48 | Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. ( Goto, A; Noda, M; Noto, H; Tsujimoto, T, 2012) |
| "Metformin also plays a direct inhibition of cancer cell growth via the inhibitory effects of AMP-activated protein kinase on the mTOR pathway, which regulates cell growth and proliferation." | 2.48 | Does use of metformin protect against cancer in Type 2 diabetes mellitus? ( Benso, A; Bo, S; Durazzo, M; Ghigo, E, 2012) |
| "An association between type 2 diabetes mellitus (DM) and cancer has long been postulated, but the biological mechanism responsible for this association has not been defined." | 2.48 | Diabetes and cancer II: role of diabetes medications and influence of shared risk factors. ( Doi, SA; Engel, JM; Glurich, I; Onitilo, AA; Stankowski, RV; Williams, GM, 2012) |
| "With the exception of colorectal cancer, significant between-study heterogeneity was observed." | 2.48 | Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. ( Bosetti, C; Catapano, A; Corrao, G; Grassi, G; La Vecchia, C; Mancia, G; Scotti, L; Soranna, D; Zambon, A, 2012) |
| " Compliance with the standard metformin formulation can be poor, due to multiple daily dosing and frequent GI side effects." | 2.48 | Overview of metformin: special focus on metformin extended release. ( Ali, S; Fonseca, V, 2012) |
| "We examined cancer outcomes and all-cause mortality in published randomised controlled trials (RCTs)." | 2.48 | Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials. ( Ali, R; Bankhead, CR; Bethel, MA; Cairns, BJ; Camisasca, RP; Crowe, FL; Farmer, AJ; Harrison, S; Hirst, JA; Holman, RR; Home, P; Kahn, SE; McLellan, JH; Perera, R; Plüddemann, A; Ramachandran, A; Roberts, NW; Rose, PW; Schweizer, A; Stevens, RJ; Viberti, G, 2012) |
| " Ongoing translational research should be useful in guiding design of clinical trials, not only to evaluate metformin at conventional antidiabetic doses, where reduction of elevated insulin levels may contribute to antineoplastic activity for certain subsets of patients, but also to explore more aggressive dosing of biguanides, which may lead to reprogramming of energy metabolism in a manner that could provide important opportunities for synthetic lethality through rational drug combinations or in the context of genetic lesions associated with hypersensitivity to energetic stress." | 2.48 | Investigating metformin for cancer prevention and treatment: the end of the beginning. ( Pollak, MN, 2012) |
| " Herein, a physiologically-based pharmacokinetic (PBPK) and pharmacodynamic framework is proposed for integrating information on physicochemical, cell-based, animal, and human studies of various biguanides to identify gaps in knowledge and to build a systems model that may facilitate the planning of randomized cancer chemoprevention trials of metformin." | 2.48 | A systems pharmacokinetic and pharmacodynamic approach to identify opportunities and pitfalls in energy stress-mediated chemoprevention: the use of metformin and other biguanides. ( Thompson, HJ; Thompson, MD, 2012) |
| "The link between cancer and metabolism has been suggested for a long time but further evidence of this hypothesis came from the recent molecular characterization of the LKB1/AMPK signaling pathway as a tumor suppressor axis." | 2.47 | LKB1/AMPK/mTOR signaling pathway in hematological malignancies: from metabolism to cancer cell biology. ( Bouscary, D; Chapuis, N; Green, AS; Lacombe, C; Mayeux, P; Tamburini, J, 2011) |
| "Metformin has been shown to improve endothelial function, decrease inflammatory activity, and regulate immune function." | 2.47 | Metformin as an antitumor agent in cancer prevention and treatment. ( Li, D, 2011) |
| "Metformin is a biguanine, the most widely used antidiabetic drug for the treatment of type 2 diabetes." | 2.47 | Metformin: a new option in cancer treatment. ( Belda-Iniesta, C; Pernía, O; Simó, R, 2011) |
| "In the pathophysiology of type 2 diabetes there are several biological processes, which may explain the higher cancer risk in type 2 diabetes." | 2.47 | [Diabetes and cancer risk: oncologic considerations]. ( Rosta, A, 2011) |
| "Type 2 diabetes is associated with increased risk of breast, colon, pancreatic and other types of cancer, while type 1 diabetes is associated with increase in stomach, pancreatic, endometrial and cervical cancer." | 2.47 | Diabetes mellitus and the risk of cancer. ( Abdallah, M; Alickaj, A; Asad, S; Forte, V; Mahmud, S; McFarlane, SI; Pandey, A, 2011) |
| "Metformin's molecular targets in cancer cells (e." | 2.47 | Metformin: multi-faceted protection against cancer. ( Bosch-Barrera, J; Cufí, S; Del Barco, S; Joven, J; Martin-Castillo, B; Menendez, JA; Oliveras-Ferraros, C; Vazquez-Martin, A, 2011) |
| "Metformin has recently gained much attention as it appears to reduce cancer incidence and improve prognosis of patients with diabetes." | 2.47 | Diabetes, cancer, and metformin: connections of metabolism and cell proliferation. ( Gallagher, EJ; LeRoith, D, 2011) |
| "Patients with type 2 diabetes are reported to have a worse response to cancer chemotherapy, have more complications, and have a poorer prognosis than patients with cancer without diabetes." | 2.46 | Insulin, insulin resistance, obesity, and cancer. ( Gallagher, EJ; LeRoith, D, 2010) |
| "Hirsutism is defined as excess hair growth in androgen-dependent areas of the body in women." | 2.46 | Hirsutism: Diagnosis and management. ( Brodell, LA; Mercurio, MG, 2010) |
| "Diabetes and cancer are common conditions, and their co-diagnosis in the same individual is not infrequent." | 2.46 | Diabetes and cancer. ( Chowdhury, TA, 2010) |
| " A dose-response relationship and a relation between duration of prior treatment with metformin and the protective effect against cancer have been reported." | 2.46 | [Anti-cancer activity of metformin: new perspectives for an old drug]. ( Beck, E; Scheen, AJ, 2010) |
| " A trend to a dose-response relationship was noted." | 2.46 | Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. ( Bonanni, B; Cazzaniga, M; Decensi, A; Gandini, S; Gennari, A; Goodwin, P; Puntoni, M, 2010) |
| "Type 2 diabetes mellitus has been associated with an increased risk of hepatic, pancreatic, colon, endometrial, breast, and bladder cancer." | 2.46 | Diabetes mellitus and increased risk of cancer: focus on metformin and the insulin analogs. ( Cripps, R; McFarland, MS, 2010) |
| "Furthermore metformin seems to decrease cancer risk in diabetic patients." | 2.46 | Metformin for aging and cancer prevention. ( Anisimov, VN, 2010) |
| "This favors not only formation of type 2 diabetes or cardiovascular diseases, but also increaseas the incidence and prevalence of malignant tumors." | 2.46 | [Antidiabetic therapy--a new possibility in the complex therapy of cancer?]. ( Bánhegyi, RJ; Martyin, T; Nagy, AK; Pikó, B; Rus-Gal, PO; Varga, R; Wágner, R, 2010) |
| "Multiple cancers have been reported to be associated with angiogenesis and are sensitive to anti-angiogenic therapies." | 1.91 | Metformin and simvastatin synergistically suppress endothelin 1-induced hypoxia and angiogenesis in multiple cancer types. ( Chen, H; Gao, X; Li, J; Li, Y; Liu, J; Liu, P; Ren, Y; Song, S; Wang, B; Wang, H; Wang, R; Wang, Y; Zhang, M, 2023) |
| "The possible anticancer activity of combination (M + E + F) of metformin (M), efavirenz (E), and fluoxetine (F) was investigated in normal HDF cells and HCT116 human colon cancer cells." | 1.91 | Combination of metformin/efavirenz/fluoxetine exhibits profound anticancer activity via a cancer cell-specific ROS amplification. ( Feng, JH; Inci, G; Jung, JS; Kang, BG; Kim, JH; Kim, SB; Kim, SC; Lee, JY; Lim, SS; Mo, YW; Park, SH; Seo, JH; Shende, M; Suh, HW, 2023) |
| "Histopathology of breast tumors revealed better control of tumors in Met pre-treated groups treated with Dox than DMBA control group." | 1.91 | Metformin pretreatment potentiates the antiproliferative action of doxorubicin against breast cancer. ( Patel, PJ; Shah, JS, 2023) |
| "Metabolic reprogramming in cancer is considered to be one of the most important hallmarks to drive proliferation, angiogenesis, and invasion." | 1.91 | Metformin May Alter the Metabolic Reprogramming in Cancer Cells by Disrupting the L-Arginine Metabolism: A Preliminary Computational Study. ( Arredondo-Espinoza, EU; Balderas-Renteria, I; Carranza-Rosales, P; Espinosa-Rodriguez, BA; Mendez-Lopez, LF; Ramirez-Cabrera, MA; Ramirez-Estrada, K; Treviño-Almaguer, D, 2023) |
| "Outcomes included total cancer and 4 site-specific cancers (breast, colorectal, lung, and prostate)." | 1.91 | Evaluating Metformin Strategies for Cancer Prevention: A Target Trial Emulation Using Electronic Health Records. ( Denaxas, S; Dickerman, BA; García-Albéniz, X; Hernán, MA; Logan, RW, 2023) |
| "Metformin has effects beyond its antihyperglycemic properties, including altering the localization of membrane receptors in cancer cells." | 1.91 | Metformin-Induced Receptor Turnover Alters Antibody Accumulation in HER-Expressing Tumors. ( Berry, NK; Brown, E; Fisher, ZT; Keltee, N; Mabry, A; Panikar, SS; Pereira, PMR; Shmuel, S; Zidel, A, 2023) |
| "Obesity, type 2 diabetes mellitus and cancers are equally endemic in our country." | 1.91 | [Investigation of glycaemic and nutritional status of patients suffering from cancer.] ( Bánhegyi, RJ; Beke, S; Mátrai, ÁA; Rácz, B; Veréb, B, 2023) |
| "Metformin was predicted to interact with transforming growth factor (TGF)-beta receptor I kinase based on molecular docking and molecular dynamics simulations." | 1.91 | Pharmacophore mapping approach to find anti-cancer phytochemicals with metformin-like activities against transforming growth factor (TGF)-beta receptor I kinase: An in silico study. ( Morshed, N; Reza, MS; Reza, R; Samdani, MN, 2023) |
| "However, differential risk of various cancers among GLP1Ra recipients is unknown." | 1.72 | Differential Risk of Cancer Associated with Glucagon-like Peptide-1 Receptor Agonists: Analysis of Real-world Databases. ( Kim, CH; Wang, J, 2022) |
| "The use of metformin in hematologic cancers has received much less attention, although allogeneic cytotoxic lymphocytes are very effective against these tumors." | 1.72 | Metformin sensitizes leukemic cells to cytotoxic lymphocytes by increasing expression of intercellular adhesion molecule-1 (ICAM-1). ( Alexia, C; Allende-Vega, N; Anel, A; Bertolini, F; Coenon, L; Constantinides, M; de Maudave, AF; Falvo, P; Gitenay, D; Marco Brualla, J; Marzo, I; Massa, P; Mitola, G; Orecchioni, S; Villalba, M, 2022) |
| " The concomitant use of nivolumab and metformin was well tolerated; adverse events (AEs) of any grade occurred in 75% of patients (mainly fatigue, pruritus, rash, and asthenia)." | 1.72 | Concurrent Nivolumab and Metformin in Diabetic Cancer Patients: Is It Safe and More Active? ( Astore, S; Bassi, P; Bove, P; Bria, E; Buti, S; Ciccarese, C; Ferrara, MG; Foschi, N; Iacovelli, R; Iacovelli, V; Massari, F; Palermo, G; Primi, F; Rossi, E; Schinzari, G; Tortora, G, 2022) |
| "As the impact of high glucose levels on cancer progression and therapy is a novel finding, further research is required." | 1.72 | Emerging Role of High Glucose Levels in Cancer Progression and Therapy. ( Cai, XJ; Li, TJ; Zhang, AB; Zhang, HY; Zhang, JY; Zhou, X, 2022) |
| "Previous studies indicate IRI induces cancer stemness in irinotecan-resistant (IRI-resistant) cells." | 1.72 | Single cell mass spectrometry analysis of drug-resistant cancer cells: Metabolomics studies of synergetic effect of combinational treatment. ( Chen, X; Sun, M; Yang, Z, 2022) |
| "Control of glucose metabolism in cancer cells has potential to serve as an anti-cancer therapy." | 1.72 | Repression of Cell-to-Matrix Adhesion by Metformin Chloride Supports Its Anti-Metastatic Potential in an In Vitro Study on Metastatic and Non-Metastatic Cancer Cells. ( Aftab, S; Khalid, Z; Shakoori, AR, 2022) |
| "Metformin (Met) is a promising drug for tumor treatment that targets hexokinase 2 (HK2) to block the glycolytic process, thereby further disrupting the metabolism of cancer cells." | 1.72 | Tumor metabolism destruction via metformin-based glycolysis inhibition and glucose oxidase-mediated glucose deprivation for enhanced cancer therapy. ( Jiang, Y; Lu, Z; Lv, Q; Meng, X; Wang, Z; Zhang, L, 2022) |
| "Metformin was shown to reduce lipid peroxidation in irradiated healthy tissues, increase tumor cytotoxicity, downregulate critical pathways involved in tumor progression and proliferation, and enhance tumor apoptosis." | 1.72 | Differential effects of cancer modifying agents during radiation therapy on Ehrlich solid tumor-bearing mice: A comparative investigation of metformin and ascorbic acid. ( Ahmed, MM; Al-Mokaddem, AK; Ali, MA; Aljuaydi, SH; Khalil, HMA; Khalil, MM, 2022) |
| "Patients with type 2 diabetes mellitus (T2DM) have an increased risk of cancer." | 1.72 | Glucose metabolism controls human γδ T-cell-mediated tumor immunosurveillance in diabetes. ( Chen, Y; He, J; Lau, YL; Leung, WH; Liu, Y; Lu, J; Mu, X; Tu, CR; Tu, W; Wang, X; Xiang, Z; Xu, Y; Yin, Z; Zhang, W; Zhang, Y, 2022) |
| "Metformin has been shown to kill cancer stem-like cells in genetically various types of breast carcinoma." | 1.72 | Docetaxel in combination with metformin enhances antitumour efficacy in metastatic breast carcinoma models: a promising cancer targeting based on PEGylated liposomes. ( Farhoudi, L; Jaafari, MR; Kharrazi, S; Mashreghi, M; Mehrabian, A; Mirzavi, F; Rezayat, SM; Sadri, K; Vakili-Ghartavol, R, 2022) |
| "Metformin (Met), a first-line drug for type 2 diabetes, lowers blood glucose levels by suppressing gluconeogenesis in the liver, presumably through the liver kinase B1-dependent activation of AMP-activated protein kinase (AMPK) after inhibiting respiratory chain complex I." | 1.72 | Nutrient Condition in the Microenvironment Determines Essential Metabolisms of CD8 ( Chao, R; Kudo, I; Nishida, M; Tokumasu, M; Udono, H; Yamashita, N; Zhao, W, 2022) |
| " The results of analyses for various subgroups, risk of site-specific cancers, cumulative duration, dose-response relationship, and sensitivity analyses of different latency periods and missing data were generally consistent with the findings of the primary analyses." | 1.72 | Sulfonylurea and Cancer Risk Among Patients With Type 2 Diabetes: A Population-Based Cohort Study. ( Lin, H; Liu, Z; Shen, P; Sun, Y; Zhan, S; Zhao, H; Zhuo, L, 2022) |
| "Metformin may offer benefits to certain cancer populations experiencing metabolic abnormalities." | 1.72 | Metformin Mitigated Obesity-Driven Cancer Aggressiveness in Tumor-Bearing Mice. ( Chang, CY; Chen, CJ; Chen, WY; Li, JR; Liao, SL; Ou, YC; Wang, JD; Wu, CC, 2022) |
| "Metformin is a promising anti-inflammatory agent with low side effects, but tumor monotherapy with an anti-inflammation drug could generate therapy resistance, cell adaptation or even promote tumor development." | 1.72 | Metformin and histone deacetylase inhibitor based anti-inflammatory nanoplatform for epithelial-mesenchymal transition suppression and metastatic tumor treatment. ( Chen, J; Gao, X; Gong, J; Huang, Y; Jiang, T; Liu, Y; Ma, F; Mei, N; Xie, L; Zhou, S, 2022) |
| "Metformin is a first-line antidiabetic drug for the treatment of type 2 diabetes mellitus (DM2); its molecular target is AMP-activated protein kinase (AMPK), which is involved in many metabolic processes." | 1.72 | [Metformin and malignant neoplasms: a possible mechanism of antitumor action and prospects for use in practice]. ( Frolova, YS; Gaimakova, DV; Galimova, AM; Islamgulov, AH; Karimova, AR; Kuznetsov, KO; Nazmieva, KA; Oganesyan, IY; Rizvanova, EV; Sadertdinova, AG; Safina, ER, 2022) |
| " As CI is a central player of cellular bioenergetics, a finely tuned dosing of targeting drugs is required to avoid side effects." | 1.72 | NDUFS3 knockout cancer cells and molecular docking reveal specificity and mode of action of anti-cancer respiratory complex I inhibitors. ( Cavina, B; De Luise, M; Fornasa, A; Gasparre, G; Ghelli, A; Iommarini, L; Iorio, M; Kurelac, I; Lama, E; Miglietta, S; Musiani, F; Nasiri, HR; Porcelli, AM; Sollazzo, M; Traversa, D, 2022) |
| "Metformin, a widely used type 2 diabetes drug is an ideal candidate to repurpose as it has a good safety profile and studies suggest that metformin can modulate the tumour microenvironment, promoting a favourable environment for T cell activation but has no direct action on T cell activation on its own." | 1.72 | Imaging Memory T-Cells Stratifies Response to Adjuvant Metformin Combined with αPD-1 Therapy. ( Cheng, P; Chin, HX; Chin, ZF; Goggi, JL; Hartimath, SV; Hwang, YY; Khanapur, S; Ramasamy, B; Robins, EG, 2022) |
| "Metformin has been in clinical use for more than half a century, yet its molecular mechanism of action is not entirely understood." | 1.72 | Multidimensional mechanisms of metformin in cancer treatment. ( Hathaway, D; Pandav, K; Paul, T; Singh-Makkar, S; Youssef, P, 2022) |
| "Metformin is a clinically-approved anti-diabetic drug with emerging antitumor potential, but its antitumor activity is highly susceptible to local glucose abundance." | 1.62 | Tumor-activatable biomineralized nanotherapeutics for integrative glucose starvation and sensitized metformin therapy. ( Cai, R; Fei, Y; Hu, Y; Li, M; Li, Y; Luo, Z; Wang, X; Wen, H; Xue, C; Yao, X, 2021) |
| "Even in sensitive cancer cells, though, biguanide treatment alone over a broad range of doses only inhibits cell replication without significantly affecting cell viability." | 1.62 | Biguanide drugs enhance cytotoxic effects of cisplatin by depleting aspartate and NAD+ in sensitive cancer cells. ( Bharti, S; Bhujwalla, Z; Gabrielson, E; Tully, E; Woo, J, 2021) |
| "Metformin could inhibit the growth of tumor under the condition of diabetes and play a role in the intestinal homeostasis in mice." | 1.62 | Metformin inhibits tumor growth and affects intestinal flora in diabetic tumor-bearing mice. ( Chen, C; Gao, X; Kang, J; Li, C; Liu, Z; Luo, D, 2021) |
| "Abnormal glucose metabolism in cancer cells causes generation and secretion of excess lactate, which results in acidification of the extracellular microenvironment." | 1.62 | Metformin induced lactic acidosis impaired response of cancer cells towards paclitaxel and doxorubicin: Role of monocarboxylate transporter. ( Bhat, MK; Chaube, B; Deb, A; Malvi, P; Mayengbam, SS; Mohammad, N; Singh, A; Singh, SV, 2021) |
| "Malignant neoplasms are the leading cause of death in Korea." | 1.62 | Metformin use in cancer survivors with diabetes reduces all-cause mortality, based on the Korean National Health Insurance Service between 2002 and 2015. ( Bae, YJ; Choi, EA; Han, YE; Kang, HT; Kim, HS; Kim, J; Kim, Y; Kim, YS; Lee, JW; You, HS, 2021) |
| "Diabetes mellitus (DM) and malignancy are recognized among the most common complications increasing mortality in patients after heart transplantation (HTx)." | 1.62 | Metformin therapy and risk of cancer in patients after heart transplantation. ( Bedanova, H; Dobsak, P; Horvath, V; Krejci, J; Nemec, P; Ondrasek, J, 2021) |
| "Metformin is a commonly used antidiabetic medication which has demonstrated promise as an anticancer agent alone and in combination with conventional treatment regimens." | 1.62 | Metformin generates profound alterations in systemic and tumor immunity with associated antitumor effects. ( Kemnade, JO; Newton, JM; Sandulache, VC; Sikora, AG; Skinner, HD; Veeramachaneni, R; Yu, W, 2021) |
| "Small-molecule inhibitors targeting cancer are useful for studying its metabolic pathways and functions and for developing anticancer drugs." | 1.62 | Identification of a Small-Molecule Glucose Transporter Inhibitor, Glutipyran, That Inhibits Cancer Cell Growth. ( Aono, H; Hashizume, D; Hiranuma, S; Kawada, M; Kawatani, M; Muroi, M; Nogawa, T; Ogawa, N; Ohba, SI; Ohishi, T; Okano, A; Osada, H; Shimizu, T, 2021) |
| "Type 2 diabetes (T2D) and cancer have been shown to be part of the DM1 phenotype." | 1.56 | Diabetes, metformin and cancer risk in myotonic dystrophy type I. ( Alsaggaf, R; Amr, S; Gadalla, SM; Greene, MH; Pfeiffer, RM; St George, DMM; Wagner, KR; Wang, Y; Zhan, M, 2020) |
| "Recipients with prior malignancy, malignancy before diabetes diagnosis, and metformin duration <30 days were excluded." | 1.56 | Impact of metformin on malignancy in solid organ transplantation. ( Bartlett, F; Horwedel, T; January, S; Malone, AF; Pottebaum, A, 2020) |
| "Metformin is an oral drug widely used for the treatment of type 2 diabetes mellitus." | 1.56 | GPD1 Enhances the Anticancer Effects of Metformin by Synergistically Increasing Total Cellular Glycerol-3-Phosphate. ( Cai, Z; Deng, Y; Feng, Y; Han, Z; Jiang, F; Liang, Y; Liu, R; Luo, Y; Mo, R; Wu, CL; Wu, Y; Xie, J; Ye, J; Zheng, Y; Zhong, W; Zhu, J; Zhu, X; Zhuo, Y, 2020) |
| "Metformin can activate SIRT1 to participate in different biological processes and exert its anticancer effects." | 1.56 | Metformin activates AMPK/SIRT1/NF-κB pathway and induces mitochondrial dysfunction to drive caspase3/GSDME-mediated cancer cell pyroptosis. ( Bian, Y; Li, G; Ren, G; Zhang, Y; Zheng, Z, 2020) |
| "Cellular starvation is typically a consequence of tissue injury that disrupts the local blood supply but can also occur where cell populations outgrow the local vasculature, as observed in solid tumors." | 1.56 | Starvation and antimetabolic therapy promote cytokine release and recruitment of immune cells. ( Chevet, E; Eldering, E; Favaro, F; Iurlaro, R; Lucendo, E; Majem, B; Marchetti, S; Muñoz-Pinedo, C; Nadal, E; Püschel, F; Redondo-Pedraza, J; Ricci, JE, 2020) |
| "This study aims to compare the risks of cancer among patients with type 2 diabetes mellitus (T2DM) on metformin-sulfonylurea dual therapy intensified with dipeptidyl peptidase 4 inhibitors (DPP4i), thiazolidinediones, or insulin." | 1.56 | DPP4i, thiazolidinediones, or insulin and risks of cancer in patients with type 2 diabetes mellitus on metformin-sulfonylurea dual therapy with inadequate control. ( Chan, EWY; Lam, CLK; Man, KKC; Tse, ETY; Wong, CKH; Wong, ICK; Wu, T, 2020) |
| "Cumulative incidence of overall cancer was 7." | 1.56 | Metformin use reduced the overall risk of cancer in diabetic patients: A study based on the Korean NHIS-HEALS cohort. ( Bae, YJ; Choi, EA; Han, YE; Kang, HT; Kim, HS; Kim, J; Kim, Y; Kim, YS; Lee, JW; You, HS, 2020) |
| "The secondary outcomes were cancer incidences of specific sites, including colon/rectum, liver, oesophagus, pancreas, stomach, lung, breast, kidney, bladder and prostate." | 1.56 | Use of metformin and aspirin is associated with delayed cancer incidence. ( Ho, JM; Lam, AS; Sung, JJ; Tsoi, KK; Yau, ST, 2020) |
| "Metformin is a widely used drug in treating type 2 diabetes and insulin resistance and nowadays scientists are searching for new poten-tial and multiple roles in prevention and treatment of carcinogenic processes." | 1.56 | Metformin and proliferation of cancer cell lines. ( Barg, E; Bodetko, D; Tądel, K; Wiatrak, B, 2020) |
| "Patients with colorectal cancer and T2DM during 2000-2012 period were identified form Lithuanian Cancer Registry and the National Health Insurance Fund database." | 1.51 | Metformin increases cancer specific survival in colorectal cancer patients-National cohort study. ( Dulskas, A; Linkeviciute-Ulinskiene, D; Patasius, A; Smailyte, G; Urbonas, V; Zabuliene, L, 2019) |
| "Patients with incident type 2 diabetes (T2DM) were identified in the Clinical Practice Research Datalink (CPRD), a database of electronic health records derived from primary care in the UK." | 1.51 | Metformin use and risk of cancer in patients with type 2 diabetes: a cohort study of primary care records using inverse probability weighting of marginal structural models. ( Bhaskaran, K; Chaturvedi, N; Farmer, RE; Ford, D; Kaplan, R; Mathur, R; Smeeth, L, 2019) |
| "Metformin has been extensively studied for its impact on cancer cell metabolism and anticancer potential." | 1.51 | Respiratory Capacity and Reserve Predict Cell Sensitivity to Mitochondria Inhibitors: Mechanism-Based Markers to Identify Metformin-Responsive Cancers. ( Casey, PJ; Newgard, CB; Teh, JT; Wang, M; Zhu, WL, 2019) |
| "Metformin users were categorized into 11 groups in terms of length of time between metformin initiation and enrollment." | 1.51 | Metformin and Reduced Risk of Cancer in the Hong Kong Diabetes Registry: Real Effect or Immortal Time Bias? ( Zhang, ZJ, 2019) |
| "As a result, FucOMDs prevent metastasis formation and efficiently suppress both primary-tumor growth and metastasis formation when combined with targeted chemotherapy." | 1.51 | Metformin and Docosahexaenoic Acid Hybrid Micelles for Premetastatic Niche Modulation and Tumor Metastasis Suppression. ( Chen, J; Chen, L; Chen, Y; Gao, X; Gu, X; Huang, Y; Jiang, T; Liang, K; Liu, S; Lu, H; Ma, F; Pei, Y; Song, Q; Wang, J; Xu, M; Zhou, S, 2019) |
| "The degree of complexity of a cancer system could be vast involving multiple endogenous and exogenous agents interacting with the over 10 trillion cells comprising the body." | 1.48 | A complex systems approach to cancer prevention. ( Jupp, PW, 2018) |
| "The association between cancer incidence and the use of antidiabetic medications in patients with T2DM has been recently examined." | 1.48 | Metformin reduces the risk of cancer in patients with type 2 diabetes: An analysis based on the Korean National Diabetes Program Cohort. ( Ahn, KJ; Baik, SH; Chun, KH; Han, SJ; Jeon, JY; Kim, DJ; Kim, HJ; Kim, YS; Lee, KW; Lee, S; Nam, MS; Woo, JT, 2018) |
| "The effects of metformin in specific cancers including colorectal, prostate, pancreatic, renal, cervical, endometrial, gastric, lung, breast, and ovarian cancer are reviewed." | 1.48 | Anti-cancer Effects of Metformin: Recent Evidences for its Role in Prevention and Treatment of Cancer. ( Kamal, MA; Kamal, W; Kheirandish, M; Mahboobi, H; Yazdanparast, M, 2018) |
| "Metformin is a popular anti-diabetic drug currently being explored for its role in cancer and gut microbiome amongst other areas." | 1.48 | High dose targeted delivery on cancer sites and the importance of short-chain fatty acids for metformin's action: Two crucial aspects of the wonder drug. ( Banerjee, D; Bhattacharyya, R; Chakrabarti, A; Maniar, K; Singh, V, 2018) |
| "In breast cancer cell lines, metformin has been shown to induce phosphorylation at specific serine sites in insulin regulated substrate of mTOR pathway that results in apoptosis over cell proliferation." | 1.48 | Bifurcation analysis of insulin regulated mTOR signalling pathway in cancer cells. ( Sriram, K, 2018) |
| "Metformin was not associated with a decreased rate of viral associated cancer (HR: 0." | 1.46 | Metformin and the incidence of viral associated cancers in patients with type 2 diabetes. ( Azoulay, L; Brassard, P; Hicks, BM; Sinyavskaya, L; Suissa, S; Yin, H, 2017) |
| "Metformin (MET) is an anti-diabetic drug used to prevent hepatic glucose release and increase tissue insulin sensitivity." | 1.46 | Modulatory effects of metformin on mutagenicity and epithelial tumor incidence in doxorubicin-treated Drosophila melanogaster. ( Constante, SAR; de Rezende, AAA; Nepomuceno, JC; Oliveira, VC; Orsolin, PC; Spanó, MA, 2017) |
| "Metformin therapy was prescribed in 190 (81%) patients." | 1.46 | Metformin use associated with lower risk of cancer in patients with diabetes mellitus type 2. ( Gušić, E; Kulo Ćesić, A; Kusturica, J; Maleškić, S; Rakanović-Todić, M; Šečić, D, 2017) |
| "An employee undergoing cancer treatment was prescribed metformin, a medication used in the treatment of type 2 diabetes and currently used as adjunct therapy for cancer." | 1.46 | Metformin: Adjunct Therapy in Cancer Treatment. ( Lurati, AR, 2017) |
| "Treatment with metformin and the development of DM after HTx were assessed as time-dependent factors in the analyses." | 1.46 | Metformin therapy reduces the risk of malignancy after heart transplantation. ( Arad, M; Asher, E; Elian, D; Freimark, D; Goldenberg, I; Har-Zahav, Y; Kassif, Y; Katz, M; Klempfner, R; Lavee, J; Peled, A; Peled, Y; Raichlin, E; Shlomo, N, 2017) |
| "Both diabetes mellitus (DM) and cancer are common diseases and they frequently occur in the same patients." | 1.46 | Risk of Cause-Specific Death in Individuals with Cancer-Modifying Role Diabetes, Statins and Metformin. ( Auvinen, A; Haukka, J; Niskanen, L, 2017) |
| "Metformin treatment reduces the risk of cancer in type 2 diabetes patients." | 1.46 | Use of metformin is associated with lower incidence of cancer in patients with type 2 diabetes. ( Junik, R; Muszyńska-Ogłaza, A; Olejniczak, H; Polaszewska-Muszyńska, M; Zarzycka-Lindner, G, 2017) |
| "The anticancer properties of ursolic acid (UA) and metformin (Met) have been well demonstrated." | 1.46 | Synergistic Chemopreventive and Therapeutic Effects of Co-drug UA-Met: Implication in Tumor Metastasis. ( Chen, X; Jiang, K; Shao, J; Shen, Z; Wu, P; Xu, A; Yang, X; Zheng, G, 2017) |
| "The rate of cancer incidence and mortality of Type 2 diabetes patients who were taking metformin seem to be decreased, comparing with those taking other drugs." | 1.46 | Metformin-dependent metabolic reprogramming contributes to efficient anti-tumor immunity. ( Eikawa, S; Tomonobu, N; Udono, H, 2017) |
| "Anisodamine was isolated from the medicinal herb, it was used in the treatment of gastrointestinal smooth muscle spasm, infective toxic shock and organophosphorus intoxication." | 1.43 | Study on the synthesis and biological activities of α-substituted arylacetates derivatives. ( Chen, C; Liu, J; Tang, J; Wu, F, 2016) |
| "Indeed, the phenomenon of cancer cells metabolizing glucose using a less efficient anaerobic process even in the presence of normal oxygen levels, termed the Warburg effect, is currently considered to be one of the hallmarks of cancer." | 1.43 | Using Boolean Logic Modeling of Gene Regulatory Networks to Exploit the Links Between Cancer and Metabolism for Therapeutic Purposes. ( Arshad, OA; Datta, A; Venkatasubramani, PS; Venkatraj, J, 2016) |
| "Hyperinsulinemia is thought to enhance cancer risk." | 1.43 | Metformin Protects Kidney Cells From Insulin-Mediated Genotoxicity In Vitro and in Male Zucker Diabetic Fatty Rats. ( Arias-Loza, PA; Kreissl, MC; Oli, RG; Othman, EM; Stopper, H, 2016) |
| "This suggests that cancer drug sensitivity and resistance are not intrinsic properties of cancer cells, and demonstrates that the environment can dictate sensitivity to therapies that impact cell metabolism." | 1.43 | Environment Dictates Dependence on Mitochondrial Complex I for NAD+ and Aspartate Production and Determines Cancer Cell Sensitivity to Metformin. ( Bush, LN; Davidson, SM; Freinkman, E; Gitego, N; Gui, DY; Hosios, AM; Luengo, A; Sullivan, LB; Thomas, CJ; Vander Heiden, MG, 2016) |
| "Metformin has utility in cancer prevention and treatment, though the mechanisms for these effects remain elusive." | 1.43 | An Ancient, Unified Mechanism for Metformin Growth Inhibition in C. elegans and Cancer. ( Carr, CE; Gygi, SP; Kacergis, MC; Li, M; Mou, F; Oshiro-Rapley, N; Paulo, JA; Soukas, AA; Talkowski, ME; Webster, CM; Wu, L; Zheng, B; Zhou, B, 2016) |
| "Among all Vanderbilt cancer patients, metformin was associated with a 22% decrease in overall mortality compared to other oral hypoglycemic medications (HR 0." | 1.42 | Validating drug repurposing signals using electronic health records: a case study of metformin associated with reduced cancer mortality. ( Aldrich, MC; Chen, Q; Dai, Q; Denny, JC; Friedman, C; Han, X; Jiang, M; Julien, JS; Levy, M; Li, Y; Liu, H; Peterson, NB; Roden, DM; Ruan, X; Shah, A; Warner, J; Xu, H, 2015) |
| "Neoplasms are highly dependent on glucose as their substrate for energy production and are generally not able to catabolize other fuel sources such as ketones and fatty acids." | 1.42 | Starvation of cancer via induced ketogenesis and severe hypoglycemia. ( Kapelner, A; Vorsanger, M, 2015) |
| "Combined use of metformin and cancer vaccine improved CD8(+) TIL multifunctionality." | 1.42 | Immune-mediated antitumor effect by type 2 diabetes drug, metformin. ( Eikawa, S; Mizukami, S; Nakayama, E; Nishida, M; Udono, H; Yamazaki, C, 2015) |
| "The occurrence of HCC or a nonliver cancer was evaluated in patients who either were or were not taking statin or metformin." | 1.42 | Cancer risk in HBV patients with statin and metformin use: a population-based cohort study. ( Chang, CJ; Chen, CI; Fang, YA; Hwang, J; Kuan, CF; Liu, JC; Liu, SH; Miser, JS; Wu, LL; Wu, SY; Yang, HC, 2015) |
| "Metformin is a biguanide widely prescribed to treat Type II diabetes that has gained interest as an antineoplastic agent." | 1.42 | Metformin Antagonizes Cancer Cell Proliferation by Suppressing Mitochondrial-Dependent Biosynthesis. ( Chen, J; DeBerardinis, RJ; Egnatchik, R; Faubert, B; Griss, T; Jones, RG; Ma, EH; Vincent, EE; Viollet, B, 2015) |
| "Metformin exposure was associated with reduced breast and prostate cancer incidence, but had no association with colon cancer risk." | 1.40 | Type 2 diabetes mellitus, glycemic control, and cancer risk. ( Berg, RL; Doi, SA; Engel, JM; Glurich, I; Onitilo, AA; Stankowski, RV; Williams, GM, 2014) |
| "In this study, we report that in human cancer cells, metformin inhibits mitochondrial complex I (NADH dehydrogenase) activity and cellular respiration." | 1.40 | Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. ( Anso, E; Budigner, GS; Chandel, NS; Dufour, E; Glasauer, A; Hamanaka, RB; Mutlu, GM; Soberanes, S; Sullivan, LB; Weinberg, SE; Wheaton, WW, 2014) |
| "Hyperglycemia is associated with increased risk of all-site cancer that may be mediated through activation of the renin-angiotensin-system (RAS) and 3-hydroxy-3-methyl-glutaryl-coenzyme-A-reductase (HMGCR) pathways." | 1.40 | Additive effects of blood glucose lowering drugs, statins and renin-angiotensin system blockers on all-site cancer risk in patients with type 2 diabetes. ( Chan, JC; Cheung, KK; Chow, CC; Kong, AP; Lee, HM; Luk, A; Ma, RC; Ozaki, R; So, WY; Xu, G; Yang, X; Yu, L, 2014) |
| "A total of 95,820 participants with type 2 diabetes who started taking metformin and other oral antidiabetes medications within 12 months of their diagnosis (initiators) were followed up for first incident cancer diagnosis without regard to any subsequent changes in pharmacotherapy." | 1.40 | Metformin does not affect cancer risk: a cohort study in the U.K. Clinical Practice Research Datalink analyzed like an intention-to-treat trial. ( Allen, NE; Ashby, D; Capothanassi, D; Ioannidis, JP; Lopez, DS; Rizos, EC; Sacerdote, C; Tsilidis, KK; Tzoulaki, I; van Veldhoven, K; Vineis, P, 2014) |
| " While Paracelsus' law for the dose-response effect has been commonly exploited for the use of some anti-cancer drugs at lower doses in non-neoplastic diseases (e." | 1.40 | Oncobiguanides: Paracelsus' law and nonconventional routes for administering diabetobiguanides for cancer treatment. ( Bosch-Barrera, J; Corominas-Faja, B; Cufí, S; Cuyàs, E; Joven, J; Martin-Castillo, B; Menendez, JA; Quirantes-Piné, R; Rodríguez-Gallego, E; Segura-Carretero, A, 2014) |
| "Metformin-treated MCF-7 cells had no increase in basal levels of reactive oxygen species but were more susceptible to oxidative stress." | 1.40 | Metformin induces microRNA-34a to downregulate the Sirt1/Pgc-1α/Nrf2 pathway, leading to increased susceptibility of wild-type p53 cancer cells to oxidative stress and therapeutic agents. ( Choi, JH; Do, MT; Jeong, HG; Kim, HG, 2014) |
| "Metformin treatment significantly reduced ATP levels in cells incubated in media with low glucose (2." | 1.40 | Mechanisms by which low glucose enhances the cytotoxicity of metformin to cancer cells both in vitro and in vivo. ( Chan, DK; Haugrud, AB; Miskimins, WK; Zhuang, Y, 2014) |
| "Metformin is a widely prescribed anti-diabetic drug and its use is associated with lower cancer incidence." | 1.39 | Metformin: a case of divide and conquer. ( Anastasiou, D, 2013) |
| "Metformin is a well-known antidiabetic medication, which, besides diabetes, may be involved into modulation of other age-related pathologies, including cancer." | 1.39 | Genetic polymorphisms potentially associated with response to metformin in postmenopausal diabetics suffering and not suffering with cancer. ( Berstein, LM; Imyanitov, EN; Iyevleva, AG; Poroshina, TE; Vasilyev, D, 2013) |
| "New diagnoses of cancer, including malignant solid tumours and haematological malignancies, occurring during the follow-up were identified from the cohort." | 1.39 | Initial metformin or sulphonylurea exposure and cancer occurrence among patients with type 2 diabetes mellitus. ( Berlin, JA; Demissie, K; Marcella, SW; Qiu, H; Rhoads, GG, 2013) |
| "Colon cancer cell lines HT29 (human) and MC26 (murine) were treated for 24 or 72 h with a range of MET concentrations (0-10 mM)." | 1.39 | Metformin--an adjunct antineoplastic therapy--divergently modulates tumor metabolism and proliferation, interfering with early response prediction by 18F-FDG PET imaging. ( Habibollahi, P; Kuruppu, D; Loda, M; Mahmood, U; van den Berg, NS, 2013) |
| "In the families of cancer-free DM2 women, DM2 was found to be significantly more frequent (30." | 1.38 | Familial diabetes is associated with reduced risk of cancer in diabetic patients: a possible role for metformin. ( Berstein, LM; Boyarkina, MP; Teslenko, SY, 2012) |
| "All-cause- and cancer-related deaths occurred in: 9." | 1.38 | Cancer mortality reduction and metformin: a retrospective cohort study in type 2 diabetic patients. ( Appendino, G; Bo, S; Ciccone, G; Ghigo, E; Grassi, G; Rosato, R; Villois, P, 2012) |
| "The association between the risk of cancer in those using metformin compared with those using sulfonylurea derivatives was analyzed using Cox proportional hazard models with cumulative duration of drug use as a time-varying determinant." | 1.38 | Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study. ( Coebergh, JW; Geelhoed-Duijvestijn, PH; Haak, HR; Herings, RM; Ruiter, R; Straus, SM; Stricker, BH; van Herk-Sukel, MP; Visser, LE, 2012) |
| "Hence, the control or destruction of cancer stem cells should be a major goal of cancer management." | 1.38 | Metformin may antagonize Lin28 and/or Lin28B activity, thereby boosting let-7 levels and antagonizing cancer progression. ( McCarty, MF, 2012) |
| "All-type cancer HRs with insulin glargine vs human insulin ranged from 0." | 1.38 | Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database. ( Abouelfath, A; Ambrosino, B; Bernard, MA; Blin, P; Droz, C; Dureau-Pournin, C; Gin, H; Lassalle, R; Le Jeunne, C; Moore, N; Pariente, A, 2012) |
| "Metformin was associated with survival benefit both in comparison with other treatments for diabetes and in comparison with a nondiabetic population." | 1.38 | Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. ( Currie, CJ; Gale, EA; Jenkins-Jones, S; Johnson, JA; Morgan, CL; Poole, CD, 2012) |
| "The anti-cancer effects of metformin, the most widely used drug for type 2 diabetes, alone or in combination with ionizing radiation were studied with MCF-7 human breast cancer cells and FSaII mouse fibrosarcoma cells." | 1.38 | Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells. ( Choi, BH; Dings, RP; Lee, H; Park, HJ; Powers, J; Santos, TD; Song, CW; Williams, B, 2012) |
| " Use of TZDs was associated with reduced risk of cancer in a dose-response manner in multivariable analysis." | 1.38 | Use of thiazolidinedione and cancer risk in Type 2 diabetes: the Hong Kong diabetes registry. ( Chan, JC; Ko, GT; Kong, AP; Lee, HM; Ma, RC; Ozaki, R; So, WY; Xu, G; Yang, X; Yu, LW, 2012) |
| "Metformin has been reported to lower cancer incidence among type II diabetics." | 1.38 | Distinct perturbation of the translatome by the antidiabetic drug metformin. ( Alain, T; Blouin, MJ; Larsson, O; Morita, M; Pollak, M; Sonenberg, N; Topisirovic, I, 2012) |
| "Metformin treatment was associated with a decreased risk of colon and liver cancer compared to sulphonylureas or insulin treatment." | 1.38 | The influence of type 2 diabetes and glucose-lowering therapies on cancer risk in the Taiwanese. ( Cheng, SM; Hsieh, MC; Lee, TC; Tseng, CH; Tu, ST; Yen, MH, 2012) |
| "Metformin and rosiglitazone suppressed cancer cell growth and induced apoptosis." | 1.37 | The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth. ( Chen, J; Feng, YH; Gully, C; Lee, MH; Velazquez-Torres, G; Yeung, SC, 2011) |
| "We hypothesize that the anticancer effects of metformin may be particularly evident in type 2 diabetic patients with low HDL cholesterol." | 1.37 | Low HDL cholesterol, metformin use, and cancer risk in type 2 diabetes: the Hong Kong Diabetes Registry. ( Chan, JC; Chow, CC; Ko, GT; Kong, AP; Lee, HM; Ma, RC; Ozaki, R; So, WY; Yang, X; Yu, LW, 2011) |
| "Metformin is associated with reduced cancer-related morbidity and mortality." | 1.37 | Metformin and cancer occurrence in insulin-treated type 2 diabetic patients. ( Balzi, D; Barchielli, A; Colombi, C; Dicembrini, I; Giannini, S; Mannucci, E; Marchionni, N; Melani, C; Monami, M; Romano, D; Rotella, CM; Vitale, V, 2011) |
| "Treatment with metformin started at the age of 3 months increased mean life span by 14% and maximum life span by 1 month." | 1.37 | If started early in life, metformin treatment increases life span and postpones tumors in female SHR mice. ( Anisimov, VN; Berstein, LM; Egormin, PA; Kovalenko, IG; Piskunova, TS; Popovich, IG; Poroshina, TE; Semenchenko, AV; Tyndyk, ML; Yurova, MN; Zabezhinski, MA, 2011) |
| "Treatment with metformin and paclitaxel resulted in an increase in the number of cells arrested in the G(2)-M phase of the cell cycle, and decreased the tumor growth and increased apoptosis in tumor-bearing mice, when compared with individual drug treatments." | 1.37 | Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth. ( Carvalheira, JB; Dias, MM; Osório-Costa, F; Rocha, GZ; Ropelle, ER; Rossato, FA; Saad, MJ; Vercesi, AE, 2011) |
| "Since eIF4E is overexpressed in many cancers, strategies which target eIF4E directly--some of which are now being assessed clinically--may have the broadest efficacy in this regard." | 1.37 | mTORC1 activity as a determinant of cancer risk--rationalizing the cancer-preventive effects of adiponectin, metformin, rapamycin, and low-protein vegan diets. ( McCarty, MF, 2011) |
| "In 1998 and 1999, 1,353 patients with type 2 diabetes were enrolled in the Zwolle Outpatient Diabetes project Integrating Available Care (ZODIAC) study in the Netherlands." | 1.36 | Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. ( Bilo, HJ; Gans, RO; Groenier, KH; Kleefstra, N; Landman, GW; van Hateren, KJ, 2010) |
| "One study showed a higher risk of cancer overall in subjects with diabetes receiving insulin or sulfonylureas than in those on metformin." | 1.36 | Diabetes therapy and cancer risk: causal effects and other plausible explanations. ( Adami, HO; Hernández-Díaz, S, 2010) |
| "Type 2 diabetes mellitus is associated with increased risk of malignancy (mainly cancer of the pancreas, breast, colon, endometrium and bladder)." | 1.36 | Metformin and cancer: licence to heal? ( Maltezos, E; Mikhailidis, DP; Papanas, N, 2010) |
| "The prevalence of type 2 diabetes in Thailand is 9." | 1.36 | Thailand Diabetic Registry cohort: predicting death in Thai diabetic patients and causes of death. ( Benjasuratwong, Y; Bunnag, P; Chetthakul, T; Deerochanawong, C; Komoltri, C; Kosachunhanun, N; Krittiyawong, S; Leelawatana, R; Mongkolsomlit, S; Ngarmukos, C; Plengvidhya, N; Pratipanawatr, T; Rawdaree, P; Suwanwalaikorn, S, 2010) |
| "Cancer was diagnosed among 7." | 1.35 | New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. ( Alessi, DR; Donnan, PT; Donnelly, LA; Evans, JM; Libby, G; Morris, AD, 2009) |
| "Metformin use was associated with lower risk of cancer of the colon or pancreas, but did not affect the risk of breast or prostate cancer." | 1.35 | The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. ( Currie, CJ; Gale, EA; Poole, CD, 2009) |
| "Metformin-treated cells compensated for this suppression of oxidative phosphorylation by increasing their rate of glycolysis in a p53-dependent manner." | 1.34 | Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. ( Amaravadi, RK; Buzzai, M; DeBerardinis, RJ; Jones, RG; Lum, JJ; Thompson, CB; Viollet, B; Zhao, F, 2007) |
| "The pathogenesis of cancer anorexia is multifactorial and associated with disturbances of the central physiological mechanisms controlling food intake." | 1.34 | A central role for neuronal adenosine 5'-monophosphate-activated protein kinase in cancer-induced anorexia. ( Carvalheira, JB; de Souza, CT; Faria, MC; Morari, J; Pauli, JR; Ropelle, ER; Saad, MJ; Ueno, M; Velloso, LA; Zecchin, KG, 2007) |
| "Patients with type 2 diabetes exposed to sulfonylureas and exogenous insulin had a significantly increased risk of cancer-related mortality compared with patients exposed to metformin." | 1.33 | Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. ( Bowker, SL; Johnson, JA; Majumdar, SR; Veugelers, P, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 19 (4.05) | 29.6817 |
| 2010's | 315 (67.16) | 24.3611 |
| 2020's | 135 (28.78) | 2.80 |
| Authors | Studies |
|---|---|
| Rana, S | 1 |
| Blowers, EC | 1 |
| Natarajan, A | 1 |
| Liu, J | 4 |
| Chen, C | 3 |
| Wu, F | 3 |
| Tang, J | 1 |
| Pinto da Silva, L | 1 |
| Núnez-Montenegro, A | 1 |
| Magalhães, CM | 1 |
| Ferreira, PJO | 1 |
| Duarte, D | 1 |
| González-Berdullas, P | 1 |
| Rodríguez-Borges, JE | 1 |
| Vale, N | 1 |
| Esteves da Silva, JCG | 1 |
| Maia, M | 1 |
| Resende, DISP | 1 |
| Durães, F | 1 |
| Pinto, MMM | 1 |
| Sousa, E | 1 |
| Wang, J | 8 |
| Kim, CH | 1 |
| Hsu, SK | 1 |
| Cheng, KC | 1 |
| Mgbeahuruike, MO | 1 |
| Lin, YH | 1 |
| Wu, CY | 2 |
| Wang, HD | 1 |
| Yen, CH | 1 |
| Chiu, CC | 1 |
| Sheu, SJ | 1 |
| Wen, H | 1 |
| Fei, Y | 1 |
| Cai, R | 1 |
| Yao, X | 1 |
| Li, Y | 15 |
| Wang, X | 11 |
| Xue, C | 1 |
| Hu, Y | 1 |
| Li, M | 5 |
| Luo, Z | 3 |
| Tseng, CH | 2 |
| Tully, E | 1 |
| Bharti, S | 1 |
| Woo, J | 1 |
| Bhujwalla, Z | 1 |
| Gabrielson, E | 1 |
| Kang, J | 2 |
| Li, C | 3 |
| Gao, X | 5 |
| Liu, Z | 7 |
| Luo, D | 1 |
| Saengboonmee, C | 2 |
| Sanlung, T | 1 |
| Wongkham, S | 1 |
| Seo, HJ | 1 |
| Oh, HS | 1 |
| Zhuang, A | 2 |
| Chai, P | 1 |
| Wang, S | 6 |
| Zuo, S | 1 |
| Yu, J | 2 |
| Jia, S | 1 |
| Ge, S | 2 |
| Jia, R | 2 |
| Zhou, Y | 4 |
| Shi, W | 1 |
| Xu, X | 2 |
| Ruan, J | 1 |
| Fan, X | 1 |
| Allende-Vega, N | 1 |
| Marco Brualla, J | 1 |
| Falvo, P | 1 |
| Alexia, C | 1 |
| Constantinides, M | 1 |
| de Maudave, AF | 1 |
| Coenon, L | 1 |
| Gitenay, D | 1 |
| Mitola, G | 1 |
| Massa, P | 1 |
| Orecchioni, S | 2 |
| Bertolini, F | 2 |
| Marzo, I | 2 |
| Anel, A | 1 |
| Villalba, M | 1 |
| Ciccarese, C | 1 |
| Iacovelli, R | 1 |
| Buti, S | 1 |
| Primi, F | 1 |
| Astore, S | 1 |
| Massari, F | 1 |
| Ferrara, MG | 1 |
| Palermo, G | 1 |
| Foschi, N | 1 |
| Iacovelli, V | 1 |
| Rossi, E | 1 |
| Schinzari, G | 1 |
| Bove, P | 1 |
| Bassi, P | 1 |
| Bria, E | 1 |
| Tortora, G | 1 |
| Żyrek, L | 1 |
| Latocha, M | 1 |
| Cai, XJ | 1 |
| Zhang, JY | 1 |
| Zhang, AB | 1 |
| Zhou, X | 3 |
| Zhang, HY | 1 |
| Li, TJ | 1 |
| Chen, X | 4 |
| Sun, M | 1 |
| Yang, Z | 2 |
| Gan, X | 1 |
| Cao, C | 2 |
| He, Y | 2 |
| Hu, X | 2 |
| Peng, X | 1 |
| Su, Y | 3 |
| Aftab, S | 1 |
| Khalid, Z | 1 |
| Shakoori, AR | 1 |
| Hasanvand, A | 1 |
| Stransky, N | 1 |
| Huber, SM | 1 |
| Meng, X | 1 |
| Lu, Z | 1 |
| Lv, Q | 1 |
| Jiang, Y | 3 |
| Zhang, L | 5 |
| Wang, Z | 4 |
| Yang, Q | 1 |
| Wang, G | 1 |
| Fang, D | 1 |
| Liang, Y | 3 |
| Wang, L | 5 |
| Wu, J | 2 |
| Zeng, M | 1 |
| Luo, M | 1 |
| Xu, Y | 5 |
| Xu, T | 1 |
| Xiong, Y | 1 |
| Huang, J | 3 |
| Ali, MA | 1 |
| Khalil, MM | 1 |
| Al-Mokaddem, AK | 1 |
| Aljuaydi, SH | 1 |
| Ahmed, MM | 1 |
| Khalil, HMA | 1 |
| Gallagher, EJ | 4 |
| Kase, NG | 1 |
| Bickell, NA | 1 |
| LeRoith, D | 4 |
| Wu, XY | 1 |
| Xu, WW | 1 |
| Huan, XK | 1 |
| Wu, GN | 1 |
| Li, G | 3 |
| Zhou, YH | 1 |
| Najafi, M | 3 |
| Mu, X | 1 |
| Xiang, Z | 1 |
| He, J | 2 |
| Lu, J | 3 |
| Chen, Y | 7 |
| Tu, CR | 1 |
| Zhang, Y | 10 |
| Zhang, W | 4 |
| Yin, Z | 1 |
| Leung, WH | 1 |
| Lau, YL | 1 |
| Liu, Y | 10 |
| Tu, W | 1 |
| Vakili-Ghartavol, R | 1 |
| Mehrabian, A | 1 |
| Mirzavi, F | 1 |
| Rezayat, SM | 1 |
| Mashreghi, M | 1 |
| Farhoudi, L | 1 |
| Kharrazi, S | 1 |
| Sadri, K | 1 |
| Jaafari, MR | 1 |
| Chao, R | 1 |
| Nishida, M | 2 |
| Yamashita, N | 1 |
| Tokumasu, M | 1 |
| Zhao, W | 1 |
| Kudo, I | 1 |
| Udono, H | 5 |
| Zhao, H | 3 |
| Zhuo, L | 1 |
| Shen, P | 1 |
| Lin, H | 1 |
| Sun, Y | 3 |
| Zhan, S | 1 |
| Mostafavi, S | 1 |
| Zalpoor, H | 1 |
| Hassan, ZM | 1 |
| Chen, CJ | 1 |
| Wu, CC | 1 |
| Chang, CY | 1 |
| Li, JR | 1 |
| Ou, YC | 1 |
| Chen, WY | 1 |
| Liao, SL | 1 |
| Wang, JD | 1 |
| Jiang, T | 2 |
| Xie, L | 2 |
| Zhou, S | 2 |
| Huang, Y | 4 |
| Mei, N | 1 |
| Ma, F | 2 |
| Gong, J | 2 |
| Chen, J | 6 |
| Bora, VR | 1 |
| Gohel, D | 1 |
| Singh, R | 1 |
| Patel, BM | 1 |
| Laskovs, M | 1 |
| Partridge, L | 1 |
| Slack, C | 1 |
| Metts, JL | 1 |
| Trucco, M | 1 |
| Weiser, DA | 1 |
| Thompson, P | 1 |
| Sandler, E | 1 |
| Smith, T | 1 |
| Crimella, J | 1 |
| Sansil, S | 1 |
| Thapa, R | 1 |
| Fridley, BL | 1 |
| Llosa, N | 1 |
| Badgett, T | 1 |
| Gorlick, R | 1 |
| Reed, D | 1 |
| Gill, J | 1 |
| Wang, H | 4 |
| Zhang, M | 6 |
| Wang, R | 1 |
| Chen, H | 4 |
| Wang, B | 1 |
| Song, S | 1 |
| Wang, Y | 6 |
| Ren, Y | 2 |
| Li, J | 12 |
| Liu, P | 1 |
| Qiao, C | 1 |
| Jia, Q | 1 |
| Chen, Z | 1 |
| Liu, X | 3 |
| Zhang, R | 1 |
| Pu, K | 1 |
| Wen, J | 1 |
| Yi, Z | 1 |
| Mao, X | 1 |
| Zeng, Y | 3 |
| Cheng, Q | 2 |
| Ye, W | 1 |
| Liu, F | 1 |
| Zhou, Z | 1 |
| Jiang, X | 2 |
| Zheng, C | 1 |
| Luo, W | 1 |
| Xiang, X | 1 |
| Qi, X | 1 |
| Shen, J | 6 |
| Feng, YY | 1 |
| Pang, H | 1 |
| Mu, W | 2 |
| Liang, G | 1 |
| Feng, Y | 2 |
| Qu, F | 1 |
| Kuznetsov, KO | 1 |
| Safina, ER | 1 |
| Gaimakova, DV | 1 |
| Frolova, YS | 1 |
| Oganesyan, IY | 1 |
| Sadertdinova, AG | 1 |
| Nazmieva, KA | 1 |
| Islamgulov, AH | 1 |
| Karimova, AR | 1 |
| Galimova, AM | 1 |
| Rizvanova, EV | 1 |
| Kurelac, I | 2 |
| Cavina, B | 1 |
| Sollazzo, M | 1 |
| Miglietta, S | 1 |
| Fornasa, A | 1 |
| De Luise, M | 1 |
| Iorio, M | 2 |
| Lama, E | 1 |
| Traversa, D | 1 |
| Nasiri, HR | 1 |
| Ghelli, A | 1 |
| Musiani, F | 1 |
| Porcelli, AM | 2 |
| Iommarini, L | 1 |
| Gasparre, G | 2 |
| Goggi, JL | 1 |
| Hartimath, SV | 1 |
| Khanapur, S | 1 |
| Ramasamy, B | 1 |
| Chin, ZF | 1 |
| Cheng, P | 1 |
| Chin, HX | 1 |
| Hwang, YY | 1 |
| Robins, EG | 1 |
| Søndergaard, CS | 3 |
| Esquivel, PN | 3 |
| Dalamaga, M | 3 |
| Magkos, F | 3 |
| Naseri, A | 2 |
| Sanaie, S | 2 |
| Hamzehzadeh, S | 2 |
| Seyedi-Sahebari, S | 2 |
| Hosseini, MS | 2 |
| Gholipour-Khalili, E | 2 |
| Rezazadeh-Gavgani, E | 4 |
| Majidazar, R | 2 |
| Seraji, P | 2 |
| Daneshvar, S | 2 |
| Kang, BG | 1 |
| Shende, M | 1 |
| Inci, G | 1 |
| Park, SH | 1 |
| Jung, JS | 1 |
| Kim, SB | 1 |
| Kim, JH | 2 |
| Mo, YW | 1 |
| Seo, JH | 1 |
| Feng, JH | 1 |
| Kim, SC | 1 |
| Lim, SS | 1 |
| Suh, HW | 1 |
| Lee, JY | 1 |
| Nojima, I | 1 |
| Wada, J | 2 |
| Kostev, K | 2 |
| Li, D | 5 |
| Li, B | 3 |
| Chu, X | 1 |
| Kong, B | 1 |
| Li, GY | 1 |
| Feng, YQ | 1 |
| Jia, YF | 1 |
| Wang, KF | 1 |
| Zhang, SJ | 1 |
| Han, SX | 1 |
| Wang, JC | 1 |
| Zhang, X | 7 |
| Jiang, Q | 1 |
| Bu, L | 1 |
| Sun, Z | 3 |
| Wu, X | 2 |
| Gao, B | 1 |
| Lin, Y | 2 |
| Xie, W | 1 |
| Guo, J | 2 |
| Lord, SR | 2 |
| Harris, AL | 1 |
| Chao, Y | 1 |
| Wei, T | 1 |
| Li, Q | 2 |
| Liu, B | 1 |
| Hao, Y | 2 |
| Chen, M | 1 |
| Wu, Y | 4 |
| Song, F | 1 |
| Chen, Q | 3 |
| Zhou, F | 1 |
| Guan, J | 1 |
| Zhou, L | 5 |
| Chen, B | 3 |
| Orchard, SG | 1 |
| Lockery, JE | 1 |
| Broder, JC | 1 |
| Ernst, ME | 1 |
| Espinoza, S | 1 |
| Gibbs, P | 1 |
| Wolfe, R | 1 |
| Polekhina, G | 1 |
| Zoungas, S | 2 |
| Loomans-Kropp, HA | 1 |
| Woods, RL | 1 |
| Patel, PJ | 1 |
| Shah, JS | 1 |
| Deng, D | 1 |
| Zhu, X | 3 |
| Espinosa-Rodriguez, BA | 1 |
| Treviño-Almaguer, D | 1 |
| Carranza-Rosales, P | 1 |
| Ramirez-Cabrera, MA | 1 |
| Ramirez-Estrada, K | 1 |
| Arredondo-Espinoza, EU | 1 |
| Mendez-Lopez, LF | 1 |
| Balderas-Renteria, I | 1 |
| Jiang, H | 1 |
| Suo, H | 1 |
| Gao, L | 1 |
| Lu, S | 1 |
| Jin, F | 1 |
| Cao, Y | 1 |
| Finisguerra, V | 1 |
| Dvorakova, T | 1 |
| Formenti, M | 1 |
| Van Meerbeeck, P | 1 |
| Mignion, L | 1 |
| Gallez, B | 1 |
| Van den Eynde, BJ | 1 |
| Cheki, M | 2 |
| Mostafaei, S | 1 |
| Hanafi, MG | 1 |
| Farasat, M | 1 |
| Talaiezadeh, A | 1 |
| Ghasemi, MS | 1 |
| Modava, M | 1 |
| Abdollahi, H | 1 |
| Scarton, L | 1 |
| Nelson, T | 1 |
| Jo, A | 1 |
| O'Neal, LJ | 1 |
| Yao, Y | 3 |
| Huggins, S | 1 |
| Legaspi, AB | 1 |
| McClaren, MJ | 1 |
| Cabassa, JS | 1 |
| Burgos Melendez, JM | 1 |
| Munoz-Pena, JM | 1 |
| Markham, MJ | 1 |
| Murphy, MC | 1 |
| Chatzkel, JA | 1 |
| Rogers, S | 1 |
| George, TJ | 1 |
| Shi, D | 1 |
| Huang, L | 1 |
| Ke, S | 1 |
| Hou, Z | 1 |
| Fan, Z | 1 |
| Dickerman, BA | 1 |
| García-Albéniz, X | 1 |
| Logan, RW | 1 |
| Denaxas, S | 1 |
| Hernán, MA | 1 |
| Panikar, SS | 1 |
| Keltee, N | 1 |
| Berry, NK | 1 |
| Shmuel, S | 1 |
| Fisher, ZT | 1 |
| Brown, E | 1 |
| Zidel, A | 1 |
| Mabry, A | 1 |
| Pereira, PMR | 1 |
| Bánhegyi, RJ | 2 |
| Veréb, B | 1 |
| Mátrai, ÁA | 1 |
| Rácz, B | 1 |
| Beke, S | 1 |
| Hua, Y | 1 |
| Zheng, Y | 3 |
| Panaampon, J | 1 |
| Dutta, S | 1 |
| Shah, RB | 1 |
| Singhal, S | 1 |
| Dutta, SB | 1 |
| Bansal, S | 1 |
| Sinha, S | 1 |
| Haque, M | 1 |
| Conza, D | 1 |
| Mirra, P | 1 |
| Fiory, F | 1 |
| Insabato, L | 1 |
| Nicolò, A | 1 |
| Beguinot, F | 1 |
| Ulianich, L | 1 |
| Yang, J | 2 |
| Zhang, C | 2 |
| Zhou, D | 1 |
| Niu, R | 1 |
| Zhu, Y | 2 |
| Fu, Y | 2 |
| Ma, N | 1 |
| Luo, Y | 2 |
| Wu, Z | 1 |
| Wang, W | 3 |
| Wei, L | 2 |
| Zhu, S | 1 |
| Chong, L | 1 |
| Jiang, YW | 1 |
| Wang, D | 1 |
| Chang, P | 1 |
| Xu, K | 1 |
| Reza, R | 1 |
| Morshed, N | 1 |
| Samdani, MN | 1 |
| Reza, MS | 1 |
| Citi, V | 1 |
| Barresi, E | 1 |
| Piragine, E | 1 |
| Spezzini, J | 1 |
| Testai, L | 1 |
| Da Settimo, F | 1 |
| Martelli, A | 1 |
| Taliani, S | 1 |
| Calderone, V | 1 |
| Xu, S | 2 |
| Herschman, HR | 1 |
| Dulskas, A | 1 |
| Patasius, A | 1 |
| Linkeviciute-Ulinskiene, D | 1 |
| Zabuliene, L | 1 |
| Urbonas, V | 1 |
| Smailyte, G | 1 |
| Xu, P | 1 |
| Yin, K | 1 |
| Tang, X | 2 |
| Tian, J | 3 |
| Ma, J | 1 |
| Xu, H | 4 |
| Xu, Q | 1 |
| Saif, MW | 1 |
| Rajagopal, S | 1 |
| Caplain, J | 1 |
| Grimm, E | 1 |
| Serebrennikova, O | 1 |
| Das, M | 1 |
| Tsichlis, PN | 1 |
| Martell, R | 1 |
| Seppälä, LK | 1 |
| Vettenranta, K | 1 |
| Pitkäniemi, J | 1 |
| Hirvonen, E | 1 |
| Leinonen, MK | 1 |
| Madanat-Harjuoja, LM | 1 |
| Alsaggaf, R | 1 |
| Pfeiffer, RM | 1 |
| St George, DMM | 1 |
| Zhan, M | 1 |
| Wagner, KR | 1 |
| Amr, S | 1 |
| Greene, MH | 1 |
| Gadalla, SM | 1 |
| Dankner, R | 2 |
| Roth, J | 1 |
| Aroldi, F | 2 |
| Mekuria, AN | 1 |
| Ayele, Y | 1 |
| Tola, A | 1 |
| Mishore, KM | 1 |
| Bahrambeigi, S | 1 |
| Shafiei-Irannejad, V | 2 |
| Salvatore, T | 1 |
| Pafundi, PC | 1 |
| Morgillo, F | 1 |
| Di Liello, R | 1 |
| Galiero, R | 1 |
| Nevola, R | 1 |
| Marfella, R | 1 |
| Monaco, L | 1 |
| Rinaldi, L | 1 |
| Adinolfi, LE | 1 |
| Sasso, FC | 1 |
| Biondo, LA | 1 |
| Teixeira, AAS | 1 |
| de O S Ferreira, KC | 1 |
| Neto, JCR | 1 |
| Chen, ZX | 1 |
| Liu, MD | 1 |
| Guo, DK | 1 |
| Zou, MZ | 1 |
| Wang, SB | 1 |
| Cheng, H | 1 |
| Zhong, Z | 1 |
| Zhang, XZ | 1 |
| Marcucci, F | 1 |
| Romeo, E | 1 |
| Caserta, CA | 1 |
| Rumio, C | 1 |
| Lefoulon, F | 1 |
| Chen, K | 2 |
| Guo, Z | 1 |
| Bartlett, F | 1 |
| January, S | 1 |
| Pottebaum, A | 1 |
| Horwedel, T | 1 |
| Malone, AF | 1 |
| Yurova, MN | 2 |
| Xie, J | 1 |
| Ye, J | 2 |
| Cai, Z | 1 |
| Deng, Y | 1 |
| Liu, R | 1 |
| Han, Z | 1 |
| Mo, R | 1 |
| Zhuo, Y | 1 |
| Jiang, F | 2 |
| Zhu, J | 4 |
| Wu, CL | 1 |
| Zhong, W | 1 |
| Zheng, Z | 1 |
| Bian, Y | 1 |
| Ren, G | 1 |
| Pácal, L | 1 |
| Kaňková, K | 1 |
| Püschel, F | 1 |
| Favaro, F | 1 |
| Redondo-Pedraza, J | 1 |
| Lucendo, E | 1 |
| Iurlaro, R | 1 |
| Marchetti, S | 1 |
| Majem, B | 1 |
| Eldering, E | 1 |
| Nadal, E | 1 |
| Ricci, JE | 1 |
| Chevet, E | 1 |
| Muñoz-Pinedo, C | 1 |
| Zhao, B | 1 |
| Luo, J | 3 |
| Yu, T | 1 |
| Lv, H | 1 |
| Shang, P | 1 |
| Ugwueze, CV | 1 |
| Ogamba, OJ | 1 |
| Young, EE | 1 |
| Onyenekwe, BM | 1 |
| Ezeokpo, BC | 1 |
| Lv, Z | 1 |
| Guo, Y | 1 |
| Chen, GG | 1 |
| Woo, PYM | 1 |
| Ng, SCP | 1 |
| Wong, GKC | 1 |
| Chan, DTM | 1 |
| van Hasselt, CA | 1 |
| Tong, MCF | 1 |
| Poon, WS | 1 |
| Wong, CKH | 1 |
| Man, KKC | 1 |
| Chan, EWY | 1 |
| Wu, T | 2 |
| Tse, ETY | 1 |
| Wong, ICK | 2 |
| Lam, CLK | 1 |
| Zhang, K | 1 |
| Bai, P | 1 |
| Dai, H | 1 |
| Deng, Z | 1 |
| Lemanska, A | 1 |
| Byford, RC | 1 |
| Cruickshank, C | 1 |
| Dearnaley, DP | 1 |
| Ferreira, F | 1 |
| Griffin, C | 1 |
| Hall, E | 1 |
| Hinton, W | 1 |
| de Lusignan, S | 1 |
| Sherlock, J | 1 |
| Faithfull, S | 1 |
| Kim, K | 1 |
| Yang, WH | 1 |
| Jung, YS | 1 |
| Cha, JH | 1 |
| Luo, S | 1 |
| Schooling, CM | 1 |
| Au Yeung, SL | 1 |
| Kim, YS | 3 |
| Choi, EA | 2 |
| Lee, JW | 2 |
| Kim, Y | 5 |
| You, HS | 2 |
| Han, YE | 2 |
| Kim, HS | 3 |
| Bae, YJ | 2 |
| Kang, HT | 2 |
| Kim, J | 2 |
| Ma, Y | 3 |
| Zhu, Q | 1 |
| Liang, J | 2 |
| Jiao, Y | 1 |
| Zhang, N | 1 |
| Tan, Y | 1 |
| Yan, L | 1 |
| Xu, M | 2 |
| Guo, H | 1 |
| Zhuang, B | 1 |
| Xie, X | 2 |
| Jin, MZ | 1 |
| Jin, WL | 1 |
| Nguépy Keubo, FR | 1 |
| Mboua, PC | 1 |
| Djifack Tadongfack, T | 1 |
| Fokouong Tchoffo, E | 1 |
| Tasson Tatang, C | 1 |
| Ide Zeuna, J | 1 |
| Noupoue, EM | 1 |
| Tsoplifack, CB | 1 |
| Folefack, GO | 1 |
| Kettani, M | 1 |
| Bandelier, P | 1 |
| Huo, J | 1 |
| Li, H | 6 |
| Yu, D | 1 |
| Arulsamy, N | 1 |
| AlAbbad, S | 1 |
| Sardot, T | 1 |
| Lekashvili, O | 1 |
| Decato, D | 1 |
| Lelj, F | 1 |
| Alexander Ross, JB | 1 |
| Rosenberg, E | 1 |
| Nazir, H | 1 |
| Muthuswamy, N | 1 |
| Louis, C | 1 |
| Jose, S | 1 |
| Prakash, J | 1 |
| Buan, MEM | 1 |
| Flox, C | 1 |
| Chavan, S | 1 |
| Shi, X | 1 |
| Kauranen, P | 1 |
| Kallio, T | 1 |
| Maia, G | 1 |
| Tammeveski, K | 1 |
| Lymperopoulos, N | 1 |
| Carcadea, E | 1 |
| Veziroglu, E | 1 |
| Iranzo, A | 1 |
| M Kannan, A | 1 |
| Arunamata, A | 1 |
| Tacy, TA | 1 |
| Kache, S | 1 |
| Mainwaring, RD | 1 |
| Ma, M | 1 |
| Maeda, K | 1 |
| Punn, R | 1 |
| Noguchi, S | 1 |
| Hahn, S | 3 |
| Iwasa, Y | 3 |
| Ling, J | 2 |
| Voccio, JP | 2 |
| Song, J | 3 |
| Bascuñán, J | 2 |
| Chu, Y | 1 |
| Tomita, M | 1 |
| Cazorla, M | 1 |
| Herrera, E | 1 |
| Palomeque, E | 1 |
| Saud, N | 1 |
| Hoplock, LB | 1 |
| Lobchuk, MM | 1 |
| Lemoine, J | 1 |
| Li, X | 12 |
| Henson, MA | 1 |
| Unsihuay, D | 1 |
| Qiu, J | 1 |
| Swaroop, S | 1 |
| Nagornov, KO | 1 |
| Kozhinov, AN | 1 |
| Tsybin, YO | 1 |
| Kuang, S | 1 |
| Laskin, J | 1 |
| Zin, NNINM | 1 |
| Mohamad, MN | 1 |
| Roslan, K | 1 |
| Abdul Wafi, S | 1 |
| Abdul Moin, NI | 1 |
| Alias, A | 1 |
| Zakaria, Y | 1 |
| Abu-Bakar, N | 1 |
| Naveed, A | 1 |
| Jilani, K | 1 |
| Siddique, AB | 1 |
| Akbar, M | 1 |
| Riaz, M | 1 |
| Mushtaq, Z | 1 |
| Sikandar, M | 1 |
| Ilyas, S | 1 |
| Bibi, I | 1 |
| Asghar, A | 1 |
| Rasool, G | 1 |
| Irfan, M | 1 |
| Li, XY | 1 |
| Zhao, S | 1 |
| Fan, XH | 1 |
| Chen, KP | 1 |
| Hua, W | 1 |
| Liu, ZM | 1 |
| Xue, XD | 1 |
| Zhou, B | 2 |
| Zhang, S | 3 |
| Xing, YL | 1 |
| Chen, MA | 1 |
| Neradilek, MB | 1 |
| Wu, XT | 1 |
| Zhang, D | 3 |
| Huang, W | 1 |
| Cui, Y | 1 |
| Yang, QQ | 1 |
| Li, HW | 1 |
| Zhao, XQ | 1 |
| Hossein Rashidi, B | 1 |
| Tarafdari, A | 1 |
| Ghazimirsaeed, ST | 1 |
| Shahrokh Tehraninezhad, E | 1 |
| Keikha, F | 1 |
| Eslami, B | 1 |
| Ghazimirsaeed, SM | 1 |
| Jafarabadi, M | 1 |
| Silvani, Y | 1 |
| Lovita, AND | 1 |
| Maharani, A | 1 |
| Wiyasa, IWA | 1 |
| Sujuti, H | 1 |
| Ratnawati, R | 1 |
| Raras, TYM | 1 |
| Lemin, AS | 1 |
| Rahman, MM | 1 |
| Pangarah, CA | 1 |
| Kiyu, A | 1 |
| Zeng, C | 2 |
| Du, H | 1 |
| Lin, D | 1 |
| Jalan, D | 1 |
| Rubagumya, F | 1 |
| Hopman, WM | 1 |
| Vanderpuye, V | 1 |
| Lopes, G | 1 |
| Seruga, B | 1 |
| Booth, CM | 1 |
| Berry, S | 1 |
| Hammad, N | 1 |
| Sajo, EA | 1 |
| Okunade, KS | 1 |
| Olorunfemi, G | 1 |
| Rabiu, KA | 1 |
| Anorlu, RI | 1 |
| Xu, C | 2 |
| Xiang, Y | 1 |
| Dong, X | 1 |
| Tang, S | 1 |
| Gao, XC | 1 |
| Wei, CH | 1 |
| Zhang, RG | 1 |
| Cai, Q | 1 |
| Tong, F | 1 |
| Dong, JH | 1 |
| Wu, G | 1 |
| Dong, XR | 1 |
| Tao, F | 1 |
| Xiang, W | 1 |
| Zhao, Y | 3 |
| Jin, L | 1 |
| Tao, H | 1 |
| Lei, Y | 2 |
| Gan, H | 1 |
| Chen, L | 5 |
| Shan, A | 1 |
| Wu, M | 2 |
| Ma, Q | 1 |
| Zhang, E | 1 |
| Zhang, J | 5 |
| Xue, F | 1 |
| Deng, L | 1 |
| Liu, L | 2 |
| Yan, Z | 2 |
| Meng, J | 1 |
| Chen, G | 2 |
| Anastassiadou, M | 1 |
| Bernasconi, G | 1 |
| Brancato, A | 1 |
| Carrasco Cabrera, L | 1 |
| Greco, L | 1 |
| Jarrah, S | 1 |
| Kazocina, A | 1 |
| Leuschner, R | 1 |
| Magrans, JO | 1 |
| Miron, I | 1 |
| Nave, S | 1 |
| Pedersen, R | 1 |
| Reich, H | 1 |
| Rojas, A | 1 |
| Sacchi, A | 1 |
| Santos, M | 1 |
| Theobald, A | 1 |
| Vagenende, B | 1 |
| Verani, A | 1 |
| Du, L | 1 |
| Li, P | 1 |
| Jiao, Q | 1 |
| Meng, P | 1 |
| Wang, F | 2 |
| Wang, YS | 1 |
| Wang, C | 4 |
| Hou, J | 1 |
| Zhang, A | 1 |
| Lv, B | 1 |
| Gao, C | 1 |
| Pang, D | 1 |
| Lu, K | 1 |
| Ahmad, NH | 1 |
| Zhuang, T | 1 |
| Tu, J | 1 |
| Zhao, Z | 3 |
| Qu, Y | 1 |
| Yao, H | 2 |
| Lee, DF | 1 |
| Wen, L | 1 |
| Huang, G | 3 |
| Zhao, Q | 2 |
| Hu, W | 1 |
| Li, W | 3 |
| Wu, W | 1 |
| Du, F | 1 |
| Ji, H | 1 |
| Yang, X | 9 |
| Xu, Z | 1 |
| Wan, L | 1 |
| Wen, Q | 1 |
| Cho, CH | 1 |
| Zou, C | 1 |
| Xiao, Z | 1 |
| Liao, J | 1 |
| Su, X | 1 |
| Bi, Z | 1 |
| Su, Q | 2 |
| Huang, H | 1 |
| Wei, Y | 2 |
| Gao, Y | 2 |
| Na, KJ | 1 |
| Choi, H | 1 |
| Oh, HR | 1 |
| Kim, YH | 1 |
| Lee, SB | 1 |
| Jung, YJ | 1 |
| Koh, J | 1 |
| Park, S | 1 |
| Lee, HJ | 1 |
| Jeon, YK | 1 |
| Chung, DH | 1 |
| Paeng, JC | 1 |
| Park, IK | 1 |
| Kang, CH | 1 |
| Cheon, GJ | 1 |
| Kang, KW | 1 |
| Lee, DS | 1 |
| Kim, YT | 1 |
| Pajuelo-Lozano, N | 1 |
| Alcalá, S | 1 |
| Sainz, B | 1 |
| Perona, R | 1 |
| Sanchez-Perez, I | 1 |
| Logotheti, S | 1 |
| Marquardt, S | 1 |
| Gupta, SK | 1 |
| Richter, C | 1 |
| Edelhäuser, BAH | 1 |
| Engelmann, D | 1 |
| Brenmoehl, J | 1 |
| Söhnchen, C | 1 |
| Murr, N | 1 |
| Alpers, M | 1 |
| Singh, KP | 1 |
| Wolkenhauer, O | 1 |
| Heckl, D | 1 |
| Spitschak, A | 1 |
| Pützer, BM | 1 |
| Liao, Y | 1 |
| Cheng, J | 1 |
| Kong, X | 1 |
| Li, S | 2 |
| Zhang, H | 2 |
| Yang, T | 3 |
| Dong, Y | 1 |
| Yuan, Z | 1 |
| Cao, J | 1 |
| Mei, Z | 1 |
| Liang, C | 1 |
| Yang, H | 1 |
| Song, Y | 1 |
| Yu, K | 1 |
| Zhu, C | 1 |
| Huang, Z | 1 |
| Qian, J | 1 |
| Ge, J | 1 |
| Hu, J | 2 |
| Mi, Y | 1 |
| Kong, H | 1 |
| Xi, D | 1 |
| Yan, W | 1 |
| Luo, X | 1 |
| Ning, Q | 1 |
| Chang, X | 2 |
| Zhang, T | 2 |
| Wang, Q | 2 |
| Rathore, MG | 1 |
| Reddy, K | 1 |
| Shin, SH | 1 |
| Ma, WY | 1 |
| Bode, AM | 1 |
| Dong, Z | 2 |
| Liu, C | 4 |
| Gao, F | 1 |
| Qi, Y | 1 |
| Lu, H | 2 |
| Cai, X | 1 |
| Ji, RY | 1 |
| Hou, Y | 4 |
| Shi, Y | 2 |
| Ying, S | 1 |
| Tan, M | 2 |
| Feng, G | 1 |
| Kuang, Y | 1 |
| Chen, D | 2 |
| Wu, D | 4 |
| Zhu, ZQ | 1 |
| Tang, HX | 1 |
| Shi, ZE | 1 |
| Liu, Q | 1 |
| Qi, J | 2 |
| Mu, J | 1 |
| Cong, Z | 1 |
| Chen, S | 3 |
| Fu, D | 1 |
| Li, Z | 3 |
| Celestrin, CP | 1 |
| Rocha, GZ | 2 |
| Stein, AM | 1 |
| Guadagnini, D | 1 |
| Tadelle, RM | 1 |
| Saad, MJA | 1 |
| Oliveira, AG | 1 |
| Bianconi, V | 1 |
| Bronzo, P | 1 |
| Banach, M | 1 |
| Sahebkar, A | 1 |
| Mannarino, MR | 1 |
| Pirro, M | 1 |
| Patsourakos, NG | 1 |
| Kouvari, M | 1 |
| Kotidis, A | 1 |
| Kalantzi, KI | 1 |
| Tsoumani, ME | 1 |
| Anastasiadis, F | 1 |
| Andronikos, P | 1 |
| Aslanidou, T | 1 |
| Efraimidis, P | 1 |
| Georgiopoulos, A | 1 |
| Gerakiou, K | 1 |
| Grigoriadou-Skouta, E | 1 |
| Grigoropoulos, P | 1 |
| Hatzopoulos, D | 1 |
| Kartalis, A | 1 |
| Lyras, A | 1 |
| Markatos, G | 1 |
| Mikrogeorgiou, A | 1 |
| Myroforou, I | 1 |
| Orkopoulos, A | 1 |
| Pavlidis, P | 1 |
| Petras, C | 1 |
| Riga, M | 1 |
| Skouloudi, M | 1 |
| Smyrnioudis, N | 1 |
| Thomaidis, K | 1 |
| Tsikouri, GE | 1 |
| Tsikouris, EI | 1 |
| Zisimos, K | 1 |
| Vavoulis, P | 1 |
| Vitali, MG | 1 |
| Vitsas, G | 1 |
| Vogiatzidis, C | 1 |
| Chantanis, S | 1 |
| Fousas, S | 1 |
| Panagiotakos, DB | 1 |
| Tselepis, AD | 1 |
| Jungen, C | 1 |
| Alken, FA | 1 |
| Eickholt, C | 1 |
| Scherschel, K | 1 |
| Kuklik, P | 1 |
| Klatt, N | 1 |
| Schwarzl, J | 1 |
| Moser, J | 1 |
| Jularic, M | 1 |
| Akbulak, RO | 1 |
| Schaeffer, B | 1 |
| Willems, S | 1 |
| Meyer, C | 1 |
| Nowak, JK | 1 |
| Szczepanik, M | 1 |
| Trypuć, M | 1 |
| Pogorzelski, A | 1 |
| Bobkowski, W | 1 |
| Grytczuk, M | 1 |
| Minarowska, A | 1 |
| Wójciak, R | 1 |
| Walkowiak, J | 1 |
| Lu, Y | 3 |
| Xi, J | 1 |
| Chen, W | 2 |
| Zhang, F | 2 |
| Wei, H | 1 |
| Gurzu, S | 1 |
| Jung, I | 1 |
| Sugimura, H | 2 |
| Stefan-van Staden, RI | 1 |
| Yamada, H | 1 |
| Natsume, H | 1 |
| Iwashita, Y | 1 |
| Szodorai, R | 1 |
| Szederjesi, J | 1 |
| Yari, D | 1 |
| Ehsanbakhsh, Z | 1 |
| Validad, MH | 1 |
| Langroudi, FH | 1 |
| Esfandiari, H | 1 |
| Prager, A | 1 |
| Hassanpour, K | 1 |
| Kurup, SP | 1 |
| Mets-Halgrimson, R | 1 |
| Yoon, H | 1 |
| Zeid, JL | 1 |
| Mets, MB | 1 |
| Rahmani, B | 1 |
| Araujo-Castillo, RV | 1 |
| Culquichicón, C | 1 |
| Solis Condor, R | 1 |
| Efendi, F | 1 |
| Sebayang, SK | 1 |
| Astutik, E | 1 |
| Hadisuyatmana, S | 1 |
| Has, EMM | 1 |
| Kuswanto, H | 1 |
| Foroutan, T | 1 |
| Ahmadi, F | 1 |
| Moayer, F | 1 |
| Khalvati, S | 1 |
| Zhang, Q | 2 |
| Lyu, Y | 1 |
| Yu, N | 1 |
| Wen, Z | 1 |
| Hou, H | 1 |
| Zhao, T | 1 |
| Gupta, A | 1 |
| Khosla, N | 1 |
| Govindasamy, V | 1 |
| Saini, A | 1 |
| Annapurna, K | 1 |
| Dhakate, SR | 1 |
| Akkaya, Ö | 1 |
| Chandgude, AL | 1 |
| Dömling, A | 1 |
| Harnett, J | 1 |
| Oakes, K | 1 |
| Carè, J | 1 |
| Leach, M | 1 |
| Brown, D | 1 |
| Cramer, H | 1 |
| Pinder, TA | 1 |
| Steel, A | 1 |
| Anheyer, D | 1 |
| Cantu, J | 1 |
| Valle, J | 1 |
| Flores, K | 1 |
| Gonzalez, D | 1 |
| Valdes, C | 1 |
| Lopez, J | 1 |
| Padilla, V | 1 |
| Alcoutlabi, M | 1 |
| Parsons, J | 1 |
| Núñez, K | 1 |
| Hamed, M | 1 |
| Fort, D | 1 |
| Bruce, D | 1 |
| Thevenot, P | 1 |
| Cohen, A | 1 |
| Weber, P | 1 |
| Menezes, AMB | 1 |
| Gonçalves, H | 1 |
| Perez-Padilla, R | 1 |
| Jarvis, D | 1 |
| de Oliveira, PD | 1 |
| Wehrmeister, FC | 1 |
| Mir, S | 1 |
| Wong, J | 1 |
| Ryan, CM | 1 |
| Bellingham, G | 1 |
| Singh, M | 2 |
| Waseem, R | 1 |
| Eckert, DJ | 1 |
| Chung, F | 1 |
| Hegde, H | 1 |
| Shimpi, N | 1 |
| Panny, A | 1 |
| Glurich, I | 3 |
| Christie, P | 1 |
| Acharya, A | 1 |
| English, KL | 1 |
| Downs, M | 1 |
| Goetchius, E | 1 |
| Buxton, R | 1 |
| Ryder, JW | 1 |
| Ploutz-Snyder, R | 1 |
| Guilliams, M | 1 |
| Scott, JM | 1 |
| Ploutz-Snyder, LL | 1 |
| Martens, C | 1 |
| Goplen, FK | 1 |
| Aasen, T | 1 |
| Gjestad, R | 1 |
| Nordfalk, KF | 1 |
| Nordahl, SHG | 1 |
| Inoue, T | 1 |
| Soshi, S | 1 |
| Kubota, M | 1 |
| Marumo, K | 1 |
| Mortensen, NP | 1 |
| Caffaro, MM | 1 |
| Patel, PR | 2 |
| Uddin, MJ | 1 |
| Aravamudhan, S | 1 |
| Sumner, SJ | 1 |
| Fennell, TR | 1 |
| Gal, RL | 1 |
| Cohen, NJ | 1 |
| Kruger, D | 1 |
| Beck, RW | 1 |
| Bergenstal, RM | 1 |
| Calhoun, P | 1 |
| Cushman, T | 1 |
| Haban, A | 1 |
| Hood, K | 1 |
| Johnson, ML | 1 |
| McArthur, T | 1 |
| Olson, BA | 1 |
| Weinstock, RS | 1 |
| Oser, SM | 1 |
| Oser, TK | 1 |
| Bugielski, B | 1 |
| Strayer, H | 1 |
| Aleppo, G | 1 |
| Maruyama, H | 1 |
| Hirayama, K | 1 |
| Yamashita, M | 1 |
| Ohgi, K | 1 |
| Tsujimoto, R | 1 |
| Takayasu, M | 1 |
| Shimohata, H | 1 |
| Kobayashi, M | 1 |
| Buscagan, TM | 1 |
| Rees, DC | 1 |
| Jaborek, JR | 1 |
| Zerby, HN | 1 |
| Wick, MP | 1 |
| Fluharty, FL | 1 |
| Moeller, SJ | 1 |
| Razavi, P | 1 |
| Dickler, MN | 1 |
| Shah, PD | 1 |
| Toy, W | 1 |
| Brown, DN | 1 |
| Won, HH | 1 |
| Li, BT | 1 |
| Shen, R | 1 |
| Vasan, N | 1 |
| Modi, S | 1 |
| Jhaveri, K | 1 |
| Caravella, BA | 1 |
| Patil, S | 1 |
| Selenica, P | 1 |
| Zamora, S | 1 |
| Cowan, AM | 1 |
| Comen, E | 1 |
| Singh, A | 2 |
| Covey, A | 1 |
| Berger, MF | 1 |
| Hudis, CA | 1 |
| Norton, L | 1 |
| Nagy, RJ | 1 |
| Odegaard, JI | 1 |
| Lanman, RB | 1 |
| Solit, DB | 1 |
| Robson, ME | 1 |
| Lacouture, ME | 1 |
| Brogi, E | 1 |
| Reis-Filho, JS | 1 |
| Moynahan, ME | 1 |
| Scaltriti, M | 1 |
| Chandarlapaty, S | 1 |
| Papouskova, K | 1 |
| Moravcova, M | 1 |
| Masrati, G | 1 |
| Ben-Tal, N | 1 |
| Sychrova, H | 1 |
| Zimmermannova, O | 1 |
| Fang, J | 1 |
| Fan, Y | 1 |
| Luo, T | 2 |
| Su, H | 1 |
| Tsetseris, L | 1 |
| Anthopoulos, TD | 1 |
| Liu, SF | 1 |
| Zhao, K | 1 |
| Sacan, O | 1 |
| Turkyilmaz, IB | 1 |
| Bayrak, BB | 1 |
| Mutlu, O | 1 |
| Akev, N | 1 |
| Yanardag, R | 1 |
| Gruber, S | 1 |
| Kamnoedboon, P | 1 |
| Özcan, M | 1 |
| Srinivasan, M | 1 |
| Jo, YH | 1 |
| Oh, HK | 1 |
| Jeong, SY | 1 |
| Lee, BG | 1 |
| Zheng, J | 1 |
| Guan, H | 1 |
| Tan, H | 1 |
| Maji, TK | 1 |
| J R, A | 1 |
| Mukherjee, S | 1 |
| Alexander, R | 1 |
| Mondal, A | 1 |
| Das, S | 1 |
| Sharma, RK | 1 |
| Chakraborty, NK | 1 |
| Dasgupta, K | 1 |
| Sharma, AMR | 1 |
| Hawaldar, R | 1 |
| Pandey, M | 1 |
| Naik, A | 1 |
| Majumdar, K | 1 |
| Pal, SK | 1 |
| Adarsh, KV | 1 |
| Ray, SK | 1 |
| Karmakar, D | 1 |
| Gao, W | 1 |
| Ma, S | 1 |
| Lin, W | 1 |
| Zhou, T | 1 |
| Wu, Q | 1 |
| Ye, C | 1 |
| He, X | 1 |
| Yuan, D | 1 |
| Hong, M | 1 |
| Hussain, M | 1 |
| Razi, SS | 1 |
| Yildiz, EA | 1 |
| Zhao, J | 1 |
| Yaglioglu, HG | 1 |
| Donato, MD | 1 |
| Jiang, J | 1 |
| Jamil, MI | 1 |
| Zhan, X | 1 |
| Chen, F | 1 |
| Cheng, D | 1 |
| Wu, CT | 1 |
| Utsunomiya, T | 1 |
| Ichii, T | 1 |
| Fujinami, S | 1 |
| Nakajima, K | 1 |
| Sanchez, DM | 1 |
| Raucci, U | 1 |
| Ferreras, KN | 1 |
| Martínez, TJ | 1 |
| Mordi, NA | 1 |
| Mordi, IR | 1 |
| Singh, JS | 1 |
| McCrimmon, RJ | 1 |
| Struthers, AD | 1 |
| Lang, CC | 1 |
| Wang, XW | 1 |
| Yuan, LJ | 1 |
| Yang, Y | 3 |
| Chen, WF | 1 |
| Luo, R | 1 |
| Yang, K | 1 |
| Amarasiri, SS | 1 |
| Attanayake, AP | 1 |
| Arawwawala, LDAM | 1 |
| Jayatilaka, KAPW | 1 |
| Mudduwa, LKB | 1 |
| Ogunsuyi, O | 2 |
| Akanni, O | 1 |
| Alabi, O | 1 |
| Alimba, C | 1 |
| Adaramoye, O | 1 |
| Cambier, S | 1 |
| Eswara, S | 1 |
| Gutleb, AC | 1 |
| Bakare, A | 1 |
| Gu, Z | 1 |
| Cong, J | 1 |
| Pellegrini, M | 1 |
| Palmieri, S | 1 |
| Ricci, A | 1 |
| Serio, A | 1 |
| Paparella, A | 1 |
| Lo Sterzo, C | 1 |
| Jadeja, SD | 1 |
| Vaishnav, J | 1 |
| Mansuri, MS | 1 |
| Shah, C | 1 |
| Mayatra, JM | 1 |
| Shah, A | 2 |
| Begum, R | 1 |
| Song, H | 2 |
| Lian, Y | 1 |
| Wan, T | 1 |
| Schultz-Lebahn, A | 1 |
| Skipper, MT | 1 |
| Hvas, AM | 1 |
| Larsen, OH | 1 |
| Hijazi, Z | 1 |
| Granger, CB | 1 |
| Hohnloser, SH | 1 |
| Westerbergh, J | 1 |
| Lindbäck, J | 1 |
| Alexander, JH | 1 |
| Keltai, M | 2 |
| Parkhomenko, A | 1 |
| López-Sendón, JL | 1 |
| Lopes, RD | 1 |
| Siegbahn, A | 1 |
| Wallentin, L | 1 |
| El-Tarabany, MS | 1 |
| Saleh, AA | 1 |
| El-Araby, IE | 1 |
| El-Magd, MA | 1 |
| van Ginkel, MPH | 1 |
| Schijven, MP | 1 |
| van Grevenstein, WMU | 1 |
| Schreuder, HWR | 1 |
| Pereira, EDM | 1 |
| da Silva, J | 1 |
| Carvalho, PDS | 1 |
| Grivicich, I | 1 |
| Picada, JN | 1 |
| Salgado Júnior, IB | 1 |
| Vasques, GJ | 1 |
| Pereira, MADS | 1 |
| Reginatto, FH | 1 |
| Ferraz, ABF | 1 |
| Vasilenko, EA | 1 |
| Gorshkova, EN | 1 |
| Astrakhantseva, IV | 1 |
| Drutskaya, MS | 1 |
| Tillib, SV | 1 |
| Nedospasov, SA | 1 |
| Mokhonov, VV | 1 |
| Nam, YW | 1 |
| Cui, M | 1 |
| Orfali, R | 1 |
| Viegas, A | 1 |
| Nguyen, M | 1 |
| Mohammed, EHM | 1 |
| Zoghebi, KA | 1 |
| Rahighi, S | 1 |
| Parang, K | 1 |
| Patterson, KC | 1 |
| Kahanovitch, U | 1 |
| Gonçalves, CM | 1 |
| Hablitz, JJ | 1 |
| Staruschenko, A | 1 |
| Mulkey, DK | 1 |
| Olsen, ML | 1 |
| Gu, L | 1 |
| Cao, X | 1 |
| Mukhtar, A | 1 |
| Wu, K | 1 |
| Zhang, YY | 1 |
| Lu, DZ | 1 |
| Dong, W | 2 |
| Bi, WJ | 1 |
| Feng, XJ | 1 |
| Wen, LM | 1 |
| Sun, H | 1 |
| Qi, MC | 1 |
| Chang, CC | 1 |
| Dinh, TK | 1 |
| Lee, YA | 1 |
| Wang, FN | 1 |
| Sung, YC | 1 |
| Yu, PL | 1 |
| Chiu, SC | 1 |
| Shih, YC | 1 |
| Huang, YD | 1 |
| Lu, TT | 1 |
| Wan, D | 1 |
| Sakizadeh, J | 1 |
| Cline, JP | 1 |
| Snyder, MA | 1 |
| Kiely, CJ | 1 |
| McIntosh, S | 1 |
| Cao, JW | 1 |
| Zhao, CK | 1 |
| Yang, R | 1 |
| Zhang, QY | 1 |
| Chen, KJ | 2 |
| Liu, H | 4 |
| He, Z | 1 |
| Du, X | 1 |
| Moore, J | 1 |
| Blank, BR | 1 |
| Eksterowicz, J | 1 |
| Sutimantanapi, D | 1 |
| Yuen, N | 1 |
| Metzger, T | 1 |
| Chan, B | 1 |
| Huang, T | 1 |
| Duong, F | 1 |
| Kong, W | 1 |
| Chang, JH | 1 |
| Sun, J | 2 |
| Zavorotinskaya, T | 1 |
| Ye, Q | 1 |
| Junttila, MR | 1 |
| Ndubaku, C | 1 |
| Friedman, LS | 1 |
| Fantin, VR | 1 |
| Sun, D | 1 |
| Fei, P | 1 |
| Xie, Q | 1 |
| Feng, H | 1 |
| Chang, Y | 1 |
| Kang, H | 1 |
| Xing, M | 1 |
| Shao, Z | 1 |
| Yuan, C | 1 |
| Allan, R | 1 |
| Canham, K | 1 |
| Wallace, R | 1 |
| Singh, D | 1 |
| Ward, J | 1 |
| Cooper, A | 1 |
| Newcomb, C | 1 |
| Nammour, S | 1 |
| El Mobadder, M | 1 |
| Maalouf, E | 1 |
| Namour, M | 1 |
| Namour, A | 1 |
| Rey, G | 1 |
| Matamba, P | 1 |
| Matys, J | 1 |
| Zeinoun, T | 1 |
| Grzech-Leśniak, K | 1 |
| Segabinazi Peserico, C | 1 |
| Garozi, L | 1 |
| Zagatto, AM | 1 |
| Machado, FA | 1 |
| Hirth, JM | 1 |
| Dinehart, EE | 1 |
| Lin, YL | 1 |
| Kuo, YF | 1 |
| Nouri, SS | 1 |
| Ritchie, C | 1 |
| Volow, A | 1 |
| McSpadden, S | 1 |
| Dearman, K | 1 |
| Kotwal, A | 1 |
| Sudore, RL | 1 |
| Ward, L | 1 |
| Thakur, A | 1 |
| Kondadasula, SV | 1 |
| Ji, K | 1 |
| Schalk, DL | 1 |
| Bliemeister, E | 1 |
| Ung, J | 1 |
| Aboukameel, A | 1 |
| Casarez, E | 1 |
| Sloane, BF | 1 |
| Lum, LG | 1 |
| Xiao, M | 2 |
| Feng, X | 1 |
| Gao, R | 2 |
| Du, B | 1 |
| Brooks, T | 1 |
| Zwirner, J | 1 |
| Hammer, N | 1 |
| Ondruschka, B | 1 |
| Jermy, M | 1 |
| Luengo, A | 3 |
| Reback, M | 1 |
| Daubit, IM | 1 |
| Fernández-Moreira, V | 1 |
| Metzler-Nolte, N | 1 |
| Gimeno, MC | 1 |
| Tonchev, I | 1 |
| Heberman, D | 1 |
| Peretz, A | 1 |
| Medvedovsky, AT | 1 |
| Gotsman, I | 1 |
| Rashi, Y | 1 |
| Poles, L | 1 |
| Goland, S | 1 |
| Perlman, GY | 1 |
| Danenberg, HD | 1 |
| Beeri, R | 1 |
| Shuvy, M | 1 |
| Fu, Q | 1 |
| Yang, D | 1 |
| Sarapulova, A | 1 |
| Pang, Q | 1 |
| Meng, Y | 1 |
| Ehrenberg, H | 1 |
| Kim, CC | 1 |
| Jeong, SH | 1 |
| Oh, KH | 1 |
| Nam, KT | 1 |
| Sun, JY | 1 |
| Ning, J | 1 |
| Duan, Z | 1 |
| Kershaw, SV | 1 |
| Rogach, AL | 1 |
| Gao, Z | 1 |
| Wang, T | 1 |
| Cao, T | 1 |
| Guo, L | 1 |
| Seeger, ZL | 1 |
| Izgorodina, EI | 1 |
| Hue, S | 1 |
| Beldi-Ferchiou, A | 1 |
| Bendib, I | 1 |
| Surenaud, M | 1 |
| Fourati, S | 1 |
| Frapard, T | 1 |
| Rivoal, S | 1 |
| Razazi, K | 1 |
| Carteaux, G | 1 |
| Delfau-Larue, MH | 1 |
| Mekontso-Dessap, A | 1 |
| Audureau, E | 1 |
| de Prost, N | 1 |
| Gao, SS | 1 |
| Duangthip, D | 1 |
| Lo, ECM | 1 |
| Chu, CH | 1 |
| Roberts, W | 1 |
| Rosenheck, RA | 1 |
| Miyake, T | 1 |
| Kimoto, E | 1 |
| Luo, L | 1 |
| Mathialagan, S | 1 |
| Horlbogen, LM | 1 |
| Ramanathan, R | 1 |
| Wood, LS | 1 |
| Johnson, JG | 1 |
| Le, VH | 1 |
| Vourvahis, M | 1 |
| Rodrigues, AD | 1 |
| Muto, C | 1 |
| Furihata, K | 1 |
| Sugiyama, Y | 1 |
| Kusuhara, H | 1 |
| Gong, Q | 1 |
| Song, W | 1 |
| Sun, B | 1 |
| Cao, P | 1 |
| Gu, S | 1 |
| Sun, X | 1 |
| Zhou, G | 1 |
| Toma, C | 1 |
| Khandhar, S | 1 |
| Zalewski, AM | 1 |
| D'Auria, SJ | 1 |
| Tu, TM | 1 |
| Jaber, WA | 1 |
| Cho, J | 2 |
| Suwandaratne, NS | 1 |
| Razek, S | 1 |
| Choi, YH | 1 |
| Piper, LFJ | 1 |
| Watson, DF | 1 |
| Banerjee, S | 1 |
| Xie, S | 1 |
| Lindsay, AP | 1 |
| Bates, FS | 1 |
| Lodge, TP | 1 |
| Chapovetsky, A | 1 |
| Liu, JJ | 1 |
| Welborn, M | 1 |
| Luna, JM | 1 |
| Do, T | 1 |
| Haiges, R | 1 |
| Miller Iii, TF | 1 |
| Marinescu, SC | 1 |
| Lopez, SA | 1 |
| Compter, I | 1 |
| Eekers, DBP | 1 |
| Hoeben, A | 1 |
| Rouschop, KMA | 1 |
| Reymen, B | 1 |
| Ackermans, L | 1 |
| Beckervordersantforth, J | 1 |
| Bauer, NJC | 1 |
| Anten, MM | 1 |
| Wesseling, P | 1 |
| Postma, AA | 1 |
| De Ruysscher, D | 1 |
| Lambin, P | 1 |
| Qiang, L | 1 |
| Yang, S | 1 |
| Cui, YH | 1 |
| He, YY | 1 |
| Kumar, SK | 1 |
| Jacobus, SJ | 1 |
| Cohen, AD | 1 |
| Weiss, M | 1 |
| Callander, N | 1 |
| Singh, AK | 1 |
| Parker, TL | 1 |
| Menter, A | 1 |
| Parsons, B | 1 |
| Kumar, P | 1 |
| Kapoor, P | 1 |
| Rosenberg, A | 1 |
| Zonder, JA | 1 |
| Faber, E | 1 |
| Lonial, S | 1 |
| Anderson, KC | 1 |
| Richardson, PG | 1 |
| Orlowski, RZ | 1 |
| Wagner, LI | 1 |
| Rajkumar, SV | 1 |
| Hou, G | 1 |
| Cui, J | 1 |
| Xie, H | 1 |
| Fang, Z | 1 |
| Dunstand-Guzmán, E | 1 |
| Hallal-Calleros, C | 1 |
| Hernández-Velázquez, VM | 1 |
| Canales-Vargas, EJ | 1 |
| Domínguez-Roldan, R | 1 |
| Pedernera, M | 1 |
| Peña-Chora, G | 1 |
| Flores-Pérez, I | 1 |
| Kim, MJ | 1 |
| Han, C | 1 |
| White, K | 2 |
| Park, HJ | 2 |
| Ding, D | 1 |
| Boyd, K | 1 |
| Rothenberger, C | 1 |
| Bose, U | 1 |
| Carmichael, P | 1 |
| Linser, PJ | 1 |
| Tanokura, M | 1 |
| Salvi, R | 1 |
| Someya, S | 1 |
| Samuni, A | 1 |
| Goldstein, S | 1 |
| Divya, KP | 1 |
| Dharuman, V | 1 |
| Feng, J | 2 |
| Qian, Y | 1 |
| Ma, H | 1 |
| Ren, X | 1 |
| Wei, Q | 1 |
| Pan, W | 1 |
| Situ, B | 1 |
| An, T | 2 |
| Zheng, L | 1 |
| Augusto, S | 1 |
| Ratola, N | 1 |
| Tarín-Carrasco, P | 1 |
| Jiménez-Guerrero, P | 1 |
| Turco, M | 1 |
| Schuhmacher, M | 1 |
| Costa, S | 1 |
| Teixeira, JP | 1 |
| Costa, C | 1 |
| Syed, A | 1 |
| Marraiki, N | 1 |
| Al-Rashed, S | 1 |
| Elgorban, AM | 1 |
| Yassin, MT | 1 |
| Chankhanittha, T | 1 |
| Nanan, S | 1 |
| Sorokina, KN | 1 |
| Samoylova, YV | 1 |
| Gromov, NV | 1 |
| Ogorodnikova, OL | 1 |
| Parmon, VN | 1 |
| Liao, W | 1 |
| Zhang, P | 2 |
| Nabi, M | 1 |
| Cai, Y | 1 |
| Li, F | 1 |
| Alsbou, EM | 1 |
| Omari, KW | 1 |
| Adeosun, WA | 1 |
| Asiri, AM | 1 |
| Marwani, HM | 1 |
| Barral, M | 1 |
| Jemal-Turki, A | 1 |
| Beuvon, F | 1 |
| Soyer, P | 1 |
| Camparo, P | 1 |
| Cornud, F | 1 |
| Atwater, BD | 1 |
| Jones, WS | 1 |
| Loring, Z | 1 |
| Friedman, DJ | 1 |
| Namburath, M | 1 |
| Papirio, S | 1 |
| Moscariello, C | 1 |
| Di Costanzo, N | 1 |
| Pirozzi, F | 1 |
| Alappat, BJ | 1 |
| Sreekrishnan, TR | 1 |
| Volpin, F | 1 |
| Woo, YC | 1 |
| Kim, H | 1 |
| Freguia, S | 1 |
| Jeong, N | 1 |
| Choi, JS | 1 |
| Phuntsho, S | 1 |
| Shon, HK | 1 |
| Domínguez-Zambrano, E | 1 |
| Pedraza-Chaverri, J | 1 |
| López-Santos, AL | 1 |
| Medina-Campos, ON | 1 |
| Cruz-Rivera, C | 1 |
| Bueno-Hernández, F | 1 |
| Espinosa-Cuevas, A | 1 |
| Bulavaitė, A | 1 |
| Dalgediene, I | 1 |
| Michailoviene, V | 1 |
| Pleckaityte, M | 1 |
| Sauerbier, P | 1 |
| Köhler, R | 1 |
| Renner, G | 1 |
| Militz, H | 1 |
| Ma, R | 1 |
| Yi, B | 1 |
| Riker, AI | 1 |
| Xi, Y | 1 |
| Tran, AA | 1 |
| Prasad, V | 1 |
| Zajda, A | 1 |
| Huttunen, KM | 1 |
| Sikora, J | 1 |
| Podsiedlik, M | 1 |
| Markowicz-Piasecka, M | 1 |
| Hassanabad, AF | 1 |
| Sung, JJ | 1 |
| Ho, JM | 1 |
| Lam, AS | 1 |
| Yau, ST | 1 |
| Tsoi, KK | 1 |
| Jang, HJ | 1 |
| Lee, J | 1 |
| Watters, K | 1 |
| Munro, N | 1 |
| Feher, M | 1 |
| Cioce, M | 1 |
| Pulito, C | 1 |
| Strano, S | 1 |
| Blandino, G | 1 |
| Fazio, VM | 1 |
| Tądel, K | 1 |
| Wiatrak, B | 1 |
| Bodetko, D | 1 |
| Barg, E | 1 |
| Singh, SV | 1 |
| Chaube, B | 1 |
| Mayengbam, SS | 1 |
| Malvi, P | 1 |
| Mohammad, N | 1 |
| Deb, A | 1 |
| Bhat, MK | 1 |
| Zuo, H | 1 |
| Yu, Y | 1 |
| Miao, L | 1 |
| Fang, HJ | 1 |
| Cao, Q | 1 |
| Mao, ZW | 1 |
| Wei, Z | 1 |
| Yong, T | 1 |
| Bie, N | 1 |
| Zhan, G | 1 |
| Liang, Q | 1 |
| Yan, Y | 1 |
| Zhang, Z | 2 |
| Zhang, B | 1 |
| Gan, L | 1 |
| Huang, B | 1 |
| Liu, W | 1 |
| Liu, M | 2 |
| Krall, AS | 1 |
| Mullen, PJ | 1 |
| Surjono, F | 1 |
| Momcilovic, M | 1 |
| Schmid, EW | 1 |
| Halbrook, CJ | 1 |
| Thambundit, A | 1 |
| Mittelman, SD | 1 |
| Lyssiotis, CA | 1 |
| Shackelford, DB | 1 |
| Knott, SRV | 1 |
| Christofk, HR | 1 |
| Celotto, S | 1 |
| Pizzol, D | 1 |
| Gasevic, D | 1 |
| Ji, MM | 1 |
| Barnini, T | 1 |
| Solmi, M | 1 |
| Stubbs, B | 1 |
| Smith, L | 1 |
| López Sánchez, GF | 1 |
| Pesolillo, G | 1 |
| Yu, Z | 1 |
| Tzoulaki, I | 2 |
| Theodoratou, E | 1 |
| Ioannidis, JPA | 1 |
| Veronese, N | 1 |
| Demurtas, J | 1 |
| Bueno, MJ | 1 |
| Ruiz-Sepulveda, JL | 1 |
| Quintela-Fandino, M | 1 |
| Bedanova, H | 1 |
| Horvath, V | 1 |
| Ondrasek, J | 1 |
| Krejci, J | 1 |
| Dobsak, P | 1 |
| Nemec, P | 1 |
| Yeh, HC | 2 |
| Maruthur, NM | 1 |
| Wang, NY | 1 |
| Jerome, GJ | 1 |
| Dalcin, AT | 1 |
| Tseng, E | 1 |
| Miller, ER | 1 |
| Juraschek, SP | 1 |
| Mueller, NT | 1 |
| Charleston, J | 1 |
| Durkin, N | 1 |
| Hassoon, A | 1 |
| Lansey, DG | 1 |
| Kanarek, NF | 1 |
| Carducci, MA | 1 |
| Appel, LJ | 1 |
| Farkhondeh, T | 1 |
| Amirabadizadeh, A | 1 |
| Aramjoo, H | 1 |
| Llorens, S | 1 |
| Roshanravan, B | 1 |
| Saeedi, F | 1 |
| Talebi, M | 1 |
| Shakibaei, M | 1 |
| Samarghandian, S | 1 |
| Meyer, FB | 1 |
| Goebel, S | 1 |
| Spangel, SB | 1 |
| Leovsky, C | 1 |
| Hoelzer, D | 1 |
| Thierbach, R | 1 |
| Chomanicova, N | 1 |
| Gazova, A | 1 |
| Adamickova, A | 1 |
| Valaskova, S | 1 |
| Kyselovic, J | 1 |
| Ahmed, ZSO | 1 |
| Golovoy, M | 1 |
| Abdullah, Y | 1 |
| Ahmed, RSI | 1 |
| Dou, QP | 1 |
| Singh-Makkar, S | 1 |
| Pandav, K | 1 |
| Hathaway, D | 1 |
| Paul, T | 1 |
| Youssef, P | 1 |
| Veeramachaneni, R | 1 |
| Yu, W | 1 |
| Newton, JM | 1 |
| Kemnade, JO | 1 |
| Skinner, HD | 2 |
| Sikora, AG | 1 |
| Sandulache, VC | 2 |
| Bremer, E | 1 |
| Kawatani, M | 1 |
| Aono, H | 1 |
| Hiranuma, S | 1 |
| Shimizu, T | 1 |
| Muroi, M | 1 |
| Ogawa, N | 1 |
| Ohishi, T | 1 |
| Ohba, SI | 1 |
| Kawada, M | 1 |
| Nogawa, T | 1 |
| Okano, A | 1 |
| Hashizume, D | 1 |
| Osada, H | 1 |
| Marini, C | 2 |
| Cossu, V | 1 |
| Bauckneht, M | 1 |
| Lanfranchi, F | 1 |
| Raffa, S | 1 |
| Orengo, AM | 1 |
| Ravera, S | 1 |
| Bruno, S | 1 |
| Sambuceti, G | 2 |
| Dan, S | 1 |
| Su, T | 1 |
| She, S | 1 |
| Jia, J | 1 |
| Zheng, M | 1 |
| Kang, B | 1 |
| Wang, YJ | 1 |
| Cuyàs, E | 3 |
| Martin-Castillo, B | 4 |
| Bosch-Barrera, J | 3 |
| Menendez, JA | 7 |
| Hicks, BM | 1 |
| Yin, H | 1 |
| Sinyavskaya, L | 1 |
| Suissa, S | 3 |
| Azoulay, L | 2 |
| Brassard, P | 1 |
| Samsuri, NAB | 1 |
| Leech, M | 1 |
| Marignol, L | 1 |
| Samadi, N | 1 |
| Salehi, R | 1 |
| Yousefi, B | 1 |
| Zarghami, N | 1 |
| Xu, W | 1 |
| Oliveira, VC | 1 |
| Constante, SAR | 1 |
| Orsolin, PC | 1 |
| Nepomuceno, JC | 1 |
| de Rezende, AAA | 1 |
| Spanó, MA | 1 |
| Molenaar, RJ | 1 |
| van de Venne, T | 1 |
| Weterman, MJ | 1 |
| Mathot, RA | 1 |
| Klümpen, HJ | 1 |
| Richel, DJ | 1 |
| Wilmink, JW | 1 |
| Romero, R | 1 |
| Erez, O | 1 |
| Hüttemann, M | 1 |
| Maymon, E | 1 |
| Panaitescu, B | 1 |
| Conde-Agudelo, A | 1 |
| Pacora, P | 1 |
| Yoon, BH | 1 |
| Grossman, LI | 1 |
| Vora, J | 1 |
| Ray, K | 1 |
| Kosiborod, M | 1 |
| Poulter, NR | 1 |
| Rajagopalan, S | 1 |
| Leiter, LA | 1 |
| Kusturica, J | 1 |
| Kulo Ćesić, A | 1 |
| Gušić, E | 1 |
| Maleškić, S | 1 |
| Rakanović-Todić, M | 1 |
| Šečić, D | 1 |
| Lurati, AR | 1 |
| Peled, Y | 1 |
| Lavee, J | 1 |
| Raichlin, E | 1 |
| Katz, M | 1 |
| Arad, M | 1 |
| Kassif, Y | 1 |
| Peled, A | 1 |
| Asher, E | 1 |
| Elian, D | 1 |
| Har-Zahav, Y | 1 |
| Shlomo, N | 1 |
| Freimark, D | 1 |
| Goldenberg, I | 1 |
| Klempfner, R | 1 |
| Ikhlas, S | 1 |
| Ahmad, M | 1 |
| Heckman-Stoddard, BM | 3 |
| DeCensi, A | 6 |
| Sahasrabuddhe, VV | 1 |
| Ford, LG | 1 |
| Campbell, JM | 1 |
| Bellman, SM | 1 |
| Stephenson, MD | 1 |
| Lisy, K | 1 |
| Haukka, J | 1 |
| Niskanen, L | 1 |
| Auvinen, A | 1 |
| Asiedu, MK | 1 |
| Barron, M | 1 |
| Aubry, MC | 1 |
| Wigle, DA | 1 |
| Byun, S | 1 |
| Lee, E | 1 |
| Lee, KW | 2 |
| Glintborg, D | 1 |
| Andersen, M | 1 |
| Muszyńska-Ogłaza, A | 1 |
| Zarzycka-Lindner, G | 1 |
| Olejniczak, H | 1 |
| Polaszewska-Muszyńska, M | 1 |
| Junik, R | 1 |
| Kunisada, Y | 1 |
| Eikawa, S | 4 |
| Tomonobu, N | 2 |
| Domae, S | 1 |
| Uehara, T | 1 |
| Hori, S | 1 |
| Furusawa, Y | 1 |
| Hase, K | 1 |
| Sasaki, A | 1 |
| Zheng, G | 1 |
| Shen, Z | 1 |
| Xu, A | 1 |
| Jiang, K | 1 |
| Wu, P | 1 |
| Shao, J | 1 |
| de Fatima Silva, F | 1 |
| Ortiz-Silva, M | 1 |
| Galia, WBS | 1 |
| Cassolla, P | 1 |
| da Silva, FG | 1 |
| Graciano, MFR | 1 |
| Carpinelli, AR | 1 |
| de Souza, HM | 3 |
| Saini, N | 1 |
| Jupp, PW | 1 |
| Bridgeman, SC | 1 |
| Ellison, GC | 1 |
| Melton, PE | 1 |
| Newsholme, P | 1 |
| Mamotte, CDS | 1 |
| Kim, HJ | 1 |
| Lee, S | 1 |
| Chun, KH | 1 |
| Jeon, JY | 1 |
| Han, SJ | 1 |
| Kim, DJ | 1 |
| Woo, JT | 1 |
| Nam, MS | 1 |
| Baik, SH | 1 |
| Ahn, KJ | 1 |
| Rezapoor, S | 1 |
| Geraily, G | 1 |
| Motevaseli, E | 1 |
| Carnovale, C | 1 |
| Clementi, E | 1 |
| Shirazi, A | 1 |
| Kheirandish, M | 1 |
| Mahboobi, H | 1 |
| Yazdanparast, M | 1 |
| Kamal, W | 1 |
| Kamal, MA | 1 |
| Lv, Y | 1 |
| Tian, N | 1 |
| Yang, M | 1 |
| Kong, L | 1 |
| Mallik, R | 1 |
| Chowdhury, TA | 2 |
| Maniar, K | 1 |
| Singh, V | 1 |
| Chakrabarti, A | 1 |
| Bhattacharyya, R | 1 |
| Banerjee, D | 1 |
| Okada, S | 1 |
| Morimoto, T | 1 |
| Ogawa, H | 1 |
| Sakuma, M | 1 |
| Matsumoto, C | 1 |
| Soejima, H | 1 |
| Nakayama, M | 1 |
| Doi, N | 1 |
| Jinnouchi, H | 1 |
| Waki, M | 1 |
| Masuda, I | 1 |
| Saito, Y | 1 |
| Sullivan, LB | 3 |
| Danai, LV | 1 |
| Bush, LN | 2 |
| Diehl, FF | 1 |
| Hosios, AM | 2 |
| Lau, AN | 1 |
| Elmiligy, S | 1 |
| Malstrom, S | 1 |
| Lewis, CA | 1 |
| Vander Heiden, MG | 2 |
| Sehdev, A | 1 |
| Karrison, T | 1 |
| Zha, Y | 1 |
| Janisch, L | 1 |
| Turcich, M | 1 |
| Cohen, EEW | 1 |
| Maitland, M | 1 |
| Polite, BN | 1 |
| Gajewski, TF | 1 |
| Salgia, R | 1 |
| Pinto, N | 1 |
| Bissonnette, MB | 1 |
| Fleming, GF | 1 |
| Ratain, MJ | 1 |
| Sharma, MR | 1 |
| Rajaei, E | 1 |
| Haybar, H | 1 |
| Mowla, K | 1 |
| Zayeri, ZD | 1 |
| Hu, D | 1 |
| Shi, G | 1 |
| Fetahu, IS | 1 |
| Rabidou, K | 1 |
| Fang, R | 1 |
| Tan, L | 1 |
| Argueta, C | 1 |
| Mao, F | 1 |
| Yan, G | 1 |
| Lv, R | 1 |
| Wang, M | 2 |
| Ye, Y | 1 |
| Duquette, D | 1 |
| Geng, S | 1 |
| Yin, C | 1 |
| Lian, CG | 1 |
| Murphy, GF | 1 |
| Adler, GK | 1 |
| Garg, R | 1 |
| Lynch, L | 1 |
| Yang, P | 1 |
| Lan, F | 1 |
| Fan, J | 1 |
| Shi, YG | 1 |
| Vancura, A | 1 |
| Bu, P | 1 |
| Bhagwat, M | 1 |
| Zeng, J | 1 |
| Vancurova, I | 1 |
| Shah, RR | 2 |
| Stonier, PD | 1 |
| Schulten, HJ | 1 |
| Zhou, J | 2 |
| Massey, S | 1 |
| Story, D | 1 |
| Li, L | 2 |
| Sriram, K | 1 |
| Amin, S | 1 |
| Lux, A | 1 |
| O'Callaghan, F | 1 |
| Mortezaee, K | 1 |
| Shabeeb, D | 1 |
| Musa, AE | 1 |
| Farhood, B | 1 |
| Müller, S | 1 |
| Versini, A | 1 |
| Sindikubwabo, F | 1 |
| Belthier, G | 1 |
| Niyomchon, S | 1 |
| Pannequin, J | 1 |
| Grimaud, L | 1 |
| Cañeque, T | 1 |
| Rodriguez, R | 1 |
| Scheen, AJ | 4 |
| Lefèbvre, PJ | 1 |
| Paquot, N | 1 |
| Benjamin, D | 1 |
| Robay, D | 1 |
| Hindupur, SK | 1 |
| Pohlmann, J | 1 |
| Colombi, M | 1 |
| El-Shemerly, MY | 1 |
| Maira, SM | 1 |
| Moroni, C | 1 |
| Lane, HA | 1 |
| Hall, MN | 1 |
| Rosario, SR | 1 |
| Long, MD | 1 |
| Affronti, HC | 1 |
| Rowsam, AM | 1 |
| Eng, KH | 1 |
| Smiraglia, DJ | 1 |
| Zhou, Q | 1 |
| Fan, S | 1 |
| Meng, F | 1 |
| Zhu, L | 1 |
| Zhao, L | 1 |
| Guan, MX | 1 |
| Jin, H | 1 |
| Farmer, RE | 2 |
| Ford, D | 2 |
| Mathur, R | 1 |
| Chaturvedi, N | 2 |
| Kaplan, R | 2 |
| Smeeth, L | 2 |
| Bhaskaran, K | 2 |
| Teh, JT | 1 |
| Zhu, WL | 1 |
| Newgard, CB | 1 |
| Casey, PJ | 1 |
| Yi, J | 1 |
| Ao, J | 1 |
| Xiao, ZX | 1 |
| Yi, Y | 2 |
| Zhang, ZJ | 2 |
| Gu, X | 1 |
| Liang, K | 1 |
| Pei, Y | 1 |
| Song, Q | 1 |
| Liu, S | 2 |
| Elgendy, M | 1 |
| Cirò, M | 1 |
| Hosseini, A | 1 |
| Weiszmann, J | 1 |
| Mazzarella, L | 1 |
| Ferrari, E | 1 |
| Cazzoli, R | 1 |
| Curigliano, G | 1 |
| Bonanni, B | 4 |
| Budillon, A | 2 |
| Pelicci, PG | 1 |
| Janssens, V | 1 |
| Ogris, M | 1 |
| Baccarini, M | 1 |
| Lanfrancone, L | 1 |
| Weckwerth, W | 1 |
| Foiani, M | 1 |
| Minucci, S | 1 |
| Umesh Ganesh, N | 1 |
| Park, J | 1 |
| Joe, Y | 1 |
| Ryter, SW | 1 |
| Surh, YJ | 1 |
| Chung, HT | 1 |
| Agay, N | 1 |
| Olmer, L | 1 |
| Murad, H | 1 |
| Keinan Boker, L | 1 |
| Balicer, RD | 1 |
| Freedman, LS | 1 |
| Pecinová, A | 1 |
| Brázdová, A | 1 |
| Drahota, Z | 1 |
| Houštěk, J | 1 |
| Mráček, T | 1 |
| Thakkar, B | 1 |
| Aronis, KN | 1 |
| Vamvini, MT | 1 |
| Shields, K | 1 |
| Mantzoros, CS | 2 |
| Lamming, DW | 1 |
| Ye, L | 1 |
| Sabatini, DM | 2 |
| Baur, JA | 1 |
| Rizos, CV | 1 |
| Elisaf, MS | 1 |
| Anastasiou, D | 1 |
| Joven, J | 5 |
| Beck, E | 3 |
| Loubière, C | 1 |
| Dirat, B | 1 |
| Tanti, JF | 3 |
| Bost, F | 3 |
| Moiseeva, O | 1 |
| Deschênes-Simard, X | 1 |
| Pollak, M | 9 |
| Ferbeyre, G | 1 |
| Bo, S | 3 |
| Castiglione, A | 1 |
| Ghigo, E | 3 |
| Gentile, L | 1 |
| Durazzo, M | 2 |
| Cavallo-Perin, P | 1 |
| Ciccone, G | 2 |
| Do, MT | 2 |
| Kim, HG | 2 |
| Khanal, T | 1 |
| Choi, JH | 2 |
| Kim, DH | 1 |
| Jeong, TC | 1 |
| Jeong, HG | 2 |
| Anisimov, VN | 6 |
| Bao, B | 1 |
| Ahmad, A | 1 |
| Azmi, AS | 1 |
| Ali, S | 2 |
| Sarkar, FH | 1 |
| Noto, H | 3 |
| Goto, A | 2 |
| Tsujimoto, T | 2 |
| Noda, M | 2 |
| Quinn, BJ | 1 |
| Kitagawa, H | 1 |
| Memmott, RM | 1 |
| Gills, JJ | 1 |
| Dennis, PA | 1 |
| Choi, YK | 1 |
| Park, KG | 1 |
| Hardie, DG | 3 |
| Lin, HC | 1 |
| Kachingwe, BH | 1 |
| Lin, HL | 1 |
| Cheng, HW | 1 |
| Uang, YS | 1 |
| Wang, LH | 1 |
| Muaddi, H | 1 |
| Chowdhury, S | 1 |
| Vellanki, R | 1 |
| Zamiara, P | 1 |
| Koritzinsky, M | 2 |
| Franciosi, M | 1 |
| Lucisano, G | 1 |
| Lapice, E | 1 |
| Strippoli, GF | 1 |
| Pellegrini, F | 1 |
| Nicolucci, A | 2 |
| Onitilo, AA | 2 |
| Stankowski, RV | 2 |
| Berg, RL | 1 |
| Engel, JM | 2 |
| Williams, GM | 2 |
| Doi, SA | 2 |
| Wang, SY | 1 |
| Chuang, CS | 1 |
| Muo, CH | 1 |
| Tu, ST | 2 |
| Lin, MC | 1 |
| Sung, FC | 1 |
| Kao, CH | 1 |
| Hajjar, J | 1 |
| Habra, MA | 1 |
| Naing, A | 2 |
| Anděl, M | 1 |
| Skrha, P | 1 |
| Trnka, J | 1 |
| Pasello, G | 1 |
| Urso, L | 1 |
| Conte, P | 1 |
| Favaretto, A | 1 |
| Gronich, N | 1 |
| Rennert, G | 1 |
| Leone, A | 1 |
| Di Gennaro, E | 1 |
| Bruzzese, F | 1 |
| Avallone, A | 1 |
| Berstein, LM | 8 |
| Iyevleva, AG | 2 |
| Vasilyev, D | 1 |
| Poroshina, TE | 6 |
| Imyanitov, EN | 2 |
| Yin, M | 1 |
| Gorak, EJ | 1 |
| Quddus, F | 1 |
| La Vecchia, C | 2 |
| Bosetti, C | 2 |
| Bonini, MG | 1 |
| Gantner, BN | 1 |
| Dallaglio, K | 1 |
| Bruno, A | 1 |
| Cantelmo, AR | 1 |
| Esposito, AI | 1 |
| Ruggiero, L | 1 |
| Calleri, A | 1 |
| Pfeffer, U | 1 |
| Noonan, DM | 2 |
| Albini, A | 2 |
| Mamtani, R | 1 |
| Pfanzelter, N | 1 |
| Haynes, K | 1 |
| Finkelman, BS | 1 |
| Keefe, SM | 1 |
| Haas, NB | 1 |
| Vaughn, DJ | 1 |
| Lewis, JD | 1 |
| Aldea, M | 1 |
| Craciun, L | 2 |
| Tomuleasa, C | 1 |
| Berindan-Neagoe, I | 1 |
| Kacso, G | 1 |
| Florian, IS | 1 |
| Crivii, C | 1 |
| Lettieri Barbato, D | 1 |
| Vegliante, R | 1 |
| Desideri, E | 1 |
| Ciriolo, MR | 1 |
| Bordeleau, L | 1 |
| Yakubovich, N | 1 |
| Dagenais, GR | 1 |
| Rosenstock, J | 1 |
| Probstfield, J | 1 |
| Chang Yu, P | 1 |
| Ryden, LE | 1 |
| Pirags, V | 1 |
| Spinas, GA | 1 |
| Birkeland, KI | 1 |
| Ratner, RE | 1 |
| Marin-Neto, JA | 1 |
| Riddle, MC | 1 |
| Bosch, J | 1 |
| Yusuf, S | 1 |
| Gerstein, HC | 1 |
| Bershteĭn, LM | 3 |
| Vasil'ev, DA | 3 |
| Ievleva, AG | 2 |
| Imianitov, EN | 2 |
| Burkewitz, K | 1 |
| Mair, WB | 1 |
| Kovalenko, IM | 1 |
| Printz, C | 1 |
| Yang, L | 1 |
| Vallianou, NG | 1 |
| Evangelopoulos, A | 1 |
| Kazazis, C | 1 |
| Wheaton, WW | 1 |
| Weinberg, SE | 2 |
| Hamanaka, RB | 1 |
| Soberanes, S | 1 |
| Anso, E | 1 |
| Glasauer, A | 1 |
| Dufour, E | 1 |
| Mutlu, GM | 1 |
| Budigner, GS | 1 |
| Chandel, NS | 2 |
| Kong, D | 1 |
| Prochilo, T | 1 |
| Di Biasi, B | 1 |
| Bertocchi, P | 1 |
| Sabatini, T | 1 |
| Meriggi, F | 1 |
| Zaniboni, A | 1 |
| Lohmann, AE | 1 |
| Goodwin, PJ | 4 |
| Chevalier, S | 1 |
| Farsijani, S | 1 |
| Kong, AP | 4 |
| So, WY | 3 |
| Luk, A | 1 |
| Ma, RC | 3 |
| Ozaki, R | 3 |
| Cheung, KK | 1 |
| Lee, HM | 3 |
| Yu, L | 1 |
| Xu, G | 2 |
| Chow, CC | 2 |
| Chan, JC | 4 |
| Tsilidis, KK | 1 |
| Capothanassi, D | 1 |
| Allen, NE | 1 |
| Rizos, EC | 1 |
| Lopez, DS | 1 |
| van Veldhoven, K | 1 |
| Sacerdote, C | 1 |
| Ashby, D | 1 |
| Vineis, P | 1 |
| Ioannidis, JP | 1 |
| Strittmatter, SM | 1 |
| Quirantes-Piné, R | 1 |
| Rodríguez-Gallego, E | 1 |
| Cufí, S | 2 |
| Corominas-Faja, B | 1 |
| Segura-Carretero, A | 1 |
| Nenu, I | 1 |
| Popescu, T | 1 |
| Aldea, MD | 1 |
| Olteanu, D | 1 |
| Tatomir, C | 1 |
| Bolfa, P | 1 |
| Ion, RM | 1 |
| Muresan, A | 1 |
| Filip, AG | 1 |
| Badrick, E | 1 |
| Renehan, AG | 1 |
| Gandini, S | 3 |
| Puntoni, M | 3 |
| Dunn, BK | 3 |
| Ford, L | 1 |
| Szabo, E | 3 |
| Lega, IC | 1 |
| Shah, PS | 1 |
| Margel, D | 1 |
| Beyene, J | 1 |
| Rochon, PA | 1 |
| Lipscombe, LL | 1 |
| Aldrich, MC | 2 |
| Peterson, NB | 1 |
| Dai, Q | 1 |
| Levy, M | 1 |
| Han, X | 1 |
| Ruan, X | 1 |
| Jiang, M | 1 |
| Julien, JS | 1 |
| Warner, J | 1 |
| Friedman, C | 1 |
| Roden, DM | 2 |
| Denny, JC | 2 |
| Steenkamp, DW | 1 |
| McDonnell, ME | 1 |
| Meibom, S | 1 |
| Lai, X | 1 |
| Xiao, T | 1 |
| Wen, A | 1 |
| Batra, S | 1 |
| Adekola, KU | 1 |
| Rosen, ST | 1 |
| Shanmugam, M | 1 |
| Leiter, A | 1 |
| Sablinski, T | 1 |
| Diefenbach, M | 1 |
| Foster, M | 1 |
| Greenberg, A | 1 |
| Holland, J | 1 |
| Oh, WK | 1 |
| Galsky, MD | 1 |
| Balasubramanyam, M | 1 |
| Vincent, EE | 2 |
| Coelho, PP | 1 |
| Blagih, J | 1 |
| Griss, T | 2 |
| Viollet, B | 5 |
| Jones, RG | 3 |
| Zhuang, Y | 1 |
| Chan, DK | 1 |
| Haugrud, AB | 1 |
| Miskimins, WK | 1 |
| Salani, B | 1 |
| Del Rio, A | 1 |
| Cordera, R | 1 |
| Maggi, D | 1 |
| Miranda, VC | 1 |
| Barroso-Sousa, R | 1 |
| Glasberg, J | 1 |
| Riechelmann, RP | 1 |
| Snima, KS | 1 |
| Pillai, P | 1 |
| Cherian, AM | 1 |
| Nair, SV | 1 |
| Lakshmanan, VK | 1 |
| Kowall, B | 1 |
| Rathmann, W | 1 |
| Chandel, N | 1 |
| Gravel, SP | 1 |
| Hulea, L | 1 |
| Toban, N | 1 |
| Birman, E | 1 |
| Blouin, MJ | 2 |
| Zakikhani, M | 1 |
| Topisirovic, I | 2 |
| St-Pierre, J | 1 |
| Morales, DR | 1 |
| Morris, AD | 3 |
| Arshad, OA | 1 |
| Venkatasubramani, PS | 1 |
| Datta, A | 1 |
| Venkatraj, J | 1 |
| Emami-Riedmaier, A | 1 |
| Schaeffeler, E | 2 |
| Nies, AT | 2 |
| Mörike, K | 1 |
| Schwab, M | 2 |
| Franco, CC | 2 |
| Miranda, RA | 2 |
| de Oliveira, JC | 2 |
| Barella, LF | 2 |
| Agostinho, AR | 1 |
| Prates, KV | 2 |
| Malta, A | 2 |
| Trombini, AB | 2 |
| Torrezan, R | 1 |
| Gravena, C | 1 |
| Tófolo, LP | 2 |
| de Sant'Anna, JR | 2 |
| de Castro Prado, MA | 1 |
| de Souza, CO | 1 |
| Beraldi, EJ | 1 |
| Mathias, PC | 2 |
| Vujic, I | 1 |
| Sanlorenzo, M | 1 |
| Posch, C | 1 |
| Esteve-Puig, R | 1 |
| Yen, AJ | 1 |
| Kwong, A | 1 |
| Tsumura, A | 1 |
| Murphy, R | 1 |
| Rappersberger, K | 1 |
| Ortiz-Urda, S | 1 |
| Jones, NP | 3 |
| Curtis, PS | 2 |
| Home, PD | 3 |
| Serrano, D | 1 |
| Lazzeroni, M | 2 |
| Kapelner, A | 1 |
| Vorsanger, M | 1 |
| Mizukami, S | 1 |
| Yamazaki, C | 1 |
| Nakayama, E | 1 |
| Chen, CI | 1 |
| Kuan, CF | 1 |
| Fang, YA | 1 |
| Liu, SH | 1 |
| Liu, JC | 1 |
| Wu, LL | 1 |
| Chang, CJ | 1 |
| Yang, HC | 1 |
| Hwang, J | 1 |
| Miser, JS | 1 |
| Wu, SY | 1 |
| Ceacareanu, AC | 1 |
| Wintrob, ZA | 1 |
| Vasilyev, DA | 1 |
| Boyarkina, MP | 2 |
| Khadzhimba, AS | 1 |
| Kinaan, M | 1 |
| Ding, H | 1 |
| Triggle, CR | 1 |
| de Souza, AA | 1 |
| Pavanello, A | 1 |
| Almeida, DL | 1 |
| Rigo, KP | 1 |
| Ribeiro, TA | 1 |
| Fabricio, GS | 1 |
| Castro-Prado, MA | 1 |
| de Morais, H | 1 |
| Wu, L | 2 |
| Prokop, LJ | 1 |
| Murad, MH | 1 |
| Zhao, M | 1 |
| Jia, P | 1 |
| Iverson, C | 1 |
| Bowton, E | 1 |
| Check Hayden, E | 1 |
| Sanduloviciu, M | 1 |
| Jornayvaz, FR | 1 |
| Coperchini, F | 1 |
| Leporati, P | 1 |
| Rotondi, M | 1 |
| Chiovato, L | 1 |
| Kabel, AM | 1 |
| Omar, MS | 1 |
| Balaha, MF | 1 |
| Borg, HM | 1 |
| Jara, JA | 1 |
| López-Muñoz, R | 1 |
| Provinciali, N | 1 |
| Cazzaniga, M | 3 |
| Gorlero, F | 1 |
| Allott, EH | 1 |
| Hursting, SD | 1 |
| Hall, SS | 1 |
| Sui, X | 1 |
| Han, W | 2 |
| Pan, H | 1 |
| Pryor, R | 1 |
| Cabreiro, F | 1 |
| Wypij, JM | 1 |
| Gong, Z | 1 |
| Aragaki, AK | 1 |
| Chlebowski, RT | 1 |
| Manson, JE | 1 |
| Rohan, TE | 1 |
| Vitolins, MZ | 1 |
| Tinker, LF | 1 |
| LeBlanc, ES | 1 |
| Kuller, LH | 1 |
| Hou, L | 1 |
| LaMonte, MJ | 1 |
| Wactawski-Wende, J | 1 |
| Egnatchik, R | 1 |
| Ma, EH | 1 |
| Faubert, B | 1 |
| DeBerardinis, RJ | 2 |
| Othman, EM | 1 |
| Oli, RG | 1 |
| Arias-Loza, PA | 1 |
| Kreissl, MC | 1 |
| Stopper, H | 1 |
| Golozar, A | 1 |
| Lin, JA | 1 |
| Peairs, K | 1 |
| Fukumura, D | 1 |
| Incio, J | 1 |
| Shankaraiah, RC | 1 |
| Jain, RK | 1 |
| Xue, CJ | 1 |
| Liu, KX | 1 |
| Hart, T | 1 |
| Dider, S | 1 |
| Kelekar, G | 1 |
| Kaur, S | 1 |
| Mita, M | 1 |
| Lee, DK | 1 |
| Igel, LI | 1 |
| Sinha, A | 1 |
| Saunders, KH | 1 |
| Apovian, CM | 1 |
| Vojta, D | 1 |
| Aronne, LJ | 1 |
| Zhou, JY | 1 |
| Xu, B | 1 |
| Chan, AT | 1 |
| Chae, YK | 1 |
| Arya, A | 1 |
| Malecek, MK | 1 |
| Shin, DS | 1 |
| Carneiro, B | 1 |
| Chandra, S | 1 |
| Kaplan, J | 1 |
| Kalyan, A | 1 |
| Altman, JK | 2 |
| Platanias, L | 1 |
| Giles, F | 1 |
| Khawaja, MR | 1 |
| Nick, AM | 1 |
| Madhusudanannair, V | 1 |
| Fu, S | 1 |
| Hong, D | 1 |
| McQuinn, LM | 1 |
| Ng, CS | 1 |
| Piha-Paul, SA | 1 |
| Janku, F | 1 |
| Subbiah, V | 1 |
| Tsimberidou, A | 1 |
| Karp, D | 1 |
| Meric-Bernstam, F | 1 |
| Lu, KH | 1 |
| Liang, X | 1 |
| Dowling, RJ | 3 |
| Lam, S | 1 |
| Bassi, C | 1 |
| Mouaaz, S | 1 |
| Aman, A | 1 |
| Kiyota, T | 1 |
| Al-Awar, R | 1 |
| Stambolic, V | 3 |
| Avizonis, D | 1 |
| Reczek, CR | 1 |
| Menz, S | 1 |
| Neuhaus, R | 1 |
| Christian, S | 1 |
| Haegebarth, A | 1 |
| Algire, C | 1 |
| Stiefelhagen, P | 1 |
| Zhang, HH | 1 |
| Guo, XL | 1 |
| Sośnicki, S | 1 |
| Kapral, M | 1 |
| Węglarz, L | 1 |
| Kannarkatt, J | 1 |
| Alkharabsheh, O | 1 |
| Tokala, H | 1 |
| Dimitrov, NV | 1 |
| Watanabe, M | 1 |
| Yamamoto, H | 1 |
| Shien, K | 1 |
| Shien, T | 1 |
| Soh, J | 1 |
| Hotta, K | 1 |
| Hinotsu, S | 1 |
| Fujiwara, T | 1 |
| Kiura, K | 1 |
| Doihara, H | 1 |
| Miyoshi, S | 1 |
| Toyooka, S | 1 |
| Christodoulou, MI | 1 |
| Scorilas, A | 1 |
| Coyle, C | 1 |
| Cafferty, FH | 1 |
| Vale, C | 1 |
| Langley, RE | 1 |
| Daugan, M | 1 |
| Dufaÿ Wojcicki, A | 1 |
| d'Hayer, B | 1 |
| Boudy, V | 1 |
| Gui, DY | 1 |
| Gitego, N | 1 |
| Davidson, SM | 1 |
| Freinkman, E | 1 |
| Thomas, CJ | 1 |
| Fernández-Arroyo, S | 1 |
| Wei, M | 1 |
| Yu, C | 1 |
| Zhou, W | 1 |
| Sacco, F | 1 |
| Calderone, A | 1 |
| Castagnoli, L | 1 |
| Cesareni, G | 1 |
| Yu, X | 2 |
| Mao, W | 1 |
| Zhai, Y | 1 |
| Tong, C | 1 |
| Ma, L | 1 |
| Castillo-Quan, JI | 1 |
| Blackwell, TK | 1 |
| Oshiro-Rapley, N | 1 |
| Paulo, JA | 1 |
| Webster, CM | 1 |
| Mou, F | 1 |
| Kacergis, MC | 1 |
| Talkowski, ME | 1 |
| Carr, CE | 1 |
| Gygi, SP | 1 |
| Zheng, B | 1 |
| Soukas, AA | 1 |
| Forbes, HJ | 1 |
| Fujita, Y | 1 |
| Inagaki, N | 1 |
| Pietrocola, F | 1 |
| Kroemer, G | 1 |
| Keller, ET | 1 |
| Qian, CN | 1 |
| Peng, M | 1 |
| Darko, KO | 1 |
| Tao, T | 1 |
| He, C | 1 |
| Yin, T | 1 |
| Wang, CP | 1 |
| Lorenzo, C | 1 |
| Habib, SL | 1 |
| Jo, B | 1 |
| Espinoza, SE | 1 |
| Podhorecka, M | 1 |
| Ibanez, B | 1 |
| Dmoszyńska, A | 1 |
| Blagosklonny, MV | 2 |
| Campisi, J | 1 |
| Egormin, PA | 3 |
| Piskunova, TS | 3 |
| Popovich, IG | 3 |
| Zabezhinski, MA | 3 |
| Tyndyk, ML | 3 |
| Yurova, MV | 2 |
| Kovalenko, IG | 4 |
| Semenchenko, AV | 3 |
| Monami, M | 3 |
| Lamanna, C | 1 |
| Balzi, D | 2 |
| Marchionni, N | 3 |
| Mannucci, E | 3 |
| Pocock, SJ | 1 |
| Beck-Nielsen, H | 2 |
| Gomis, R | 1 |
| Hanefeld, M | 1 |
| Komajda, M | 1 |
| McMurray, JJ | 1 |
| Libby, G | 1 |
| Donnelly, LA | 2 |
| Donnan, PT | 1 |
| Alessi, DR | 2 |
| Evans, JM | 2 |
| Currie, CJ | 2 |
| Poole, CD | 2 |
| Gale, EA | 2 |
| Duncan, BB | 1 |
| Schmidt, MI | 1 |
| Vazquez-Martin, A | 2 |
| Oliveras-Ferraros, C | 2 |
| Lopez-Bonet, E | 1 |
| Landman, GW | 1 |
| Kleefstra, N | 1 |
| van Hateren, KJ | 1 |
| Groenier, KH | 1 |
| Gans, RO | 2 |
| Bilo, HJ | 1 |
| Chong, CR | 1 |
| Chabner, BA | 1 |
| Hernández-Díaz, S | 1 |
| Adami, HO | 1 |
| Bowker, SL | 2 |
| Yasui, Y | 2 |
| Veugelers, P | 2 |
| Johnson, JA | 4 |
| Brodell, LA | 1 |
| Mercurio, MG | 1 |
| Ben Sahra, I | 1 |
| Le Marchand-Brustel, Y | 2 |
| Feng, YH | 1 |
| Velazquez-Torres, G | 1 |
| Gully, C | 1 |
| Lee, MH | 1 |
| Yeung, SC | 1 |
| Kahn, SE | 2 |
| Noronha, D | 1 |
| Viberti, G | 2 |
| Papanas, N | 1 |
| Maltezos, E | 1 |
| Mikhailidis, DP | 1 |
| Jalving, M | 1 |
| Gietema, JA | 1 |
| Lefrandt, JD | 1 |
| de Jong, S | 1 |
| Reyners, AK | 1 |
| de Vries, EG | 1 |
| Goodwin, P | 1 |
| Gennari, A | 1 |
| McFarland, MS | 1 |
| Cripps, R | 1 |
| MacKenzie, MJ | 1 |
| Ernst, S | 1 |
| Johnson, C | 1 |
| Winquist, E | 1 |
| Yu, LW | 2 |
| Ko, GT | 2 |
| Colombi, C | 1 |
| Dicembrini, I | 2 |
| Giannini, S | 1 |
| Melani, C | 2 |
| Vitale, V | 1 |
| Romano, D | 1 |
| Barchielli, A | 1 |
| Rotella, CM | 2 |
| Baur, DM | 1 |
| Klotsche, J | 1 |
| Hamnvik, OP | 1 |
| Sievers, C | 1 |
| Pieper, L | 1 |
| Wittchen, HU | 1 |
| Stalla, GK | 1 |
| Schmid, RM | 1 |
| Kales, SN | 1 |
| Jermendy, G | 1 |
| Rus-Gal, PO | 1 |
| Nagy, AK | 1 |
| Martyin, T | 1 |
| Wágner, R | 1 |
| Varga, R | 1 |
| Pikó, B | 1 |
| Rosenfeld, SV | 1 |
| Teslenko, SY | 1 |
| Pratipanawatr, T | 1 |
| Rawdaree, P | 1 |
| Chetthakul, T | 1 |
| Bunnag, P | 1 |
| Ngarmukos, C | 1 |
| Benjasuratwong, Y | 1 |
| Leelawatana, R | 1 |
| Kosachunhanun, N | 1 |
| Plengvidhya, N | 1 |
| Deerochanawong, C | 1 |
| Suwanwalaikorn, S | 1 |
| Krittiyawong, S | 1 |
| Mongkolsomlit, S | 1 |
| Komoltri, C | 1 |
| Kourelis, TV | 1 |
| Siegel, RD | 1 |
| Birnbaum, MJ | 1 |
| Shaw, RJ | 1 |
| Mellbin, LG | 1 |
| Malmberg, K | 1 |
| Norhammar, A | 1 |
| Wedel, H | 1 |
| Rydén, L | 1 |
| Boiarkina, MP | 1 |
| Revskoĭ, SIu | 1 |
| Kovalevskiĭ, AIu | 1 |
| Iliopoulos, D | 1 |
| Hirsch, HA | 1 |
| Struhl, K | 1 |
| Stefansdottir, G | 1 |
| Chalmers, J | 1 |
| Kengne, AP | 1 |
| Knol, MJ | 1 |
| Leufkens, HG | 1 |
| Patel, A | 1 |
| Woodward, M | 1 |
| Grobbee, DE | 1 |
| De Bruin, ML | 1 |
| Oleksyszyn, J | 1 |
| Dias, MM | 1 |
| Ropelle, ER | 2 |
| Osório-Costa, F | 1 |
| Rossato, FA | 1 |
| Vercesi, AE | 1 |
| Saad, MJ | 2 |
| Carvalheira, JB | 2 |
| Green, AS | 1 |
| Chapuis, N | 1 |
| Lacombe, C | 1 |
| Mayeux, P | 1 |
| Bouscary, D | 1 |
| Tamburini, J | 1 |
| Belda-Iniesta, C | 1 |
| Pernía, O | 1 |
| Simó, R | 1 |
| Rosta, A | 1 |
| Rosato, R | 1 |
| Villois, P | 1 |
| Appendino, G | 1 |
| Grassi, G | 2 |
| McCarty, MF | 2 |
| Aljada, A | 1 |
| Mousa, SA | 1 |
| Vakana, E | 1 |
| Platanias, LC | 1 |
| Cheong, JH | 1 |
| Park, ES | 1 |
| Dennison, JB | 1 |
| Tsavachidou, D | 1 |
| Nguyen-Charles, C | 1 |
| Wa Cheng, K | 1 |
| Hall, H | 1 |
| Ravoori, M | 1 |
| Kundra, V | 1 |
| Ajani, J | 1 |
| Lee, JS | 1 |
| Ki Hong, W | 1 |
| Mills, GB | 1 |
| Pandey, A | 1 |
| Forte, V | 1 |
| Abdallah, M | 1 |
| Alickaj, A | 1 |
| Mahmud, S | 1 |
| Asad, S | 1 |
| McFarlane, SI | 1 |
| Ruiter, R | 1 |
| Visser, LE | 1 |
| van Herk-Sukel, MP | 1 |
| Coebergh, JW | 1 |
| Haak, HR | 1 |
| Geelhoed-Duijvestijn, PH | 1 |
| Straus, SM | 1 |
| Herings, RM | 1 |
| Stricker, BH | 1 |
| Guigas, B | 2 |
| Sanz Garcia, N | 1 |
| Leclerc, J | 1 |
| Foretz, M | 2 |
| Andreelli, F | 1 |
| Sahra, IB | 1 |
| Del Barco, S | 1 |
| Blin, P | 1 |
| Lassalle, R | 1 |
| Dureau-Pournin, C | 1 |
| Ambrosino, B | 1 |
| Bernard, MA | 1 |
| Abouelfath, A | 1 |
| Gin, H | 1 |
| Le Jeunne, C | 1 |
| Pariente, A | 1 |
| Droz, C | 1 |
| Moore, N | 1 |
| Taubes, G | 1 |
| Jenkins-Jones, S | 1 |
| Morgan, CL | 1 |
| Niraula, S | 1 |
| Geraldine, N | 1 |
| Marc, A | 1 |
| Carla, T | 1 |
| Chantal, M | 1 |
| Stefaan, B | 1 |
| Welcome, W | 1 |
| Frank, B | 1 |
| Gonzalez-Angulo, AM | 1 |
| Bhalla, K | 1 |
| Hwang, BJ | 1 |
| Dewi, RE | 1 |
| Twaddel, W | 1 |
| Goloubeva, OG | 1 |
| Wong, KK | 1 |
| Saxena, NK | 1 |
| Biswal, S | 1 |
| Girnun, GD | 1 |
| Benso, A | 1 |
| Sheen, YJ | 1 |
| Sheu, WH | 1 |
| Song, CW | 1 |
| Lee, H | 1 |
| Dings, RP | 1 |
| Williams, B | 1 |
| Powers, J | 1 |
| Santos, TD | 1 |
| Choi, BH | 1 |
| Martin, M | 1 |
| Marais, R | 1 |
| Kalinsky, K | 1 |
| Hershman, DL | 1 |
| Larsson, O | 1 |
| Morita, M | 1 |
| Alain, T | 1 |
| Sonenberg, N | 1 |
| Soranna, D | 1 |
| Scotti, L | 1 |
| Zambon, A | 1 |
| Catapano, A | 1 |
| Mancia, G | 1 |
| Corrao, G | 1 |
| Pierotti, MA | 1 |
| Berrino, F | 1 |
| Gariboldi, M | 1 |
| Mogavero, A | 1 |
| Negri, T | 1 |
| Pasanisi, P | 1 |
| Pilotti, S | 1 |
| Hsieh, MC | 1 |
| Lee, TC | 1 |
| Cheng, SM | 1 |
| Yen, MH | 1 |
| Barrière, G | 1 |
| Tartary, M | 1 |
| Rigaud, M | 1 |
| Birsoy, K | 1 |
| Possemato, R | 1 |
| Fonseca, V | 1 |
| Brower, V | 1 |
| Tosetti, F | 1 |
| Li, VW | 1 |
| Li, WW | 1 |
| Stevens, RJ | 2 |
| Ali, R | 1 |
| Bankhead, CR | 1 |
| Bethel, MA | 1 |
| Cairns, BJ | 2 |
| Camisasca, RP | 1 |
| Crowe, FL | 1 |
| Farmer, AJ | 1 |
| Harrison, S | 1 |
| Hirst, JA | 1 |
| Home, P | 1 |
| McLellan, JH | 1 |
| Perera, R | 1 |
| Plüddemann, A | 1 |
| Ramachandran, A | 1 |
| Roberts, NW | 1 |
| Rose, PW | 1 |
| Schweizer, A | 1 |
| Holman, RR | 2 |
| Pollak, MN | 1 |
| Smith-Vikos, T | 1 |
| Ross, FA | 1 |
| Hawley, SA | 1 |
| Qiu, H | 1 |
| Rhoads, GG | 1 |
| Berlin, JA | 1 |
| Marcella, SW | 1 |
| Demissie, K | 1 |
| Thompson, MD | 1 |
| Thompson, HJ | 1 |
| Mahmood, K | 1 |
| Naeem, M | 1 |
| Rahimnajjad, NA | 1 |
| Emami Riedmaier, A | 1 |
| Fisel, P | 1 |
| Korsse, SE | 1 |
| Peppelenbosch, MP | 1 |
| van Veelen, W | 1 |
| Tan, X | 1 |
| Filippi, L | 1 |
| Ungar, A | 1 |
| Sgrilli, F | 1 |
| Antenore, A | 1 |
| Bagnoli, P | 1 |
| Habibollahi, P | 1 |
| van den Berg, NS | 1 |
| Kuruppu, D | 1 |
| Loda, M | 1 |
| Mahmood, U | 1 |
| Lund, SS | 1 |
| Emslie-Smith, AM | 1 |
| Majumdar, SR | 1 |
| Towler, MC | 1 |
| Buzzai, M | 1 |
| Amaravadi, RK | 1 |
| Lum, JJ | 1 |
| Zhao, F | 1 |
| Thompson, CB | 1 |
| Pauli, JR | 1 |
| Zecchin, KG | 1 |
| Ueno, M | 1 |
| de Souza, CT | 1 |
| Morari, J | 1 |
| Faria, MC | 1 |
| Velloso, LA | 1 |
| Pollack, MN | 1 |
| Roth, GS | 1 |
| Ingram, DK | 1 |
| Lane, MA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prospective Evaluation of Clinical Safety of Combining Metformin With Anticancer Chemotherapy[NCT01442870] | Phase 1 | 105 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| Prevention of Pre-eclampsia Using Metformin: a Randomized Control Trial[NCT04855513] | 414 participants (Anticipated) | Interventional | 2022-03-24 | Not yet recruiting | |||
| A Multi-center, Prospective, Cohort Study to Elucidate the Effects of Metformin Treatment on Steroid Hormones and Social Behavior. Linking Autistic Behaviorial Symptoms to Changes in Steroid Hormone Availability[NCT04930471] | 45 participants (Anticipated) | Observational | 2021-06-30 | Not yet recruiting | |||
| The Role of Sirolimus in Preventing Functional Decline in Older Adults[NCT05237687] | Phase 2 | 14 participants (Anticipated) | Interventional | 2024-03-31 | Not yet recruiting | ||
| Safety of Lanreotide 120 mg ATG in Combination With Metformin in Patients With Progressive Advanced Well-differentiated Gastro-intestinal (GI) or Lung Carcinoids: A Pilot, One-arm, Open-label, Prospective Study: the MetNET-2 Trial[NCT02823691] | Early Phase 1 | 20 participants (Actual) | Interventional | 2016-04-30 | Active, not recruiting | ||
| Pasta and Other Durum Wheat-based Products: Effects on Post-prandial Glucose Metabolism[NCT03024983] | 18 participants (Actual) | Interventional | 2015-09-30 | Completed | |||
| Pasta and Bread Prepared With Durum Wheat Semolina: Effect on Post-prandial Glucose and Insulin Metabolism[NCT03104686] | 30 participants (Actual) | Interventional | 2017-04-10 | Completed | |||
| Pasta and Couscous Prepared With Durum Wheat Semolina: Effect on Post-prandial Glucose and Insulin Metabolism[NCT03098017] | 30 participants (Actual) | Interventional | 2017-03-13 | Completed | |||
| A Multicenter, International Randomized, 2x2 Factorial Design Study to Evaluate the Effects of Lantus (Insulin Glargine) Versus Standard Care, and of Omega-3 Fatty Acids Versus Placebo, in Reducing Cardiovascular Morbidity and Mortality in High Risk Peopl[NCT00069784] | Phase 3 | 12,537 participants (Actual) | Interventional | 2003-08-31 | Completed | ||
| A Randomized Phase 3 Trial of Metformin in Patients Initiating Androgen Deprivation Therapy as Prevention and Intervention of Metabolic Syndrome: The Prime Study[NCT03031821] | Phase 3 | 168 participants (Actual) | Interventional | 2018-07-12 | Terminated (stopped due to Manufacturer discontinued the production of study drugs.) | ||
| Metformin Pharmacology in Human Cancers[NCT03477162] | Early Phase 1 | 18 participants (Actual) | Interventional | 2018-05-15 | Terminated (stopped due to Enrollment was closed as efforts had become more challenging, and the lab indicated that they were able to obtain their primary objective with the number that had already been enrolled.) | ||
| A Long Term, Open Label, Randomised Study in Patients With Type 2 Diabetes, Comparing the Combination of Rosiglitazone and Either Metformin or Sulfonylurea With Metformin Plus Sulfonylurea on Cardiovascular Endpoints and Glycaemia[NCT00379769] | Phase 3 | 4,447 participants (Actual) | Interventional | 2001-04-30 | Completed | ||
| Neoadjuvant Chemotherapy With or Without Metformin in Early Breast Cancer.[NCT04387630] | Phase 2/Phase 3 | 120 participants (Anticipated) | Interventional | 2020-06-05 | Recruiting | ||
| Effectiveness of the Treatment With Dapagliflozin and Metformin Compared to Metformin Monotherapy for Weight Loss on Diabetic and Prediabetic Patients With Obesity Class III[NCT03968224] | Phase 2/Phase 3 | 90 participants (Anticipated) | Interventional | 2018-07-07 | Recruiting | ||
| "Randomized, Double-blind, Placebo-controlled Study to Assess the Effect of Metformin, an Activator of AMPK, on Cognitive Measures of Progression in Huntington's Disease Patients"[NCT04826692] | Phase 3 | 60 participants (Anticipated) | Interventional | 2021-12-10 | Recruiting | ||
| A Prospective, Randomized Open-Label Phase II Study of the Safety and Tolerability of Metformin in Combination With Standard Antimicrobial Treatment of Pulmonary Tuberculosis in People With TB and Co-infected With HIV[NCT04930744] | Phase 2 | 112 participants (Anticipated) | Interventional | 2021-08-03 | Recruiting | ||
| Metformin and Neo-adjuvant Temozolomide and Hypofractionated Accelerated Limited-margin Radiotherapy Followed by Adjuvant Temozolomide in Patients With Glioblastoma Multiforme (M-HARTT STUDY)[NCT02780024] | Phase 2 | 50 participants (Anticipated) | Interventional | 2015-03-31 | Active, not recruiting | ||
| Adaptive Study for Efficacy and Safety of Metformin Glycinate for the Treatment of Patients With MS and DM2, Hospitalized With Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2. Randomized, Double-Blind, Phase IIIb.[NCT04626089] | Phase 2 | 0 participants (Actual) | Interventional | 2021-02-28 | Withdrawn (stopped due to Administrative decision of the company) | ||
| The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma[NCT02978547] | Phase 2 | 20 participants (Anticipated) | Interventional | 2019-01-31 | Not yet recruiting | ||
| A Meta Analysis of Malignancy Serious Adverse Events in the ADOPT, 49653/048, and RECORD, 49653/231, Studies, Comparing Metformin With Rosiglitazone.[NCT01195259] | 1 participants (Actual) | Observational | 2009-10-31 | Completed | |||
| Drug Repurposing Using Metformin for Improving the Therapeutic Outcome in Multiple Sclerosis Patients[NCT05298670] | Phase 2 | 80 participants (Anticipated) | Interventional | 2022-02-01 | Recruiting | ||
| Mansmed Trial : Repurposing Metformin as Anticancer Drug, RCT in Advanced Prostate Cancer[NCT03137186] | Phase 2 | 120 participants (Anticipated) | Interventional | 2017-01-31 | Recruiting | ||
| ADVANCE - Action in Diabetes and Vascular Disease: Preterax and Diamicron - MR Controlled Evaluation[NCT00145925] | Phase 3 | 11,140 participants (Actual) | Interventional | 2001-06-30 | Completed | ||
| Phase II Trial of Metformin Combined to Irinotecan for Refractory Metastatic or Recurrent Colorectal Cancer[NCT01930864] | Phase 2 | 41 participants (Anticipated) | Interventional | 2015-09-01 | Recruiting | ||
| Assessing the Efficacy and Safety of Metformin in Treatment of Moderate Psoriasis: A Prospective Randomized Double Blind Controlled Study[NCT02644954] | Phase 3 | 40 participants (Anticipated) | Interventional | 2016-01-31 | Not yet recruiting | ||
| Multicenter, Randomized, Controlled Clinical Trial Research Evaluating the Use of Combination Therapy of Glucocorticoids and Metformin to Decrease Glucocorticoids Side Effects in Patients With Autoimmune Uveitis[NCT03525028] | 138 participants (Anticipated) | Interventional | 2018-11-01 | Recruiting | |||
| Phase II Trial, Open Label, Clinical Activity of Metformin in Combination With High-dose of Dexamethasone (HDdexa) in Patients With Relapsed/Refractory Multiple Myeloma[NCT02967276] | Phase 2 | 28 participants (Anticipated) | Interventional | 2017-01-31 | Recruiting | ||
| Effect of Metformin on ABCB1 and AMPK Expression in Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia[NCT05326984] | 20 participants (Anticipated) | Interventional | 2021-02-09 | Recruiting | |||
| Phase II Randomized Study of Neoadjuvant Metformin Plus Letrozole vs Placebo Plus Letrozole for ER-positive Postmenopausal Breast Cancer[NCT01589367] | Phase 2 | 208 participants (Actual) | Interventional | 2012-05-31 | Completed | ||
| Evaluation of Longevity Diet and Fasting Mimicking Diet Programs on Body Composition, Disease Risk Factors, and Aging Markers: a Randomized Clinical Trial[NCT05698654] | 501 participants (Anticipated) | Interventional | 2023-01-30 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The incidence was determined by calculating the proportion of randomized participants without diabetes at randomization who either developed diabetes during the study or who were classified as having possible diabetes based on results of two oral glucose tolerance tests (OGTT) performed after the last follow-up visit (within 21-28 days for OGTT#1 and within 10-14 weeks for OGTT#2). (NCT00069784)
Timeframe: from randomization until the last follow-up visit or last OGTT (median duration of follow-up: 6.2 years)
| Intervention | percentage of patients (Number) |
|---|---|
| Insulin Glargine | 24.7 |
| Standard Care | 31.2 |
Data on cancers that occurred in association with hospitalizations were collected systematically in both groups from the start of the study. All reported cancers occurring during the trial (new or recurrent) were adjudicated by the Event Adjudication Committee. (NCT00069784)
Timeframe: from randomization until study cut-off date (median duration of follow-up: 6.2 years)
| Intervention | participants (Number) |
|---|---|
| Insulin Glargine | 559 |
| Standard Care | 561 |
Number of deaths due to any cause (NCT00069784)
Timeframe: from randomization until study cut-off date (median duration of follow-up: 6.2 years)
| Intervention | participants (Number) |
|---|---|
| Insulin Glargine | 951 |
| Standard Care | 965 |
"The composite outcome used to analyze microvascular disease progression contained components of clinical events:~the occurrence of laser surgery or vitrectomy for diabetic retinopathy (DR);~the development of blindness due to DR;~the occurrence of renal death or renal replacement therapy; as well as the following laboratory-based events:~doubling of serum creatinine; or~progression of albuminuria (from none to microalbuminuria [at least 30 mg/g creatinine], to macroalbuminuria [at least 300 mg/g creatinine])." (NCT00069784)
Timeframe: from randomization until study cut-off date (median duration of follow-up: 6.2 years)
| Intervention | participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Participants with a composite endpoint | Endpoint's composition: vitrectomy | Endpoint's composition: laser therapy for DR | Endpoint's composition: dialysis | Endpoint's composition: renal transplant | Endpoint's composition: serum creatinine doubled | Endpoint's composition: death due to renal failure | Endpoint's composition: albuminuria progression | |
| Insulin Glargine | 1323 | 24 | 57 | 18 | 0 | 82 | 4 | 1153 |
| Standard Care | 1363 | 25 | 67 | 28 | 0 | 88 | 3 | 1171 |
"Number of participants with a first occurrence of one of the above events.~The outcome's evaluation is based on the number of such positively-adjudicated first events occurring for patients assigned to the study groups. Assessments of the above events were reviewed by the Event Adjudication Committee who was kept blinded to the group assignment of participants.~Statistical analysis is performed on the time from randomization to the first occurrence of the events. Number of participants with a composite endpoint (i.e. with first occurrence of CV death, nonfatal MI or nonfatal stroke) is provided in the first row of the statistical table." (NCT00069784)
Timeframe: from randomization until study cut-off date (median duration of follow-up: 6.2 years)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Participants with a composite endpoint | Endpoint's composition: CV death | Endpoint's composition: nonfatal MI | Endpoint's composition: nonfatal stroke | |
| Insulin Glargine | 1041 | 484 | 297 | 261 |
| Standard Care | 1013 | 476 | 282 | 256 |
"Number of participants with a first occurrence of one of the above events (revascularization procedures included coronary artery bypass graft, percutaneous transluminal coronary angioplasty (PTCA) i.e. balloon, PTCA with stent, other percutaneous intervention, carotid angioplasty with/without stent, carotid endarterectomy, peripheral angioplasty with or without stent, peripheral vascular surgery, and limb amputation due to vascular disease).~The outcome's evaluation is based on the number of such positively-adjudicated first events occurring for patients assigned to the study groups. Assessments of the above events were reviewed by the Event Adjudication Committee who was kept blinded to the group assignment of participants.~Statistical analysis is performed on the time from randomization to the first occurrence of the events. Number of participants with a composite endpoint (i.e. with first occurrence of the events) is provided in the first row of the statistical table." (NCT00069784)
Timeframe: from randomization until study cut-off date (median duration of follow-up: 6.2 years)
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Participants with a composite endpoint | Endpoint's composition: CV death | Endpoint's composition: nonfatal MI | Endpoint's composition: nonfatal stroke | Endpoint's composition: revascularization | Endpoint's composition: hospitalization for HF | |
| Insulin Glargine | 1792 | 350 | 257 | 231 | 763 | 249 |
| Standard Care | 1727 | 339 | 238 | 227 | 717 | 259 |
"Symptomatic hypoglycemia was defined as an event with clinical symptoms consistent with hypoglycemia, based on data recorded in the participant's diary. These were further categorized as confirmed (ie, with a concomitant home glucose reading ≤54 mg/dL [≤3.0 mmol/L]) or unconfirmed.~Severe hypoglycemia was defined as an event with clinical symptoms consistent with hypoglycemia in which the participant required the assistance of another person, and one of the following:~the event was associated with a documented self-measured or laboratory plasma glucose level ≤36 mg/dL (≤2.0 mmol/L), or~the event was associated with prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration." (NCT00069784)
Timeframe: on-treatment period (median duration of follow-up: 6.2 years)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Patients with hypoglycemia events | Patients with non-severe hypoglycemia | Patients with confirmed non-severe hypoglycemia | Patients with severe hypoglycemia | |
| Insulin Glargine | 3597 | 3533 | 2581 | 352 |
| Standard Care | 1624 | 1582 | 904 | 113 |
To determine the concentration of metformin in adipose tissue. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/g (Median) |
|---|---|
| Metformin | 70 |
To determine the concentration of metformin in plasma. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/mL (Median) |
|---|---|
| Metformin | 450 |
To determine the concentration of metformin in tumor-adjacent normal tissue. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/g (Median) |
|---|---|
| Metformin | 749 |
To determine the concentration of metformin in whole blood. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/mL (Median) |
|---|---|
| Metformin | 514 |
To determine the intra-tumor concentrations of metformin, with a standard deviation ≤25% of the mean, in patients with solid tumors of thoracic origin administered metformin extended release. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/g (Median) |
|---|---|
| Metformin | 1290 |
IR was based on original RECORD endpoint definitions. CV death= no unequivocal non-CV cause (sudden death, death from acute vascular events, heart failure, acute MI, other CV causes, and deaths adjudicated as unknown cause). MI event=hospitalization + elevation of specific cardiac biomarkers above the upper limit of normal + cardiac ischemia symptoms/new pathological electrocardiogram findings. Stroke event=hospitalization + rapidly developed clinical signs of focal/global disturbance of cerebral function for more than 24 hours, with no apparent cause other than a vascular origin. (NCT00379769)
Timeframe: Baseline through End of Study (up to 7.5 years)
| Intervention | participants (Number) |
|---|---|
| Combined RSG | 181 |
| Combined MET/SU | 188 |
Par. with a stroke (fatal or non-fatal) event as determined by independent re-adjudication using the original RECORD endpoint definitions was recorded. A stroke event=hospitalization plus rapidly developed clinical signs of focal (or global) disturbance of cerebral function lasting more than 24 hours (unless interrupted by thrombolysis, surgery, or death), with no apparent cause other than a vascular origin, including par. presenting clinical signs/symptoms suggestive of subarachnoid haemorrhage/intracerebral haemorrhage/cerebral ischemic necrosis or cause of death adjudicated as stroke. (NCT00379769)
Timeframe: Baseline through End of Study (up to 7.5 years)
| Intervention | participants (Number) |
|---|---|
| Combined RSG | 50 |
| Combined MET/SU | 63 |
All deaths identified during the original record study and discovered after the re-adjudication efforts began were included. (NCT00379769)
Timeframe: Baseline through End of Study (up to 7.5 years)
| Intervention | participants (Number) |
|---|---|
| Combined RSG | 139 |
| Combined MET/SU | 160 |
The number of participants with a CV (or unknown) death as determined by independent re-adjudication using the Standard Data Collection for Cardiovascular Trials Initiative (draft October 2011) endpoint definitions was recorded. CV death included death resulting from an acute myocardial infarction (MI), sudden cardiac death, death due to heart failure, death due to stroke, and death due to other CV causes. Deaths of unknown cause were counted as CV deaths. (NCT00379769)
Timeframe: Baseline through End of Study (up to 7.5 years)
| Intervention | participants (Number) |
|---|---|
| Combined RSG | 88 |
| Combined MET/SU | 96 |
"The number of participants with a CV death (or unknown) as determined by independent re-adjudication using the original RECORD endpoint definitions was recorded. CV death was defined as any death for which an unequivocal non-CV cause could not be established. CV death included death following heart failure, death following acute myocardial infarction (MI), sudden death, death due to acute vascular events, and other CV causes. Deaths due to unknown causes were classified as unknown deaths, but were counted as CV deaths for the analysis of this endpoint." (NCT00379769)
Timeframe: Baseline through End of Study (up to 7.5 years)
| Intervention | participants (Number) |
|---|---|
| Combined RSG | 88 |
| Combined MET/SU | 96 |
Independent re-adjudication was based on the Standard Data Collection for Cardiovascular Trials Initiative (draft October 2011) endpoint definitions. CV death included death resulting from an acute MI; sudden cardiac death and death due to heart failure, stroke, and to other CV causes. Deaths of unknown cause were counted as CV deaths. MI was defined as evidence of myocardial necrosis in a clinical setting consistent with myocardial ischemia. Stroke was defined as an acute episode of neurological dysfunction caused by focal or global brain, spinal cord, or retinal vascular injury. (NCT00379769)
Timeframe: Baseline through End of Study (up to 7.5 years)
| Intervention | participants (Number) |
|---|---|
| Combined RSG | 186 |
| Combined MET/SU | 191 |
The number of participants with an MI (fatal or non-fatal) event as determined by independent re-adjudication using the Standard Data Collection for Cardiovascular Trials Initiative (draft October 2011) endpoint definitions was recorded. An event of MI was defined as evidence of myocardial necrosis in a clinical setting consistent with myocardial ischemia. (NCT00379769)
Timeframe: Baseline through End of Study (up to 7.5 years)
| Intervention | participants (Number) |
|---|---|
| Combined RSG | 72 |
| Combined MET/SU | 62 |
The number of participants with an MI (fatal or non-fatal) event as determined by independent re-adjudication using the original RECORD endpoint definitions was recorded. An event of MI was defined as hospitalization plus elevation of cardiac biomarkers troponin (TN) I and/or TNT above the upper limit of normal (ULN) or creatinine kinase (CK) MB (M=muscle type; B=brain type) isoenzyme >= 2x the ULN or CK > 2x the ULN plus typical symptoms of cardiac ischemia or new pathological electrocardiogram findings, or cause of death adjudicated as MI. (NCT00379769)
Timeframe: Baseline through End of Study (up to 7.5 years)
| Intervention | participants (Number) |
|---|---|
| Combined RSG | 68 |
| Combined MET/SU | 60 |
The number of participants with a stroke (fatal or non-fatal) event as determined by independent re-adjudication using the Standard Data Collection for Cardiovascular Trials Initiative (draft October 2011) endpoint definitions was recorded. An event of stroke was defined as an acute episode of neurological dysfunction caused by focal or global brain, spinal cord, or retinal vascular injury. (NCT00379769)
Timeframe: Baseline through End of Study (up to 7.5 years)
| Intervention | participants (Number) |
|---|---|
| Combined RSG | 53 |
| Combined MET/SU | 64 |
Model adjusted (adjusted for any imbalances in the baseline values between within stratum treatment groups) change from baseline in alanine aminotransferase was calculated as the value at Month 60 minus the Baseline value. (NCT00379769)
Timeframe: Baseline to Month 60 of the randomised dual therapy treatment phase
| Intervention | U/L (Units/Liter) (Mean) |
|---|---|
| RSG in Addition to Background MET | -37.43 |
| SU in Addition to Background MET | -21.73 |
| RSG in Addition to Background SU | -30.17 |
| MET in Addition to Background SU | -24.00 |
Model adjusted (adjusted for any imbalances in the baseline values between within stratum treatment groups) change from baseline in body weight was calculated as the value at Month 60 minus the Baseline value. (NCT00379769)
Timeframe: Baseline to Month 60 of the randomised dual therapy treatment phase
| Intervention | kilograms (Mean) |
|---|---|
| RSG in Addition to Background MET | 3.93 |
| SU in Addition to Background MET | -0.54 |
| RSG in Addition to Background SU | 4.72 |
| MET in Addition to Background SU | -2.16 |
Model adjusted (adjusted for any imbalances in the baseline values between within stratum treatment groups) change from baseline in fasting plasma glucose was calculated as the value at Month 60 minus the Baseline value. (NCT00379769)
Timeframe: Baseline to Month 60 of the randomised dual therapy treatment period
| Intervention | mmol/L (millimoles/Liter) (Mean) |
|---|---|
| RSG in Addition to Background MET | -1.38 |
| SU in Addition to Background MET | -0.29 |
| RSG in Addition to Background SU | -2.00 |
| MET in Addition to Background SU | -0.94 |
Model adjusted (adjusted for any imbalances in the baseline values between within stratum treatment groups) change from baseline in HbA1c was calculated as the value at Month 60 minus the Baseline value. (NCT00379769)
Timeframe: Baseline and Month 60 of randomised dual therapy treatment period
| Intervention | Percent (Mean) |
|---|---|
| RSG in Addition to Background MET | -0.14 |
| SU in Addition to Background MET | 0.17 |
| RSG in Addition to Background SU | -0.24 |
| MET in Addition to Background SU | -0.10 |
Model adjusted (adjusted for any imbalances in the baseline values between within stratum treatment groups) change from baseline in waist circumference was calculated as the value at Month 60 minus the Baseline value. (NCT00379769)
Timeframe: Baseline to Month 60 of the randomised dual therapy treatment phase
| Intervention | cm (centimeters) (Mean) |
|---|---|
| RSG in Addition to Background MET | 2.70 |
| SU in Addition to Background MET | 0.65 |
| RSG in Addition to Background SU | 3.00 |
| MET in Addition to Background SU | -0.60 |
The model adjusted (adjusted for any imbalances in the baseline [BL] values between within stratum treatment groups) ratio to BL in Apo-B was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100*[GM^-1]). (NCT00379769)
Timeframe: Baseline to Month 60 of the randomised dual therapy treatment period
| Intervention | percent change (Geometric Mean) |
|---|---|
| RSG in Addition to Background MET | -13.77 |
| SU in Addition to Background MET | -11.63 |
| RSG in Addition to Background SU | -9.68 |
| MET in Addition to Background SU | -12.09 |
The model adjusted (adjusted for any imbalances in the baseline [BL] values between within stratum treatment groups) ratio to BL in C-Reactive Protein was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100*[GM^-1]). (NCT00379769)
Timeframe: Baseline to Month 60 of the randomised dual therapy treatment phase
| Intervention | percent change (Geometric Mean) |
|---|---|
| RSG in Addition to Background MET | -57.40 |
| SU in Addition to Background MET | -28.92 |
| RSG in Addition to Background SU | -56.50 |
| MET in Addition to Background SU | -36.29 |
The model adjusted (adjusted for any imbalances in the baseline [BL] values between within stratum treatment groups) ratio to BL in fibrinogen was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100*[GM^-1]). (NCT00379769)
Timeframe: Baseline to Month 60 of the randomised dual therapy treatment phase
| Intervention | percent change (Geometric Mean) |
|---|---|
| RSG in Addition to Background MET | 2.12 |
| SU in Addition to Background MET | 5.74 |
| RSG in Addition to Background SU | -0.23 |
| MET in Addition to Background SU | 3.14 |
The model adjusted (adjusted for any imbalances in the baseline [BL] values between within stratum treatment groups) ratio to BL in plasminogen activator inhibitor-1 (PAI-1) antigen was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100*[GM^-1]). (NCT00379769)
Timeframe: Baseline to Month 60 of the randomised dual therapy treatment phase
| Intervention | percent change (Geometric Mean) |
|---|---|
| RSG in Addition to Background MET | -9.85 |
| SU in Addition to Background MET | 15.01 |
| RSG in Addition to Background SU | -7.79 |
| MET in Addition to Background SU | -0.64 |
The model adjusted (adjusted for any imbalances in the baseline [BL] values between within stratum treatment groups) ratio to BL in urinary albumin creatinine ratio was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100*[GM^-1]). (NCT00379769)
Timeframe: Baseline to Month 60 of the randomised dual therapy treatment phase
| Intervention | percent change (Geometric Mean) |
|---|---|
| RSG in Addition to Background MET | 8.31 |
| SU in Addition to Background MET | 15.17 |
| RSG in Addition to Background SU | -3.43 |
| MET in Addition to Background SU | 11.91 |
The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. (NCT00379769)
Timeframe: From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)
| Intervention | participants (Number) |
|---|---|
| Combined RSG: Main Study and Observational Follow-up | 0 |
| Combined MET/SU: Main Study and Observational Follow-up | 0 |
The number of participants with cardiovascular death events (death due to cardiovascular causes or deaths with insufficient information to rule out a cardiovascular cause) and cardiovascular hospitalisation events (hospitalisation for a cardiovascular event, excluding planned admissions not associated with a worsening of the disease/condition of the participant) was recorded. (NCT00379769)
Timeframe: Baseline through End of Study (up to 7.5 years)
| Intervention | participants (Number) |
|---|---|
| Combined RSG | 321 |
| Combined MET/SU | 323 |
Participants with first cardiovascular death (death due to cardiovascular causes or deaths with insufficient information to rule out a cardiovascular cause) and cardiovascular hospitalisation (hospitalisation for a cardiovascular event, excluding planned admissions not associated with a worsening of the disease/condition of the participant) were recorded by study stratum. (NCT00379769)
Timeframe: Baseline through End of Study (up to 7.5 years)
| Intervention | partcipants (Number) |
|---|---|
| RSG in Addition to Background MET | 158 |
| SU in Addition to Background MET | 154 |
| RSG in Addition to Background SU | 163 |
| MET in Addition to Background SU | 169 |
Failure of glycaemic control was defined as two consecutive HbA1c values of ≥8.5 percent, or HbA1c ≥8.5percent at a single visit, after which the subject was either moved to the post-randomised treatment phase or triple therapy was started. (NCT00379769)
Timeframe: Baseline through to end of randomised dual therapy
| Intervention | participants (Number) |
|---|---|
| RSG in Addition to Background MET | 281 |
| SU in Addition to Background MET | 451 |
| RSG in Addition to Background SU | 365 |
| MET in Addition to Background SU | 424 |
The number of participants starting insulin at any time during the study was recorded. (NCT00379769)
Timeframe: Baseline through End of Study (up to 7.5 years)
| Intervention | participants (Number) |
|---|---|
| RSG in Addition to Background MET | 126 |
| SU in Addition to Background MET | 276 |
| RSG in Addition to Background SU | 168 |
| MET in Addition to Background SU | 259 |
Model adjusted (adjusted for any imbalances in the baseline values between within treatment groups) change from baseline in SBP and DBP was calculated as the value at Month 60 minus the Baseline value. (NCT00379769)
Timeframe: Baseline to Month 60 of the randomised dual therapy treatment phase
| Intervention | mmHg (millimeters of mercury) (Mean) | |
|---|---|---|
| SBP | DBP | |
| MET in Addition to Background SU | -0.6 | -2.3 |
| RSG in Addition to Background MET | -1.9 | -3.6 |
| RSG in Addition to Background SU | -2.3 | -3.6 |
| SU in Addition to Background MET | -2.2 | -3.4 |
Model adjusted (adjusted for any imbalances in the baseline values between within stratum treatment groups) change from baseline in insulin and pro-insulin was calculated as the value at Month 60 minus the Baseline value. (NCT00379769)
Timeframe: Baseline to Month 60 of the randomised dual therapy treatment period
| Intervention | picamoles/liter (pmol/L) (Mean) | |
|---|---|---|
| Insulin, Adjusted Change from Baseline | Pro-insulin, Adjusted Change from Baseline | |
| MET in Addition to Background SU | -12.1 | -3.0 |
| RSG in Addition to Background MET | -18.6 | -2.4 |
| RSG in Addition to Background SU | -16.9 | -3.2 |
| SU in Addition to Background MET | 3.7 | 4.2 |
The model adjusted (adjusted for any imbalances in the baseline [BL] values between within stratum treatment groups) ratio to BL in TC, LDL cholesterol, HDL cholesterol, triglycerides, and FFAs was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100*[GM^-1]). (NCT00379769)
Timeframe: Baseline to Month 60 of the randomised dual therapy treatment phase
| Intervention | percent change (Geometric Mean) | ||||
|---|---|---|---|---|---|
| Total cholesterol | HDL-cholesterol | LDL-cholesterol | Triglycerides | Free fatty acids | |
| MET in Addition to Background SU | -9.68 | 6.14 | -17.80 | -2.50 | 4.47 |
| RSG in Addition to Background MET | -5.49 | 9.95 | -12.70 | -7.97 | -16.46 |
| RSG in Addition to Background SU | -2.91 | 7.73 | -8.99 | -2.68 | -11.58 |
| SU in Addition to Background MET | -9.09 | 2.57 | -17.68 | -1.95 | 2.79 |
The model adjusted (adjusted for any imbalances in the baseline [BL] values between within stratum treatment groups) ratio to BL in TC:HDL cholesterol and LDL cholesterol:HDL cholesterol was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100*[GM^-1]). (NCT00379769)
Timeframe: Baseline to Month 60 of the randomised dual therapy treatment period
| Intervention | percent change (Geometric Mean) | |
|---|---|---|
| Total Cholesterol: HDL Cholesterol Ratio | LDL Cholesterol: HDL-Cholesterol Ratio | |
| MET in Addition to Background SU | -15.01 | -22.53 |
| RSG in Addition to Background MET | -14.20 | -20.89 |
| RSG in Addition to Background SU | -9.93 | -15.85 |
| SU in Addition to Background MET | -11.33 | -20.04 |
The model adjusted (adjusted for any imbalances in the baseline [BL] values between within stratum treatment groups) ratio to BL in HOMA beta-cell function and insulin sensitivity was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100*[GM^-1]). (NCT00379769)
Timeframe: Baseline to Month 60 of the randomised dual therapy treatment phase
| Intervention | percent change (Geometric Mean) | |
|---|---|---|
| Beta cell function | Insulin sensitivity | |
| MET in Addition to Background SU | 12.43 | 23.90 |
| RSG in Addition to Background MET | 20.54 | 42.57 |
| RSG in Addition to Background SU | 32.35 | 42.07 |
| SU in Addition to Background MET | 19.28 | -3.45 |
"The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. The indicated fracture outcome was pre-specified in the CRF and included Unknown as a category. Fracture events with missing outcome data were reported as Data unavailable." (NCT00379769)
Timeframe: From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)
| Intervention | bone fracture events (Number) | |||||
|---|---|---|---|---|---|---|
| Number of bone fracture events | Unknown | Normal healing with standard management | Complication | Additional therapeutic measures required | Data unavailable | |
| Combined MET/SU: Main Study and Observational Follow-up | 174 | 5 | 142 | 13 | 9 | 5 |
| Combined RSG: Main Study and Observational Follow-up | 299 | 7 | 250 | 14 | 16 | 12 |
"The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. The indicated fracture outcome was pre-specified in the CRF and included Unknown as a category. Fracture events with missing outcome data were reported as Data unavailable." (NCT00379769)
Timeframe: From the end of the RECORD study through the end of the observational follow-up (up to 4.0 years)
| Intervention | bone fracture events (Number) | |||||
|---|---|---|---|---|---|---|
| Number of bone fracture events | Unknown | Normal healing with standard management | Complication | Additional therapeutic measures required | Data unavailable | |
| Combined MET/SU: Observational Follow-up | 41 | 1 | 33 | 4 | 2 | 1 |
| Combined RSG: Observational Follow-up | 70 | 1 | 51 | 7 | 3 | 8 |
Number of responders, i.e., participants meeting glycaemic targets (HbA1c less than or equal to 7 percent, FPG less than or equal to 7 mmol/L) (NCT00379769)
Timeframe: Baseline to Month 60 of the randomised dual therapy treatment period
| Intervention | participants (Number) | |
|---|---|---|
| HbA1c Responders | FPG Responders | |
| MET in Addition to Background SU | 180 | 154 |
| RSG in Addition to Background MET | 265 | 300 |
| RSG in Addition to Background SU | 235 | 257 |
| SU in Addition to Background MET | 208 | 180 |
The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE. (NCT00379769)
Timeframe: From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)
| Intervention | participants (Number) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any cancer-related death | Any gastrointestinal event | Pancreatic | Colon/rectal | Gastric | Liver | Gall bladder/biliary | Gastrointestinal event; not specified | Any genitourinary event | Renal | Uterine | Prostate | Bladder | Ovarian | Lung | Any hematologic event | Skin (melanoma) | Skin (non-melanomatous) | Metastases | Breast | Head and neck | Any neurologic event | Endocrine | Not specified | |
| Combined MET/SU: Main Study and Observational Follow-up | 72 | 34 | 12 | 11 | 3 | 4 | 3 | 1 | 15 | 3 | 5 | 2 | 3 | 2 | 11 | 0 | 0 | 0 | 4 | 3 | 2 | 2 | 0 | 1 |
| Combined RSG: Main Study and Observational Follow-up | 59 | 25 | 4 | 6 | 7 | 4 | 4 | 0 | 6 | 2 | 1 | 1 | 1 | 1 | 13 | 4 | 3 | 1 | 2 | 2 | 1 | 2 | 1 | 0 |
The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE. (NCT00379769)
Timeframe: From the end of the RECORD study through the end of the observational follow-up (up to 4.0 years)
| Intervention | participants (Number) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any cancer-related death | Any gastrointestinal event | Pancreatic | Colon/rectal | Gastric | Liver | Gall bladder/biliary | Gastrointestinal event; not specified | Any genitourinary event | Renal | Uterine | Prostate | Bladder | Ovarian | Lung | Any hematologic event | Skin (melanoma) | Skin (non-melanomatous) | Metastases | Breast | Head and neck | Any neurologic event | Endocrine | Not specified | |
| Combined MET/SU: Observational Follow-up | 24 | 14 | 3 | 6 | 1 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 1 | 3 | 0 | 1 | 0 | 0 |
| Combined RSG: Observational Follow-up | 25 | 10 | 3 | 2 | 2 | 2 | 1 | 0 | 2 | 1 | 1 | 0 | 0 | 0 | 4 | 4 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 |
The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. (NCT00379769)
Timeframe: From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)
| Intervention | participants (Number) | ||
|---|---|---|---|
| Overall, n=2220, 2227 | Male, n=1142, 1152 | Female, n=1078, 1075 | |
| Combined MET/SU: Main Study and Observational Follow-up | 151 | 60 | 91 |
| Combined RSG: Main Study and Observational Follow-up | 238 | 82 | 156 |
The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. (NCT00379769)
Timeframe: From the end of the RECORD study through the end of the observational follow-up (up to 4.0 years)
| Intervention | participants (Number) | ||
|---|---|---|---|
| Overall, n=1280, 1250 | Male, n=665, 635 | Female, n=615, 615 | |
| Combined MET/SU: Observational Follow-up | 37 | 11 | 26 |
| Combined RSG: Observational Follow-up | 64 | 25 | 39 |
The OFU was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the OFU. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE. (NCT00379769)
Timeframe: From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Any event | Upper limb | Distal lower limb | Femur/hip | Spinal | Pelvic | Other | |
| Combined MET/SU: Main Study and Observational Follow-up | 57 | 17 | 16 | 11 | 9 | 3 | 4 |
| Combined RSG: Main Study and Observational Follow-up | 81 | 41 | 24 | 15 | 7 | 0 | 7 |
The OFU was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the OFU. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE. (NCT00379769)
Timeframe: From the end of the RECORD study through the end of the observational follow-up (up to 4.0 years)
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Any event | Upper limb | Distal lower limb | Femur/hip | Spinal | Pelvic | Other | |
| Combined MET/SU: Observational Follow-up | 21 | 5 | 8 | 4 | 3 | 1 | 1 |
| Combined RSG: Observational Follow-up | 35 | 17 | 9 | 6 | 2 | 0 | 2 |
The number of participants with addition of a third oral agent or switch to insulin from randomised dual combination treatment were recorded. (NCT00379769)
Timeframe: Baseline through End of Study (up to 7.5 years)
| Intervention | participants (Number) | ||
|---|---|---|---|
| Participants with an event | First Event - Triple Therapy | First Event - Insulin | |
| MET in Addition to Background SU | 171 | 6 | 165 |
| RSG in Addition to Background MET | 295 | 257 | 38 |
| RSG in Addition to Background SU | 344 | 296 | 49 |
| SU in Addition to Background MET | 183 | 7 | 176 |
The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. (NCT00379769)
Timeframe: From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Any event | Non-traumatic event | Traumatic event | Pathologic | Unknown | Data unavailable | |
| Combined MET/SU: Main Study and Observational Follow-up | 151 | 55 | 77 | 4 | 19 | 3 |
| Combined RSG: Main Study and Observational Follow-up | 238 | 113 | 110 | 1 | 20 | 9 |
"The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. The indicated fracture outcome was pre-specified in the CRF and included Unknown as a category. Fracture events with missing outcome data were reported as Data unavailable." (NCT00379769)
Timeframe: From the end of the RECORD study through the end of the observational follow-up (up to 4.0 years)
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Any event | Non-traumatic event, | Traumatic event | Pathologic | Unknown | Data unavailable | |
| Combined MET/SU: Observational Follow-up | 37 | 14 | 17 | 2 | 4 | 1 |
| Combined RSG: Observational Follow-up | 64 | 36 | 24 | 1 | 1 | 3 |
Composites of participants with first cardiovascular (CV) hospitalisations and CV death or all-cause death and individual first events of acute myocardial infarction (MI) , stroke, congestive heart failure (CHF), CV death, and all-cause death. (NCT00379769)
Timeframe: Baseline through End of Study (up to 7.5 years)
| Intervention | participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| CV death, acute MI, stroke | CV death, acute MI, stroke, unstable angina | CV death, acute MI, stroke, unstable angina, CHF | All-cause death,acuteMI,stroke,unstable angina,CHF | Acute MI (fatal or non-fatal) | Stroke (fatal or non-fatal) | CHF (fatal or non-fatal) | Death from CV causes | Death (all cause) during CV follow-up | Death (all-cause) including survival status | |
| Combined MET/SU | 165 | 184 | 206 | 268 | 56 | 63 | 29 | 71 | 139 | 157 |
| Combined RSG | 154 | 171 | 204 | 251 | 64 | 46 | 61 | 60 | 111 | 136 |
The number of participants with first cardiovascular or microvascular events (renal, foot, eye) were recorded. (NCT00379769)
Timeframe: Baseline through End of Study (up to 7.5 years)
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Participants with a CV/Microvascular event | Participants with any microvascular event | Participants with any eye event | Participants with any foot event | Participants with any renal event | |
| Combined MET/SU | 385 | 78 | 52 | 28 | 0 |
| Combined RSG | 363 | 59 | 42 | 19 | 0 |
The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. The following bone fractures were grouped and were identified as potentially high morbidity bone fractures: hip, pelvis, upper leg, vertebral (lumbar spine, thoracic spine, cervical spine, spine - site unknown). (NCT00379769)
Timeframe: From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)
| Intervention | participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Any H/UA/FF event, overall, n=2220, 2227 | Any H/UA/FF event, male, n=1142, 1152 | Any H/UA/FF event, female, n=1078, 1075 | High morbidity fractures, overall, n=2220, 2227 | High morbidity fractures, male, n=1142, 1152 | High morbidity fractures, female, n=1078, 1075 | Non-high morbidity fractures, overall, n=2220, 222 | Non-high morbidity fractures, male, n=1142, 1152 | Non-high morbidity fractures, female, n=1078, 1075 | |
| Combined MET/SU: Main Study and Observational Follow-up | 46 | 15 | 31 | 1 | 0 | 1 | 4 | 3 | 1 |
| Combined RSG: Main Study and Observational Follow-up | 86 | 28 | 58 | 5 | 0 | 5 | 15 | 2 | 13 |
The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. The following bone fractures were grouped and were identified as potentially high morbidity bone fractures: hip, pelvis, upper leg, vertebral (lumbar spine, thoracic spine, cervical spine, spine - site unknown). (NCT00379769)
Timeframe: From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)
| Intervention | participants (Number) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any event, overall, n=2220, 2227 | Any event, male, n=1142, 1152 | Any event, female, n=1078, 1075 | Hip, overall, n=2220, 2227 | Hip, male, n=1142, 1152 | Hip, female, n=1078, 1075 | Pelvis, overall, n=2220, 2227 | Pelvis, male, n=1142, 1152 | Pelvis, female, n=1078, 1075 | Upper leg, overall, n=2220, 2227 | Upper leg, male, n=1142, 1152 | Upper leg, female, n=1078, 1075 | Any vertebral event, overall, n=2220, 2227 | Any vertebral event, male, n=1142, 1152 | Any vertebral event, female, n=1078, 1075 | Lumbar spine, overall, n=2220, 2227 | Lumbar spine, male, n=1142, 1152 | Lumbar spine, female, n=1078, 1075 | Thoracic spine, overall, n=2220, 2227 | Thoracic spine, male, n=1142, 1152 | Thoracic spine, female, n=1078, 1075 | Cervical spine, overall, n=2220, 2227 | Cervical spine, male, n=1142, 1152 | Cervical spine, female, n=1078, 1075 | |
| Combined MET/SU: Main Study and Observational Follow-up | 31 | 13 | 18 | 7 | 1 | 6 | 5 | 4 | 1 | 6 | 0 | 6 | 13 | 8 | 5 | 4 | 3 | 1 | 8 | 4 | 4 | 1 | 1 | 0 |
| Combined RSG: Main Study and Observational Follow-up | 31 | 10 | 21 | 9 | 0 | 9 | 0 | 0 | 0 | 7 | 4 | 3 | 16 | 6 | 10 | 10 | 5 | 5 | 5 | 1 | 4 | 1 | 0 | 1 |
The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date that had the same Higher Level Group Term (HLGT) for fracture location, per participant. (NCT00379769)
Timeframe: From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)
| Intervention | participants (Number) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any event, overall; n=2220, 2227 | Any event, male; n=1142, 1152 | Any event, female; n=1078, 1075 | Upper limb, any event, overall; n=2220, 2227 | Upper limb, any event, male; n=1142, 1152 | Upper limb, any event, female; n=1078, 1075 | Distal lower limb, any event, overall; n=2220, 222 | Distal lower limb, any event, male; n=1142, 1152 | Distal lower limb, any event, female; n=1078, 1075 | Femur/hip, any event, overall; n=2220, 2227 | Femur/hip, any event, male; n=1142, 1152 | Femur/hip, any event, female; n=1078, 1075 | Spinal, any event, overall; n=2220, 2227 | Spinal, any event, male; n=1142, 1152 | Spinal, any event, female; n=1078, 1075 | Pelvic, any event, overall; n=2220, 2227 | Pelvic, any event, male; n=1142, 1152 | Pelvic, any event, female; n=1078, 1075 | Unclassified, any event, overall; n=2220, 2227 | Unclassified, any event, male; n=1142, 1152 | Unclassified, any event, female; n=1078, 1075 | Other, any event, overall; n=2220, 2227 | Other, any event, male; n=1142, 1152 | Other, any event, female; n=1078, 1075 | |
| Combined MET/SU: Main Study and Observational Follow-up | 151 | 60 | 91 | 70 | 22 | 48 | 40 | 14 | 26 | 13 | 1 | 12 | 14 | 9 | 5 | 5 | 4 | 1 | 0 | 0 | 0 | 26 | 16 | 10 |
| Combined RSG: Main Study and Observational Follow-up | 238 | 82 | 156 | 116 | 32 | 84 | 88 | 31 | 57 | 16 | 4 | 12 | 18 | 7 | 11 | 0 | 0 | 0 | 1 | 1 | 0 | 31 | 18 | 13 |
The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date that had the same Higher Level Group Term (HLGT) for fracture location, per participant. (NCT00379769)
Timeframe: From the end of the RECORD study through the end of the observational follow-up (up to 4.0 years)
| Intervention | participants (Number) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any event, overall; n=1280, 1250 | Any event, male; n=665, 635 | Any event, female; n=615, 615 | Upper limb, any event, overall; n=1280, 1250 | Upper limb, any event, male; n=665, 635 | Upper limb, any event, female; n=615, 615 | Distal lower limb, any event, overall; n=1280,1250 | Distal lower limb, any event, male; n=665, 635 | Distal lower limb, any event, female; n=615, 615 | Femur/hip, any event, overall; n=1280, 1250 | Femur/hip, any event, male; n=665, 635 | Femur/hip, any event, female; n=615, 615 | Spinal, any event, overall; n=1280, 1250 | Spinal, any event, male; n=665, 635 | Spinal, any event, female; n=615, 615 | Pelvic, any event, overall; n=1280, 1250 | Pelvic, any event, male; n=665, 635 | Pelvic, any event, female; n=615, 615 | Unclassified, any event, overall; n=1280, 1250 | Unclassified, any event, male; n=665, 635 | Unclassified, any event, female; n=615, 615 | Other, any event, overall; n=1280, 1250 | Other, any event, male; n=665, 635 | Other, any event, female; n=615, 615 | |
| Combined MET/SU: Observational Follow-up | 37 | 11 | 26 | 15 | 3 | 12 | 13 | 4 | 9 | 5 | 0 | 5 | 5 | 4 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| Combined RSG: Observational Follow-up | 64 | 25 | 39 | 33 | 10 | 23 | 18 | 9 | 9 | 6 | 1 | 5 | 4 | 1 | 3 | 0 | 0 | 0 | 1 | 1 | 0 | 6 | 4 | 2 |
The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE. (NCT00379769)
Timeframe: From the end of the RECORD study through the end of the observational follow-up (up to 4.0 years)
| Intervention | participants (Number) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any event | Ankle fracture | Prostate cancer | Lung neoplasm malignant | Breast cancer | Basal cell carcinoma | Pancreatic carcinoma | Colon cancer | Humerus fracture | Upper limb fracture | Malignant melanoma | Uterine cancer | Gastric cancer | Wrist fracture | Hip fracture | Radius fracture | Forearm fracture | Hepatic neoplasm malignant | Rectal cancer | Renal cancer | Foot fracture | Renal cell carcinoma | Femur fracture | Femoral neck fracture | Lumbar vertebral fracture | Metastases to bone | Metastases to liver | Bladder cancer | Fall | Metastases to central nervous system | Rib fracture | Squamous cell carcinoma | Acute myocardial infarction | Brain neoplasm | Gastric neoplasm | Metastases to lung | Patella fracture | Death | Abdominal pain | Acute myeloid leukaemia | Acute respiratory failure | Anaemia | Benign salivary gland neoplasm | Biliary colic | Biliary neoplasm | Bone neoplasm malignant | Bronchial carcinoma | Cardiac failure acute | Chest pain | Chronic lymphocytic leukaemia | Colon neoplasm | Contusion | Drowning | Dysplasia | Endometrial cancer stage I | Leukaemia | Lower limb fracture | Lung squamous cell carcinoma stage unspecified | Lymphoma | Malignant neoplasm of pleura | Metastases to skin | Metastases to testicle | Metastatic renal cell carcinoma | Oesophageal carcinoma | Osteoarthritis | Pancreatic necrosis | Rectal cancer stage II | Spinal fracture | T-cell lymphoma | Urinary tract infection | Uterine leiomyosarcoma | Biliary cancer metastatic | Cervix carcinoma | Chronic obstructive pulmonary disease | Comminuted fracture | Craniocerebral injury | Gastrointestinal neoplasm | Hepatic lesion | Joint dislocation | Laryngeal cancer | Lip neoplasm malignant stage unspecified | Lung neoplasm | Metastases to lymph nodes | Metastasis | Musculoskeletal chest pain | Myocardial infarction | Non-Hodgkin's lymphoma | Pubis fracture | Pulmonary embolism | Rectal cancer recurrent | Rectal neoplasm | Skin cancer | Skin ulcer | Small cell lung cancer stage unspecified | Sternal fracture | Subdural haemorrhage | Sudden death | Thoracic vertebral fracture | Thyroid cancer | Vulval cancer | |
| Combined MET/SU: Observational Follow-up | 76 | 3 | 1 | 4 | 6 | 3 | 3 | 6 | 1 | 1 | 2 | 3 | 0 | 0 | 1 | 1 | 2 | 2 | 2 | 2 | 3 | 0 | 1 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Combined RSG: Observational Follow-up | 99 | 6 | 7 | 4 | 2 | 4 | 4 | 1 | 5 | 5 | 3 | 2 | 4 | 4 | 3 | 3 | 2 | 2 | 2 | 2 | 1 | 3 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
The observational follow-up (OFU) was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the OFU. The neoplasms/cancer events of bladder, breast, colon, liver, pancreatic, prostate cancer, and melanoma were pre-specified as cancers of interest for the OFU. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE. (NCT00379769)
Timeframe: From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)
| Intervention | participants (Number) | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any genitourinary | Prostate | Renal | Uterine | Bladder | Vaginal/vulvar | Ovarian | Any gastrointestinal | Colon/rectal cancer | Colon | Gastric | Pancreatic | Liver | Gall bladder/biliary | Gastrointestinal; not specified | Any hematologic | Lung | Skin (non-melanomatous) | Skin (melanomatous) | Metastases | Breast | Head and neck | Neurologic | Endocrine | Not specified | Other | |
| Combined MET/SU: Main Study and Observational Follow-up | 57 | 22 | 9 | 16 | 5 | 1 | 4 | 62 | 30 | 21 | 5 | 16 | 5 | 5 | 1 | 6 | 15 | 13 | 4 | 18 | 23 | 7 | 3 | 6 | 1 | 3 |
| Combined RSG: Main Study and Observational Follow-up | 57 | 22 | 12 | 11 | 8 | 1 | 5 | 48 | 22 | 14 | 13 | 5 | 4 | 4 | 0 | 12 | 19 | 19 | 6 | 12 | 12 | 4 | 3 | 3 | 0 | 0 |
The observational follow-up (OFU) was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the OFU. The neoplasms/cancer events of bladder, breast, colon, liver, pancreatic, prostate cancer, and melanoma were pre-specified as cancers of interest for the OFU. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE. (NCT00379769)
Timeframe: From the end of the RECORD study through the end of the observational follow-up (up to 4.0 years)
| Intervention | participants (Number) | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any genitourinary | Prostate | Renal | Uterine | Bladder | Vaginal/vulvar | Ovarian | Any gastrointestinal | Colon/rectal cancer | Colon | Gastric | Pancreatic | Liver | Gall bladder/biliary | Gastrointestinal; not specified | Any hematologic | Lung | Skin (non-melanomatous) | Skin (melanomatous) | Metastases | Breast | Head and neck | Neurologic | Endocrine | Not specified | Other | |
| Combined MET/SU: Observational Follow-up | 8 | 1 | 2 | 4 | 0 | 1 | 0 | 19 | 11 | 7 | 1 | 3 | 2 | 1 | 1 | 1 | 6 | 5 | 2 | 6 | 7 | 1 | 1 | 1 | 0 | 0 |
| Combined RSG: Observational Follow-up | 18 | 7 | 5 | 4 | 2 | 0 | 0 | 17 | 5 | 2 | 5 | 4 | 2 | 1 | 0 | 6 | 6 | 6 | 3 | 3 | 2 | 2 | 1 | 0 | 0 | 0 |
The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE. (NCT00379769)
Timeframe: From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)
| Intervention | participants (Number) | ||
|---|---|---|---|
| All neoplasms/cancer (N/C) (benign/malignant) | Malignant (Mal.) N/C | Mal. N/C; excluding non-melanomatous skin cancers | |
| Combined MET/SU: Main Study and Observational Follow-up | 215 | 195 | 186 |
| Combined RSG: Main Study and Observational Follow-up | 196 | 179 | 164 |
The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE. (NCT00379769)
Timeframe: From the end of the RECORD study through the end of the observational follow-up (up to 4.0 years)
| Intervention | participants (Number) | ||
|---|---|---|---|
| All neoplasms/cancer (N/C) (benign/malignant) | Malignant (Mal.) N/C | Mal. N/C; excluding non-melanomatous skin cancers | |
| Combined MET/SU: Observational Follow-up | 51 | 51 | 46 |
| Combined RSG: Observational Follow-up | 60 | 59 | 55 |
The total number of events for individual components of cardiovascular (CV) hospitalisations and cardiovascular deaths were recorded. MI, myocardial infarction. (NCT00379769)
Timeframe: Baseline through End of Study (up to 7.5 years)
| Intervention | Number of events (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CV deaths | Death due to acute MI | Death due to heart failure | Sudden death | Death due to acute vascular events | Other CV mortality | Death of presumed CV cause | Cardiovascular hospitalisation | Hospitalisation for acute MI | Hospitalisation for unstable angina | Hospitalisation for congestive heart failure | Hospitalisation for stroke | Hospitalisation for transient ischaemic attack | Hospitalisation for invasive CV procedure | Hospitalisation for amputation of extremities | Other CV hospitalisations | |
| Combined MET/SU | 71 | 10 | 2 | 12 | 10 | 4 | 33 | 490 | 57 | 28 | 36 | 67 | 10 | 116 | 23 | 153 |
| Combined RSG | 60 | 7 | 10 | 8 | 1 | 6 | 28 | 483 | 66 | 28 | 69 | 51 | 10 | 99 | 6 | 154 |
204 reviews available for metformin and Benign Neoplasms
| Article | Year |
|---|---|
Small molecule adenosine 5'-monophosphate activated protein kinase (AMPK) modulators and human diseases.
Topics: Adenine Nucleotides; Allosteric Regulation; AMP-Activated Protein Kinases; Humans; Intracellular Sig | 2015 |
Xanthenes in Medicinal Chemistry - Synthetic strategies and biological activities.
Topics: Anti-Infective Agents; Antineoplastic Agents; Bacteria; Chemistry, Pharmaceutical; Fungi; Humans; Ne | 2021 |
New Insight into the Effects of Metformin on Diabetic Retinopathy, Aging and Cancer: Nonapoptotic Cell Death, Immunosuppression, and Effects beyond the AMPK Pathway.
Topics: Aging; AMP-Activated Protein Kinases; Blood Glucose; Cell Death; Diabetes Mellitus, Type 2; Diabetic | 2021 |
Repurposing Metformin for Cancer Treatment: A Great Challenge of a Promising Drug.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Reposit | 2021 |
[A multidirectional effect of metformin].
Topics: Aging; Animals; Diabetes Mellitus; Female; Hypoglycemic Agents; Metformin; Neoplasms | 2022 |
Metformin has no Significant Anticancer Effect on Patients with Advanced or Unresectable Cancer: A Systematic Review and Meta-analysis.
Topics: Humans; Metformin; Neoplasms | 2022 |
The role of AMPK-dependent pathways in cellular and molecular mechanisms of metformin: a new perspective for treatment and prevention of diseases.
Topics: AMP-Activated Protein Kinases; Cell Proliferation; Hepatocytes; Humans; Hypoglycemic Agents; Metform | 2022 |
The role of MicroRNA networks in tissue-specific direct and indirect effects of metformin and its application.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; MicroRNAs; Neoplasms | 2022 |
Mechanisms of cancer cell killing by metformin: a review on different cell death pathways.
Topics: Apoptosis; Autophagy; Cell Death; Humans; Hypoglycemic Agents; Metformin; Neoplasms | 2023 |
Molecular inhibition of RAS signalling to target ageing and age-related health.
Topics: Acarbose; Aged; Antineoplastic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Metfo | 2022 |
Efficacy of metformin therapy in patients with cancer: a meta-analysis of 22 randomised controlled trials.
Topics: Adult; Combined Modality Therapy; Humans; Metformin; Neoplasms; Randomized Controlled Trials as Topi | 2022 |
Role of metformin in inflammation.
Topics: AMP-Activated Protein Kinases; Animals; Anti-Inflammatory Agents; Diabetes Mellitus, Type 2; Inflamm | 2023 |
Metformin: A Promising Antidiabetic Medication for Cancer Treatment.
Topics: Apoptosis; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Neoplasms | 2023 |
Use of Antihyperglycemic Drugs and Risk of Cancer in Patients with Diabetes.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Metformin; Neoplasms; Systematic Re | 2023 |
Use of Antihyperglycemic Drugs and Risk of Cancer in Patients with Diabetes.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Metformin; Neoplasms; Systematic Re | 2023 |
Use of Antihyperglycemic Drugs and Risk of Cancer in Patients with Diabetes.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Metformin; Neoplasms; Systematic Re | 2023 |
Use of Antihyperglycemic Drugs and Risk of Cancer in Patients with Diabetes.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Metformin; Neoplasms; Systematic Re | 2023 |
Metformin: new applications for an old drug.
Topics: Cardiovascular Diseases; COVID-19; Female; Humans; Hypoglycemic Agents; Metformin; Neoplasms; Off-La | 2023 |
Metformin: new applications for an old drug.
Topics: Cardiovascular Diseases; COVID-19; Female; Humans; Hypoglycemic Agents; Metformin; Neoplasms; Off-La | 2023 |
Metformin: new applications for an old drug.
Topics: Cardiovascular Diseases; COVID-19; Female; Humans; Hypoglycemic Agents; Metformin; Neoplasms; Off-La | 2023 |
Metformin: new applications for an old drug.
Topics: Cardiovascular Diseases; COVID-19; Female; Humans; Hypoglycemic Agents; Metformin; Neoplasms; Off-La | 2023 |
Metformin and Its Immune-Mediated Effects in Various Diseases.
Topics: AMP-Activated Protein Kinases; Diabetes Mellitus, Type 2; Humans; Mechanistic Target of Rapamycin Co | 2023 |
STAT3 as a therapeutic target in the metformin-related treatment.
Topics: AMP-Activated Protein Kinases; Humans; Metformin; Neoplasms; Signal Transduction; STAT3 Transcriptio | 2023 |
Is it still worth pursuing the repurposing of metformin as a cancer therapeutic?
Topics: Drug Repositioning; Humans; Hypoglycemic Agents; Metformin; Neoplasms | 2023 |
Action Mechanism of Metformin and Its Application in Hematological Malignancy Treatments: A Review.
Topics: AMP-Activated Protein Kinases; Diabetes Mellitus, Type 2; Hematologic Neoplasms; Humans; Metformin; | 2023 |
The function, mechanisms, and clinical applications of metformin: potential drug, unlimited potentials.
Topics: Aging; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Neoplasms | 2023 |
Metformin and cancer hallmarks: shedding new lights on therapeutic repurposing.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Repositioning; Humans; Hypoglycemic Agents; Insulins; | 2023 |
Metformin as a booster of cancer immunotherapy.
Topics: Humans; Hypoglycemic Agents; Immunotherapy; Metformin; Neoplasms; Tumor Microenvironment | 2023 |
Metformin: A Review of Potential Mechanism and Therapeutic Utility Beyond Diabetes.
Topics: AMP-Activated Protein Kinases; Diabetes Mellitus, Type 2; Female; Glucose; Humans; Hypoglycemic Agen | 2023 |
Current status and frontier tracking of clinical trials on Metformin for cancer treatment.
Topics: Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Neoplasms | 2023 |
A Tumor Agnostic Therapeutic Strategy for Hexokinase 1-Null/Hexokinase 2-Positive Cancers.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Glycolysis; Hexokinase; H | 2019 |
More recent, better designed studies have weakened links between antidiabetes medications and cancer risk.
Topics: Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide-1 Receptor; Glycoside H | 2020 |
Window of opportunity clinical trial designs to study cancer metabolism.
Topics: Clinical Trials as Topic; Drug Repositioning; Humans; Metabolomics; Metformin; Neoplasms; Research D | 2020 |
Monotherapy with Metformin versus Sulfonylureas and Risk of Cancer in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Incidence; Metformin; Neoplasms; Sulfonylure | 2019 |
Immune-mediated anti-tumor effects of metformin; targeting metabolic reprogramming of T cells as a new possible mechanism for anti-cancer effects of metformin.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Energy Metabolism; Humans; Immunotherapy; Metf | 2020 |
Metformin: An old drug against old age and associated morbidities.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Metformin; Mo | 2020 |
Pharmacological Strategies for Insulin Sensitivity in Obesity and Cancer: Thiazolidinediones and Metformin.
Topics: Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Neoplasms; Obesi | 2020 |
Context-Dependent Pharmacological Effects of Metformin on the Immune System.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Immune System; Metformin; Neoplasms | 2020 |
Metformin: current clinical applications in nondiabetic patients with cancer.
Topics: Humans; Hypoglycemic Agents; Immunologic Factors; Metformin; Neoplasms | 2020 |
[Geroprotective drugs - mTOR inhibitors in the treatment of cancer patients.]
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Metformin; Neoplasms; | 2019 |
Metformin in Oncology - How Far Is Its Repurposing as an Anticancer Drug?
Topics: Animals; Antineoplastic Agents; Chemotherapy, Adjuvant; Diabetes Mellitus, Type 2; Drug Repositionin | 2020 |
Anticancer mechanisms of metformin: A review of the current evidence.
Topics: Antineoplastic Agents; Energy Metabolism; Epigenesis, Genetic; Humans; Metformin; Mitochondria; Neop | 2020 |
Metformin: A Possible Option in Cancer Chemotherapy.
Topics: Adjuvants, Pharmaceutic; Animals; Carcinogens; Clinical Trials as Topic; Humans; Metformin; Neoplasm | 2020 |
Metformin and Its Benefits for Various Diseases.
Topics: Aging; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Metformin; Neoplasms; Signal | 2020 |
Impact of metformin on immunological markers: Implication in its anti-tumor mechanism.
Topics: Animals; Antineoplastic Agents; Cytokines; Humans; Immunotherapy; Macrophages; Metformin; Neoplasms; | 2020 |
Metformin and risk of cancer among patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
Topics: Diabetes Mellitus, Type 2; Glucose Intolerance; Humans; Hypoglycemic Agents; Metformin; Neoplasms | 2021 |
A new aspect of an old friend: the beneficial effect of metformin on anti-tumor immunity.
Topics: Humans; Immunotherapy; Killer Cells, Natural; Lymphocytes, Tumor-Infiltrating; Metformin; Neoplasms; | 2020 |
The updated landscape of tumor microenvironment and drug repurposing.
Topics: Drug Repositioning; Humans; Metformin; Molecular Targeted Therapy; Neoplasms; Tumor Microenvironment | 2020 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Metformin and cancer immunity.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Enzyme Activation; Gene Expression Re | 2020 |
Is metformin a geroprotector? A peek into the current clinical and experimental data.
Topics: Aging; Animals; Cardiovascular Diseases; Clinical Trials as Topic; Humans; Metformin; Neoplasms | 2020 |
The addition of metformin to systemic anticancer therapy in advanced or metastatic cancers: a meta-analysis of randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Metformin; Neoplasm Metastasis; Neoplasm Sta | 2020 |
Metformin: Metabolic Rewiring Faces Tumor Heterogeneity.
Topics: Animals; Genetic Heterogeneity; Humans; Metformin; Neoplasms; Neoplastic Stem Cells; Signal Transduc | 2020 |
Pleiotropic Effects of Metformin on the Antitumor Efficiency of Immune Checkpoint Inhibitors.
Topics: Animals; Humans; Immune Checkpoint Inhibitors; Metformin; Neoplasms | 2020 |
Metformin and health outcomes: An umbrella review of systematic reviews with meta-analyses.
Topics: Body Mass Index; Cardiovascular Diseases; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Fema | 2021 |
Mitochondrial Inhibition: a Treatment Strategy in Cancer?
Topics: Antineoplastic Agents; Humans; Immunomodulating Agents; Metabolic Networks and Pathways; Metformin; | 2021 |
Impact of Metformin on Cancer Biomarkers in Non-Diabetic Cancer Patients: A Systematic Review and Meta-Analysis of Clinical Trials.
Topics: Biomarkers, Tumor; Clinical Trials as Topic; Humans; Insulin; Insulin Resistance; Metformin; Neoplas | 2021 |
The role of AMPK/mTOR signaling pathway in anticancer activity of metformin.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Apoptosis; Drug Repositioning; Humans | 2021 |
Repurposing of Metformin for Cancer Therapy: Updated Patent and Literature Review.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Repositioning; | 2021 |
Metformin and Cancer Glucose Metabolism: At the Bench or at the Bedside?
Topics: AMP-Activated Protein Kinases; Animals; Biomedical Research; Carbohydrate Dehydrogenases; Cell Proli | 2021 |
Metformin and improved treatment outcomes in radiation therapy - A review.
Topics: Diabetes Mellitus; Disease-Free Survival; Humans; Hypoglycemic Agents; Metformin; Neoplasms; Surviva | 2017 |
New insights into antidiabetic drugs: Possible applications in cancer treatment.
Topics: AMP-Activated Protein Kinase Kinases; Biguanides; Cell Proliferation; Diabetes Mellitus, Type 2; Hum | 2017 |
Enemies or weapons in hands: investigational anti-diabetic drug glibenclamide and cancer risk.
Topics: Animals; ATP-Binding Cassette Transporters; Diabetes Mellitus, Type 2; Glyburide; Humans; Hypoglycem | 2017 |
Metformin, the aspirin of the 21st century: its role in gestational diabetes mellitus, prevention of preeclampsia and cancer, and the promotion of longevity.
Topics: Diabetes, Gestational; Female; Fetal Development; Humans; Hypoglycemic Agents; Longevity; Maternal N | 2017 |
Cancer risks of anti-hyperglycemic drugs for type 2 diabetes treatment - a clinical appraisal.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Incretins; Insulin | 2017 |
Metformin: Insights into its anticancer potential with special reference to AMPK dependent and independent pathways.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Cell Proliferation; Humans; Metformin | 2017 |
Repurposing metformin for the prevention of cancer and cancer recurrence.
Topics: Animals; Diabetes Mellitus, Type 2; Drug Repositioning; Humans; Hypoglycemic Agents; Metformin; Neop | 2017 |
Metformin reduces all-cause mortality and diseases of ageing independent of its effect on diabetes control: A systematic review and meta-analysis.
Topics: Aging; Cardiovascular Diseases; Case-Control Studies; Diabetes Mellitus, Type 2; Humans; Hypoglycemi | 2017 |
Therapeutic Implications of Autophagy Inducers in Immunological Disorders, Infection, and Cancer.
Topics: Adaptive Immunity; Animals; Autoimmune Diseases; Autophagy; Benzylisoquinolines; Cholecalciferol; Hu | 2017 |
Medical comorbidity in polycystic ovary syndrome with special focus on cardiometabolic, autoimmune, hepatic and cancer diseases: an updated review.
Topics: Body Mass Index; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Fatty Liver; Femal | 2017 |
Metformin as an anti-cancer agent: actions and mechanisms targeting cancer stem cells.
Topics: Antineoplastic Agents; Cell Differentiation; Cell Proliferation; Humans; Hypoglycemic Agents; Metfor | 2018 |
Epigenetic effects of metformin: From molecular mechanisms to clinical implications.
Topics: Acetylation; Animals; Anticarcinogenic Agents; Diabetes Complications; Diabetes Mellitus, Type 2; DN | 2018 |
Metformin: Prevention of genomic instability and cancer: A review.
Topics: Genomic Instability; Humans; Hypoglycemic Agents; Metformin; Neoplasms | 2018 |
Metformin in cancer.
Topics: Animals; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Metformin; Neoplasms | 2018 |
Metformin one in a Million Efficient Medicines for Rheumatoid Arthritis Complications: Inflammation, Osteoblastogenesis, Cardiovascular Disease, Malignancies.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Bone and Bones; Bone Diseases; Cardiovascular | 2019 |
Metformin as an Anticancer Agent.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Diabetes Mellitus, Type 2; Electron T | 2018 |
Repurposing old drugs in oncology: Opportunities with clinical and regulatory challenges ahead.
Topics: Antineoplastic Agents; Astemizole; Cost-Benefit Analysis; Drug Repositioning; Genomics; Humans; Metf | 2019 |
Pleiotropic Effects of Metformin on Cancer.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Drug Screening Assays, Antitumor; Gluconeogenesi | 2018 |
Metformin: An Old Drug with New Applications.
Topics: Animals; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Metabolic Syndrome; Metform | 2018 |
The journey of metformin from glycaemic control to mTOR inhibition and the suppression of tumour growth.
Topics: Animals; Blood Glucose; Cardiovascular Diseases; Cell Line, Tumor; Clinical Trials as Topic; Cogniti | 2019 |
Metformin as a Radiation Modifier; Implications to Normal Tissue Protection and Tumor Sensitization.
Topics: Animals; Antioxidants; Humans; Metformin; Neoplasms; Radiation Injuries; Radiation-Protective Agents | 2019 |
The multifaceted effects of metformin on tumor microenvironment.
Topics: Animals; Antineoplastic Agents; Fibroblasts; Humans; Hypoglycemic Agents; Macrophages; Metformin; Ne | 2020 |
Similarities and Distinctions in the Effects of Metformin and Carbon Monoxide in Immunometabolism.
Topics: Animals; Carbon Monoxide; Endoplasmic Reticulum Stress; Humans; Immune System; Metabolic Diseases; M | 2019 |
Mitochondrial targets of metformin-Are they physiologically relevant?
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; | 2019 |
Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies.
Topics: Animals; Anticarcinogenic Agents; Carcinogens; Diabetes Mellitus, Type 2; Drug Therapy, Combination; | 2013 |
Rapalogs and mTOR inhibitors as anti-aging therapeutics.
Topics: Aging; Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Autophagy; Humans; Metformin; Molec | 2013 |
Metformin and cancer.
Topics: Animals; Antineoplastic Agents; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; N | 2013 |
[Which anti-tumour benefits to be expected from metformin?].
Topics: Case-Control Studies; Cohort Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents | 2013 |
[New perspectives for metformin in cancer therapy].
Topics: Animals; Antineoplastic Agents; Diabetes Mellitus, Type 2; Drug Repositioning; Humans; Hypoglycemic | 2013 |
Overview of cancer stem cells (CSCs) and mechanisms of their regulation: implications for cancer therapy.
Topics: Biomarkers, Tumor; Humans; Hypoglycemic Agents; Metformin; MicroRNAs; Models, Animal; Neoplasms; Neo | 2013 |
[Diabetes mellitus related common medical disorders: recent progress in diagnosis and treatment. Topics: I. Pathophysiology, diagnosis and treatment; 6. Diabetes and cancer].
Topics: Diabetes Complications; Humans; Insulin; Japan; Metformin; Neoplasms; Risk Factors; Treatment Outcom | 2013 |
Repositioning metformin for cancer prevention and treatment.
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Disease Models, Animal; Humans; Hypogl | 2013 |
Metabolic roles of AMPK and metformin in cancer cells.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Cell Death; Clinical Trials, Phase II | 2013 |
AMPK: a target for drugs and natural products with effects on both diabetes and cancer.
Topics: Adenylate Kinase; Diabetes Mellitus, Type 2; Energy Metabolism; Humans; Hypoglycemic Agents; Metform | 2013 |
Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review.
Topics: Diabetes Complications; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Meta-Analysis as Top | 2013 |
Diabetes, antihyperglycemic medications and cancer risk: smoke or fire?
Topics: Animals; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Incretins; Insulin; Metformin; Neop | 2013 |
Metformin: an old drug with new potential.
Topics: Animals; Antineoplastic Agents; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; N | 2013 |
[Metformin: the overlap of diabetology and oncology].
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Neoplasms; Prognosis; Risk | 2013 |
Effects of sulfonylureas on tumor growth: a review of the literature.
Topics: Apoptosis; Cell Proliferation; Diabetes Mellitus, Type 2; Humans; Imidazoles; Insulin; Insulin-Like | 2013 |
Beyond aspirin-cancer prevention with statins, metformin and bisphosphonates.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bone Density Conservation Agents; Diphosp | 2013 |
New perspective for an old antidiabetic drug: metformin as anticancer agent.
Topics: Animals; Antineoplastic Agents; Humans; Hypoglycemic Agents; Metformin; Mice; Neoplasms | 2014 |
[Metformin, an antidiabetic molecule with anti-cancer properties].
Topics: Antineoplastic Agents; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Neoplasms | 2013 |
Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: a systematic review and meta-analysis.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Neoplasms | 2013 |
The multifaceted activities of AMPK in tumor progression--why the "one size fits all" definition does not fit at all?
Topics: AMP-Activated Protein Kinases; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Tran | 2013 |
Repositioning metformin in cancer: genetics, drug targets, and new ways of delivery.
Topics: Animals; Chemoembolization, Therapeutic; Humans; Metformin; Mutation; Nanoparticles; Neoplasms; Orga | 2014 |
Metformin's potential in oncology.
Topics: Animals; Humans; Hypoglycemic Agents; Metformin; Neoplasms; Portraits as Topic | 2013 |
Managing lipid metabolism in proliferating cells: new perspective for metformin usage in cancer therapy.
Topics: AMP-Activated Protein Kinases; Cell Proliferation; Glucose; Humans; Hypoglycemic Agents; Lipid Metab | 2014 |
AMPK at the nexus of energetics and aging.
Topics: Aging; AMP-Activated Protein Kinases; Animals; Aspirin; Energy Metabolism; Humans; Metabolic Disease | 2014 |
Use of biguanides to improve response to chemotherapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Humans; Metformin | 2014 |
Metformin and cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Humans; Hypoglycemic Agents; Metformin; Mice; Neoplasms; | 2013 |
Cancer risks from diabetes therapies: evaluating the evidence.
Topics: Animals; Diabetes Mellitus; Drug Design; Endocannabinoids; Glucose; Humans; Hypoglycemic Agents; Ins | 2014 |
Blind Snipers: Relevant Off Target Effects of Non-chemotherapeutic Agents in Oncology: Review of the Literature.
Topics: Adrenergic beta-Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Glycosides; Humans; H | 2014 |
Hype versus hope: metformin and vitamin D as anticancer agents.
Topics: Antineoplastic Agents; Humans; Metformin; Neoplasms; Risk Factors; Survival Analysis; Vitamin D | 2014 |
Cancer cachexia and diabetes: similarities in metabolic alterations and possible treatment.
Topics: Adipose Tissue; Animals; Cachexia; Diabetes Mellitus, Type 2; Energy Metabolism; Glucose; Humans; Hy | 2014 |
Diabetes and cancer: 5 years into the recent controversy.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Metformin; Neoplasms; Risk Factors | 2014 |
Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Neoplasms; Risk | 2014 |
The effect of metformin on mortality following cancer among patients with diabetes.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Neoplasms | 2014 |
Combined cancer therapy with non-conventional drugs: all roads lead to AMPK.
Topics: AMP-Activated Protein Kinases; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Cell Line, T | 2014 |
Cancer metabolism as a therapeutic target.
Topics: Glucose; Glucose Transport Proteins, Facilitative; Glycolysis; HIV Protease Inhibitors; Humans; Hypo | 2013 |
Metformin, cancer and glucose metabolism.
Topics: Animals; Antineoplastic Agents; Glucose; Humans; Hypoglycemic Agents; Metformin; Neoplasms | 2014 |
Exploring the role of metformin in anticancer treatments: a systematic review.
Topics: Humans; Hypoglycemic Agents; Metformin; Neoplasms | 2014 |
Anti-diabetic drug metformin: challenges and perspectives for cancer therapy.
Topics: Animals; Antineoplastic Agents; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; N | 2014 |
Metformin in cancer treatment and prevention.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Neoplasms | 2015 |
Stratified medicine for the use of antidiabetic medication in treatment of type II diabetes and cancer: where do we go from here?
Topics: Administration, Oral; Biguanides; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Evidence-Base | 2015 |
Cancer chemoprevention: Much has been done, but there is still much to do. State of the art and possible new approaches.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aromatase Inhibitors; Cancer Vaccines; Chemoprevention; Est | 2015 |
Metformin: An Old Drug for the Treatment of Diabetes but a New Drug for the Protection of the Endothelium.
Topics: Adenylyl Cyclases; AMP-Activated Protein Kinases; Diabetes Mellitus, Type 2; Dose-Response Relations | 2015 |
Pharmacologic Therapy of Diabetes and Overall Cancer Risk and Mortality: A Meta-Analysis of 265 Studies.
Topics: Diabetes Mellitus, Type 2; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Insulin; Met | 2015 |
[Metformin: new data for an old molecule].
Topics: Blood Glucose; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic | 2015 |
Expanding the therapeutic spectrum of metformin: from diabetes to cancer.
Topics: Antineoplastic Agents; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Neoplasms | 2015 |
Metformin and cancer: Between the bioenergetic disturbances and the antifolate activity.
Topics: Animals; Antimetabolites; Energy Metabolism; Folic Acid Antagonists; Humans; Hypoglycemic Agents; In | 2015 |
Metformin: risk-benefit profile with a focus on cancer.
Topics: Diabetes Mellitus; Humans; Hypoglycemic Agents; Incidence; Insulin Resistance; Metformin; Neoplasms; | 2015 |
Obesity and cancer: mechanistic insights from transdisciplinary studies.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Breast Neoplasms; Caloric R | 2015 |
Metformin: A Novel Biological Modifier of Tumor Response to Radiation Therapy.
Topics: Animals; Cell Hypoxia; Cell Proliferation; Cell Survival; Diabetes Mellitus; Humans; Hypoglycemic Ag | 2015 |
Metformin: A Novel but Controversial Drug in Cancer Prevention and Treatment.
Topics: Antineoplastic Agents; Humans; Hypoglycemic Agents; Metformin; Neoplasms | 2015 |
Repurposing metformin: an old drug with new tricks in its binding pockets.
Topics: Biguanides; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Metformin; Neoplasms; Protei | 2015 |
Repurposing metformin: an old drug with new tricks in its binding pockets.
Topics: Biguanides; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Metformin; Neoplasms; Protei | 2015 |
Repurposing metformin: an old drug with new tricks in its binding pockets.
Topics: Biguanides; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Metformin; Neoplasms; Protei | 2015 |
Repurposing metformin: an old drug with new tricks in its binding pockets.
Topics: Biguanides; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Metformin; Neoplasms; Protei | 2015 |
Relationship Between Metabolic Reprogramming and Mitochondrial Activity in Cancer Cells. Understanding The Anticancer Effect of Metformin and Its Clinical Implications.
Topics: Energy Metabolism; Glycolysis; Humans; Hypoglycemic Agents; Metformin; Mitochondria; Neoplasms; Prog | 2015 |
Does Metformin Reduce Cancer Risks? Methodologic Considerations.
Topics: Animals; Bias; Diabetes Complications; Diabetes Mellitus; Humans; Metformin; Neoplasms; Observationa | 2016 |
Obesity and Cancer: An Angiogenic and Inflammatory Link.
Topics: Animals; Drug Resistance, Neoplasm; Humans; Inflammation; Metformin; Neoplasms; Neovascularization, | 2016 |
[Advances of the anti-tumor research of metformin].
Topics: Antineoplastic Agents; Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Metformin; Neoplasms | 2015 |
The expanding role of metformin in cancer: an update on antitumor mechanisms and clinical development.
Topics: Humans; Hypoglycemic Agents; Metformin; Neoplasms | 2016 |
Repurposing Drugs for Cancer Prevention.
Topics: Anticarcinogenic Agents; Aspirin; Drug Repositioning; Humans; Metformin; Neoplasms; Pioglitazone; Th | 2016 |
Metformin: an Old Therapy that Deserves a New Indication for the Treatment of Obesity.
Topics: Anti-Obesity Agents; Cardiovascular Diseases; Diabetes Mellitus; Humans; Metformin; Neoplasms; Obesi | 2016 |
A New Role for an Old Drug: Metformin Targets MicroRNAs in Treating Diabetes and Cancer.
Topics: Animals; Antineoplastic Agents; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; M | 2015 |
Repurposing old drugs to chemoprevention: the case of metformin.
Topics: Animals; Anticarcinogenic Agents; Chemoprevention; Diabetes Mellitus; Drug Repositioning; Humans; Hy | 2016 |
Repurposing metformin for cancer treatment: current clinical studies.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Clinical Trials as Topic; Coho | 2016 |
Finding New Tricks for Old Drugs: Tumoricidal Activity of Non-Traditional Antitumor Drugs.
Topics: Animals; Antineoplastic Agents; Aspirin; Clinical Trials as Topic; Flavonoids; Humans; Metformin; Ne | 2016 |
Combinational strategies of metformin and chemotherapy in cancers.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Multiple; Drug Resistance, | 2016 |
Molecular targets of metformin antitumor action.
Topics: Animals; Antineoplastic Agents; Drug Delivery Systems; Humans; Hypoglycemic Agents; Metformin; Molec | 2016 |
Metformin and Angiogenesis in Cancer - Revisited.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Humans; Metformin; Neoplasm | 2016 |
Metformin and Anti-Cancer Therapeutics: Hopes for a More Enhanced Armamentarium Against Human Neoplasias?
Topics: Antineoplastic Agents; Cell Proliferation; Chemotherapy, Adjuvant; Diabetes Mellitus, Type 2; Humans | 2017 |
Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis.
Topics: Chemotherapy, Adjuvant; Disease-Free Survival; Humans; Metformin; Neoplasm Staging; Neoplasms | 2016 |
Metformin: An anti-diabetic drug to fight cancer.
Topics: Antineoplastic Agents; Cell Proliferation; Humans; Hypoglycemic Agents; Metformin; Neoplasms; Signal | 2016 |
The cell-autonomous mechanisms underlying the activity of metformin as an anticancer drug.
Topics: Antineoplastic Agents; Cell Death; Cell Proliferation; Disease Progression; Humans; Metformin; Neopl | 2016 |
Anti-tumor activity of metformin: from metabolic and epigenetic perspectives.
Topics: Antineoplastic Agents; Apoptosis; Epigenesis, Genetic; Humans; Metformin; Neoplasms | 2017 |
Hyperglycaemia Induced by Novel Anticancer Agents: An Undesirable Complication or a Potential Therapeutic Opportunity?
Topics: Animals; Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Hyperglycemia; Hypoglycemic Agent | 2017 |
Metformin and cancer in type 2 diabetes: a systematic review and comprehensive bias evaluation.
Topics: Bias; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Neoplasms; Observational St | 2017 |
Metformin: New Preparations and Nonglycemic Benefits.
Topics: Blood Glucose; Cardiovascular Diseases; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Huma | 2017 |
Metformin targets multiple signaling pathways in cancer.
Topics: Animals; Antineoplastic Agents; Humans; Hypoglycemic Agents; Metformin; Neoplasms; Neoplastic Stem C | 2017 |
Combination of metformin with chemotherapeutic drugs via different molecular mechanisms.
Topics: Androgen Antagonists; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic C | 2017 |
Metformin - its potential anti-cancer and anti-aging effects.
Topics: Animals; Antineoplastic Agents; Cell Death; Glucose; Humans; Hypoglycemic Agents; Metformin; Neoplas | 2017 |
Insulin, insulin-like growth factors and neoplasia.
Topics: Humans; Hypoglycemic Agents; Insulin; Metformin; Neoplasms; Receptors, Somatomedin; Signal Transduct | 2008 |
Epidemiological aspects of neoplasms in diabetes.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Hepatocellular; Case-Control Studies; Cell Divis | 2010 |
Insulin, insulin resistance, obesity, and cancer.
Topics: Diabetes Mellitus, Type 2; Humans; Insulin; Insulin Resistance; Metformin; Neoplasms; Obesity | 2010 |
Hirsutism: Diagnosis and management.
Topics: 5-alpha Reductase Inhibitors; Adrenal Hyperplasia, Congenital; Causality; Contraceptives, Oral; Diag | 2010 |
Metformin in cancer therapy: a new perspective for an old antidiabetic drug?
Topics: Adenylate Kinase; Animals; Antineoplastic Agents; Cell Proliferation; Humans; Hypoglycemic Agents; I | 2010 |
Metformin in cancer therapy: a new perspective for an old antidiabetic drug?
Topics: Adenylate Kinase; Animals; Antineoplastic Agents; Cell Proliferation; Humans; Hypoglycemic Agents; I | 2010 |
Metformin in cancer therapy: a new perspective for an old antidiabetic drug?
Topics: Adenylate Kinase; Animals; Antineoplastic Agents; Cell Proliferation; Humans; Hypoglycemic Agents; I | 2010 |
Metformin in cancer therapy: a new perspective for an old antidiabetic drug?
Topics: Adenylate Kinase; Animals; Antineoplastic Agents; Cell Proliferation; Humans; Hypoglycemic Agents; I | 2010 |
Metformin: taking away the candy for cancer?
Topics: Adipokines; Antineoplastic Agents; Apoptosis; Cell Cycle; Clinical Trials as Topic; Diabetes Mellitu | 2010 |
Diabetes and cancer.
Topics: Adipokines; Diabetes Complications; Diabetes Mellitus; Epigenesis, Genetic; Female; Humans; Hyperins | 2010 |
Modern approach to metabolic rehabilitation of cancer patients: biguanides (phenformin and metformin) and beyond.
Topics: Diet Therapy; Exercise Therapy; Humans; Hypoglycemic Agents; Metformin; Neoplasms; Phenformin | 2010 |
Metformin and other biguanides in oncology: advancing the research agenda.
Topics: Animals; Antineoplastic Agents; Biguanides; Biomedical Research; Humans; Hypoglycemic Agents; Medica | 2010 |
[Anti-cancer activity of metformin: new perspectives for an old drug].
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Neoplasms | 2010 |
Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Incidence; Metformin; Neoplasms; Risk | 2010 |
Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Incidence; Metformin; Neoplasms; Risk | 2010 |
Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Incidence; Metformin; Neoplasms; Risk | 2010 |
Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Incidence; Metformin; Neoplasms; Risk | 2010 |
Diabetes mellitus and increased risk of cancer: focus on metformin and the insulin analogs.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Act | 2010 |
Metformin for aging and cancer prevention.
Topics: Aging; Animals; Antineoplastic Agents; Biguanides; Caloric Restriction; Humans; Hyperglycemia; Hypog | 2010 |
[New clinical data with metformin therapy in patients with diabetes mellitus].
Topics: Administration, Oral; Adult; Aged; Biomarkers; Clinical Trials as Topic; Diabetes Complications; Dia | 2010 |
[Antidiabetic therapy--a new possibility in the complex therapy of cancer?].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Diabetes Mellitus, Type 2; Feeding Behavior; Humans; | 2010 |
Metformin and cancer: new applications for an old drug.
Topics: Diabetes Complications; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Neoplasms | 2012 |
Understanding the benefit of metformin use in cancer treatment.
Topics: Antineoplastic Agents; Drug Therapy, Combination; Humans; Metformin; Neoplasms | 2011 |
Understanding the benefit of metformin use in cancer treatment.
Topics: Antineoplastic Agents; Drug Therapy, Combination; Humans; Metformin; Neoplasms | 2011 |
Understanding the benefit of metformin use in cancer treatment.
Topics: Antineoplastic Agents; Drug Therapy, Combination; Humans; Metformin; Neoplasms | 2011 |
Understanding the benefit of metformin use in cancer treatment.
Topics: Antineoplastic Agents; Drug Therapy, Combination; Humans; Metformin; Neoplasms | 2011 |
LKB1/AMPK/mTOR signaling pathway in hematological malignancies: from metabolism to cancer cell biology.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Hem | 2011 |
Metformin as an antitumor agent in cancer prevention and treatment.
Topics: Anticarcinogenic Agents; Antineoplastic Agents; Humans; Metformin; Neoplasms | 2011 |
Metformin: a new option in cancer treatment.
Topics: Animals; Antineoplastic Agents; Humans; Hypoglycemic Agents; Metformin; Neoplasms; Prognosis | 2011 |
[Diabetes and cancer risk: oncologic considerations].
Topics: Adipokines; Age Factors; Animals; Cytokines; Diabetes Complications; Diabetes Mellitus, Type 2; Feed | 2011 |
Metformin and neoplasia: implications and indications.
Topics: AMP-Activated Protein Kinases; Animals; Anticarcinogenic Agents; Antineoplastic Agents; Humans; Insu | 2012 |
Diabetes mellitus and the risk of cancer.
Topics: Diabetes Complications; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Humans; Hypoglycemic A | 2011 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Metformin and cancer therapy.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; | 2012 |
Metformin: multi-faceted protection against cancer.
Topics: Cell Transformation, Neoplastic; Cellular Senescence; Diabetes Mellitus; DNA Damage; Epithelial-Mese | 2011 |
Diabetes, cancer, and metformin: connections of metabolism and cell proliferation.
Topics: Androgens; Animals; Caloric Restriction; Cell Proliferation; Diabetes Complications; Diabetes Mellit | 2011 |
Metformin in cancer: translational challenges.
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Drug Evaluation, Preclinical; Humans; Metfor | 2012 |
Metformin in cancer: translational challenges.
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Drug Evaluation, Preclinical; Humans; Metfor | 2012 |
Metformin in cancer: translational challenges.
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Drug Evaluation, Preclinical; Humans; Metfor | 2012 |
Metformin in cancer: translational challenges.
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Drug Evaluation, Preclinical; Humans; Metfor | 2012 |
Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Incidence; Meta-An | 2012 |
Does use of metformin protect against cancer in Type 2 diabetes mellitus?
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma; Clinical Trials as Topic; Diabetes Mellitus, Typ | 2012 |
Diabetes and cancer II: role of diabetes medications and influence of shared risk factors.
Topics: Diabetes Mellitus, Type 2; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin; Metformin; Neoplas | 2012 |
Metformin in obesity, cancer and aging: addressing controversies.
Topics: Aging; Animals; Body Weight; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Metform | 2012 |
Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Neoplasms; Risk Factors; Sulfonyl | 2012 |
Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multi-faceted effects.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; | 2013 |
Metformin: a rising star to fight the epithelial mesenchymal transition in oncology.
Topics: Animals; Epithelial-Mesenchymal Transition; Humans; Metformin; Neoplasms | 2013 |
Overview of metformin: special focus on metformin extended release.
Topics: Animals; Cardiovascular Diseases; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Humans; Hy | 2012 |
Cancer prevention by targeting angiogenesis.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Apoptosis; | 2012 |
Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials.
Topics: Adult; Aged; Diabetes Complications; Diabetes Mellitus; Female; Follow-Up Studies; Humans; Hypoglyce | 2012 |
Investigating metformin for cancer prevention and treatment: the end of the beginning.
Topics: Anticarcinogenic Agents; Antineoplastic Agents; Humans; Hypoglycemic Agents; Metformin; Neoplasms | 2012 |
AMP-activated protein kinase: a target for drugs both ancient and modern.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Anti-Bacterial Agents; Diabetes | 2012 |
A systems pharmacokinetic and pharmacodynamic approach to identify opportunities and pitfalls in energy stress-mediated chemoprevention: the use of metformin and other biguanides.
Topics: Animals; Biguanides; Chemoprevention; Energy Metabolism; Humans; Hypoglycemic Agents; Metformin; Neo | 2012 |
Metformin and the risk of cancer: time-related biases in observational studies.
Topics: Animals; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Neoplasms | 2012 |
Metformin: the hidden chronicles of a magic drug.
Topics: Animals; Female; Humans; Hypoglycemic Agents; Inflammation; Male; Metabolic Syndrome; Metformin; Neo | 2013 |
Metformin and cancer: from the old medicine cabinet to pharmacological pitfalls and prospects.
Topics: Animals; Anticarcinogenic Agents; Humans; Hypoglycemic Agents; Metformin; Neoplasms | 2013 |
Targeting LKB1 signaling in cancer.
Topics: AMP-Activated Protein Kinase Kinases; Animals; Cell Polarity; Humans; Metformin; Neoplasms; Protein | 2013 |
Association of metformin use with cancer incidence and mortality: a meta-analysis.
Topics: Humans; Hypoglycemic Agents; Incidence; Metformin; Neoplasms; Survival Rate | 2013 |
Further data on beta-blockers and cancer risk: observational study and meta-analysis of randomized clinical trials.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Benzopyrans; Bisoprolol; Carbazoles; Carvedilol; Diabet | 2013 |
AMP-activated protein kinase in metabolic control and insulin signaling.
Topics: Adenosine Monophosphate; Adenosine Triphosphate; Adipocytes; Amino Acid Sequence; Aminoimidazole Car | 2007 |
Insulin, insulin-like growth factors, insulin resistance, and neoplasia.
Topics: Diabetes Complications; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Life Style; Metfor | 2007 |
Caloric restriction in primates and relevance to humans.
Topics: Aging; Animals; Biomarkers; Blood Glucose; Body Temperature; Cardiovascular Diseases; Deoxyglucose; | 2001 |
21 trials available for metformin and Benign Neoplasms
| Article | Year |
|---|---|
A phase I trial of metformin in combination with vincristine, irinotecan, and temozolomide in children with relapsed or refractory solid and central nervous system tumors: A report from the national pediatric cancer foundation.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Central Nervous System Neo | 2023 |
Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes.
Topics: Aged; Aspirin; Diabetes Mellitus, Type 2; Humans; Incidence; Metformin; Neoplasms | 2023 |
A nurse-led intervention in patients with newly diagnosed cancer and Type 2 diabetes: A pilot randomized controlled trial feasibility study.
Topics: Adult; Diabetes Mellitus, Type 2; Feasibility Studies; Glycated Hemoglobin; Humans; Metformin; Neopl | 2023 |
A phase I delayed-start, randomized and pharmacodynamic study of metformin and chemotherapy in patients with solid tumors.
Topics: Adolescent; Adult; Aged; AMP-Activated Protein Kinases; Antineoplastic Combined Chemotherapy Protoco | 2019 |
Linkage of the CHHiP randomised controlled trial with primary care data: a study investigating ways of supplementing cancer trials and improving evidence-based practice.
Topics: Aged; England; Evidence-Based Practice; Humans; Male; Metformin; Neoplasms; Primary Health Care | 2020 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Effects of Behavioral Weight Loss and Metformin on IGFs in Cancer Survivors: A Randomized Trial.
Topics: Body Mass Index; Cancer Survivors; Female; Health Behavior; Humans; Insulin-Like Growth Factor Bindi | 2021 |
A phase Ib study of everolimus combined with metformin for patients with advanced cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Everolimus; Female; Hum | 2018 |
Effect of Aspirin on Cancer Chemoprevention in Japanese Patients With Type 2 Diabetes: 10-Year Observational Follow-up of a Randomized Controlled Trial.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Chemoprevention; Diabetes Mellitus | 2018 |
A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarke | 2018 |
Effects of metformin dose on cancer risk reduction in patients with type 2 diabetes mellitus: a 6-year follow-up study.
Topics: Adult; Aged; Cohort Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Fo | 2014 |
The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia.
Topics: Antineoplastic Agents; Diabetes Mellitus, Type 2; Double-Blind Method; Fatty Acids, Omega-3; Female; | 2014 |
Cancer and bone fractures in observational follow-up of the RECORD study.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Stu | 2015 |
Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dose-Res | 2016 |
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.
Topics: Administration, Oral; Angina, Unstable; Body Weight; Cholesterol, HDL; Cholesterol, LDL; Diabetes Me | 2009 |
Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Neoplasms; Rosiglitazone; Sulfony | 2010 |
A phase I study of temsirolimus and metformin in advanced solid tumours.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administrati | 2012 |
Prognostic implications of glucose-lowering treatment in patients with acute myocardial infarction and diabetes: experiences from an extended follow-up of the Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) 2 Study.
Topics: Aged; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Hu | 2011 |
[Influence of metformin and N-acetylcysteine on hormonal and genotoxic effects of estrogens and glucose in convalescent cancer patients].
Topics: Acetylcysteine; Aged; Blood Glucose; Body Mass Index; Breast Neoplasms; Colonic Neoplasms; Drug Admi | 2010 |
Intensive glucose control and risk of cancer in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Hypoglycemic Agents; Ins | 2011 |
Further data on beta-blockers and cancer risk: observational study and meta-analysis of randomized clinical trials.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Benzopyrans; Bisoprolol; Carbazoles; Carvedilol; Diabet | 2013 |
246 other studies available for metformin and Benign Neoplasms
| Article | Year |
|---|---|
Study on the synthesis and biological activities of α-substituted arylacetates derivatives.
Topics: Acetates; alpha-Glucosidases; Animals; Antineoplastic Agents; Cell Line, Tumor; Glycoside Hydrolase | 2016 |
Single-molecule chemiluminescent photosensitizer for a self-activating and tumor-selective photodynamic therapy of cancer.
Topics: Cell Line, Tumor; Cell Survival; Computer Simulation; Humans; Imidazoles; Light; Neoplasms; Photoche | 2019 |
Differential Risk of Cancer Associated with Glucagon-like Peptide-1 Receptor Agonists: Analysis of Real-world Databases.
Topics: Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Male; Metf | 2022 |
Tumor-activatable biomineralized nanotherapeutics for integrative glucose starvation and sensitized metformin therapy.
Topics: Animals; Cell Line, Tumor; Glucose; Glucose Oxidase; Humans; Hydrogen Peroxide; Metformin; Neoplasms | 2021 |
Metformin Is Associated with a Lower Incidence of Benign Brain Tumors: A Retrospective Cohort Study in Patients with Type 2 Diabetes Mellitus.
Topics: Aged; Brain Neoplasms; Cohort Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agent | 2021 |
Biguanide drugs enhance cytotoxic effects of cisplatin by depleting aspartate and NAD+ in sensitive cancer cells.
Topics: Antineoplastic Agents; Aspartic Acid; Cisplatin; Metformin; NAD; Neoplasms; Pharmaceutical Preparati | 2021 |
Metformin inhibits tumor growth and affects intestinal flora in diabetic tumor-bearing mice.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Correlation of Data; Diabetes Mellitus, Experiment | 2021 |
Effects of early medication treatment and metformin use for cancer prevention in diabetes patients: a nationwide sample cohort study in Korea using extended landmark time analysis.
Topics: Cohort Studies; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Neoplasms; Retros | 2021 |
Metformin promotes histone deacetylation of optineurin and suppresses tumour growth through autophagy inhibition in ocular melanoma.
Topics: Animals; Autophagy; Cell Cycle Proteins; Disease Models, Animal; Eye; Histone Demethylases; Melanoma | 2022 |
Metformin sensitizes leukemic cells to cytotoxic lymphocytes by increasing expression of intercellular adhesion molecule-1 (ICAM-1).
Topics: Animals; Humans; Intercellular Adhesion Molecule-1; Killer Cells, Natural; Male; Metformin; Mice; Mi | 2022 |
Concurrent Nivolumab and Metformin in Diabetic Cancer Patients: Is It Safe and More Active?
Topics: Aged; B7-H1 Antigen; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Immune Checkpoi | 2022 |
Emerging Role of High Glucose Levels in Cancer Progression and Therapy.
Topics: Glucose; Glycemic Index; Humans; Metformin; Neoplasms; Neoplastic Processes | 2022 |
Single cell mass spectrometry analysis of drug-resistant cancer cells: Metabolomics studies of synergetic effect of combinational treatment.
Topics: Anti-Infective Agents; Irinotecan; Mass Spectrometry; Metabolomics; Metformin; Neoplasms | 2022 |
Repression of Cell-to-Matrix Adhesion by Metformin Chloride Supports Its Anti-Metastatic Potential in an In Vitro Study on Metastatic and Non-Metastatic Cancer Cells.
Topics: Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Chlorides; Humans; Hypoglycemic Agents; Metform | 2022 |
Comment on Chen et al. Dual Blockade of Lactate/GPR81 and PD-1/PD-L1 Pathways Enhances the Anti-Tumor Effects of Metformin.
Topics: B7-H1 Antigen; Humans; Lactic Acid; Metformin; Neoplasms; Programmed Cell Death 1 Receptor | 2022 |
Tumor metabolism destruction via metformin-based glycolysis inhibition and glucose oxidase-mediated glucose deprivation for enhanced cancer therapy.
Topics: Adenosine Triphosphate; AMP-Activated Protein Kinases; Cell Line, Tumor; Drug Therapy; Glucose; Gluc | 2022 |
[Metformin inhibits proliferation and promotes apoptosis of HER-2 positive breast cancer cells possibly through the Hippo-YAP pathway].
Topics: Apoptosis; Cadherins; Cell Proliferation; ErbB Receptors; Fibronectins; Metformin; Neoplasms; Protei | 2022 |
Differential effects of cancer modifying agents during radiation therapy on Ehrlich solid tumor-bearing mice: A comparative investigation of metformin and ascorbic acid.
Topics: Animals; Ascorbic Acid; Carcinoma, Ehrlich Tumor; Lipid Peroxidation; Metformin; Mice; Neoplasms | 2022 |
Metformin and Cancer: Is This the End?
Topics: Breast Neoplasms; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Neopl | 2022 |
Glucose metabolism controls human γδ T-cell-mediated tumor immunosurveillance in diabetes.
Topics: AMP-Activated Protein Kinases; Diabetes Mellitus, Type 2; Glucose; Humans; Lymphocyte Activation; Me | 2022 |
Docetaxel in combination with metformin enhances antitumour efficacy in metastatic breast carcinoma models: a promising cancer targeting based on PEGylated liposomes.
Topics: Ammonium Sulfate; Animals; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Liposomes; Metformin; | 2022 |
Nutrient Condition in the Microenvironment Determines Essential Metabolisms of CD8
Topics: AMP-Activated Protein Kinases; Animals; CD8-Positive T-Lymphocytes; Diabetes Mellitus, Type 2; Gluco | 2022 |
Sulfonylurea and Cancer Risk Among Patients With Type 2 Diabetes: A Population-Based Cohort Study.
Topics: Cohort Studies; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Neoplasms; Retros | 2022 |
The promising therapeutic effects of metformin on metabolic reprogramming of cancer-associated fibroblasts in solid tumors.
Topics: Cancer-Associated Fibroblasts; Fibroblasts; Glycolysis; Humans; Lactates; Metformin; Neoplasms; Tumo | 2022 |
Metformin Mitigated Obesity-Driven Cancer Aggressiveness in Tumor-Bearing Mice.
Topics: Animals; Diet, High-Fat; HMGB1 Protein; Metformin; Mice; Mice, Inbred C57BL; Neoplasms; Obesity | 2022 |
Metformin and histone deacetylase inhibitor based anti-inflammatory nanoplatform for epithelial-mesenchymal transition suppression and metastatic tumor treatment.
Topics: Anti-Inflammatory Agents; Cell Line, Tumor; Epithelial-Mesenchymal Transition; Histone Deacetylase I | 2022 |
Evaluation of selected antidiabetics in cardiovascular complications associated with cancer cachexia.
Topics: Cachexia; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Neoplasms; Sodium-Gluco | 2023 |
Metformin and simvastatin synergistically suppress endothelin 1-induced hypoxia and angiogenesis in multiple cancer types.
Topics: Animals; Cell Line, Tumor; Endothelin-1; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Metform | 2023 |
Redox dyshomeostasis modulation of the tumor intracellular environment through a metabolic intervention strategy for enhanced photodynamic therapy.
Topics: Buthionine Sulfoximine; Cell Line, Tumor; Glutathione; Humans; Hypoxia; Lipids; Metal-Organic Framew | 2022 |
Metformin modified chitosan as a multi-functional adjuvant to enhance cisplatin-based tumor chemotherapy efficacy.
Topics: Adjuvants, Immunologic; Antineoplastic Agents; B7-H1 Antigen; Cell Line, Tumor; Chitosan; Cisplatin; | 2023 |
[Metformin and malignant neoplasms: a possible mechanism of antitumor action and prospects for use in practice].
Topics: AMP-Activated Protein Kinases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resis | 2022 |
NDUFS3 knockout cancer cells and molecular docking reveal specificity and mode of action of anti-cancer respiratory complex I inhibitors.
Topics: Electron Transport Complex I; Humans; Metformin; Molecular Docking Simulation; NADH Dehydrogenase; N | 2022 |
Imaging Memory T-Cells Stratifies Response to Adjuvant Metformin Combined with αPD-1 Therapy.
Topics: Adjuvants, Immunologic; Diabetes Mellitus, Type 2; Humans; Memory T Cells; Metformin; Neoplasms; Tum | 2022 |
Combination of metformin/efavirenz/fluoxetine exhibits profound anticancer activity via a cancer cell-specific ROS amplification.
Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Cell Line, Tumor; Fluoxetine; HCT116 Cells; Human | 2023 |
Metformin, cancer, COVID-19, and longevity.
Topics: COVID-19; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Longevity; Metformin; Neoplasms | 2023 |
Metformin enhances T lymphocyte anti-tumor immunity by increasing the infiltration via vessel normalization.
Topics: Animals; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Lymphocytes, Tumor-Infiltrating; Me | 2023 |
AMPK phosphorylates and stabilises copper transporter 1 to synergise metformin and copper chelator for breast cancer therapy.
Topics: AMP-Activated Protein Kinases; Animals; Cation Transport Proteins; Chelating Agents; Copper; Copper | 2023 |
Metformin-containing hydrogel scaffold to augment CAR-T therapy against post-surgical solid tumors.
Topics: Diabetes Mellitus, Type 2; Humans; Hydrogels; Immunotherapy, Adoptive; Metformin; Neoplasms; Recepto | 2023 |
Metformin pretreatment potentiates the antiproliferative action of doxorubicin against breast cancer.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Doxorubicin; Female; Metformin; Neoplasms; Rats; Rats, Wi | 2023 |
Metformin May Alter the Metabolic Reprogramming in Cancer Cells by Disrupting the L-Arginine Metabolism: A Preliminary Computational Study.
Topics: AMP-Activated Protein Kinases; Antimalarials; Biguanides; Buformin; Creatine; Humans; Metformin; Mol | 2023 |
Metformin plays an antitumor role by downregulating inhibitory cells and immune checkpoint molecules while activating protective immune responses in breast cancer.
Topics: Animals; Cell Line, Tumor; Immune Checkpoint Proteins; Immunity; Macrophages; Metformin; Mice; Myelo | 2023 |
Metformin improves cancer immunotherapy by directly rescuing tumor-infiltrating CD8 T lymphocytes from hypoxia-induced immunosuppression.
Topics: Animals; CD8-Positive T-Lymphocytes; Humans; Hypoxia; Immunosuppression Therapy; Immunosuppressive A | 2023 |
Radioproteomics modeling of metformin-enhanced radiosensitivity: an animal study.
Topics: AMP-Activated Protein Kinases; Animals; Female; Metformin; Mice; Neoplasms; Radiation Tolerance; TOR | 2023 |
Bioengineered nanogenerator with sustainable reactive oxygen species storm for self-reinforcing sono-chemodynamic oncotherapy.
Topics: Biomedical Engineering; Cell Line, Tumor; Copper; Drug Liberation; Glutathione; Humans; Hydrogen Per | 2023 |
Evaluating Metformin Strategies for Cancer Prevention: A Target Trial Emulation Using Electronic Health Records.
Topics: Diabetes Mellitus; Diabetes Mellitus, Type 2; Electronic Health Records; Humans; Hypoglycemic Agents | 2023 |
Metformin-Induced Receptor Turnover Alters Antibody Accumulation in HER-Expressing Tumors.
Topics: Animals; Antibodies, Monoclonal; Cell Line, Tumor; ErbB Receptors; Humans; Metformin; Mice; Neoplasm | 2023 |
[Investigation of glycaemic and nutritional status of patients suffering from cancer.]
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Metformin; Neoplasms; N | 2023 |
Metformin: A New Inhibitor of the Wnt Signaling Pathway in Cancer.
Topics: AMP-Activated Protein Kinases; Diabetes Mellitus, Type 2; Female; Humans; Metformin; Neoplasms; Wnt | 2023 |
Ultra-efficient radio-immunotherapy for reprogramming the hypoxic and immunosuppressive tumor microenvironment with durable innate immune memory.
Topics: Humans; Hypoxia; Immunosuppressive Agents; Immunotherapy; Manganese Compounds; Metformin; Neoplasms; | 2023 |
Targeting and repolarizing M2-like tumor-associated macrophage-mediated MR imaging and tumor immunotherapy by biomimetic nanoparticles.
Topics: Biomimetics; Humans; Immunotherapy; Magnetic Resonance Imaging; Metformin; Nanoparticles; Neoplasms; | 2023 |
Pharmacophore mapping approach to find anti-cancer phytochemicals with metformin-like activities against transforming growth factor (TGF)-beta receptor I kinase: An in silico study.
Topics: Diabetes Mellitus, Type 2; Humans; Ligands; Metformin; Molecular Docking Simulation; Molecular Dynam | 2023 |
Anti-Proliferative Properties of the Novel Hybrid Drug Met-ITC, Composed of the Native Drug Metformin with the Addition of an Isothiocyanate H
Topics: Cell Line; Diabetes Mellitus, Type 2; Humans; Hydrogen Sulfide; Isothiocyanates; Metformin; Neoplasm | 2023 |
Metformin increases cancer specific survival in colorectal cancer patients-National cohort study.
Topics: Aged; Cohort Studies; Female; Humans; Hypoglycemic Agents; Male; Metformin; Neoplasms; Prospective S | 2019 |
Metformin inhibits the function of granulocytic myeloid-derived suppressor cells in tumor-bearing mice.
Topics: AMP-Activated Protein Kinase Kinases; Animals; Cell Line, Tumor; Female; Immunotherapy; Metformin; M | 2019 |
Maternal diabetes and risk of childhood cancer in the offspring.
Topics: Adolescent; Case-Control Studies; Child; Child, Preschool; Diabetes Mellitus; Diabetes, Gestational; | 2020 |
Diabetes, metformin and cancer risk in myotonic dystrophy type I.
Topics: Adolescent; Adult; Case-Control Studies; Child; Child, Preschool; Diabetes Mellitus, Type 1; Female; | 2020 |
A MSN-based tumor-targeted nanoplatform to interfere with lactate metabolism to induce tumor cell acidosis for tumor suppression and anti-metastasis.
Topics: Antineoplastic Agents; Cell Line, Tumor; Fluvastatin; Folic Acid; Humans; Lactates; Manganese Compou | 2020 |
Impact of metformin on malignancy in solid organ transplantation.
Topics: Aged; Humans; Metformin; Neoplasms; Organ Transplantation; Retrospective Studies; Risk Factors; Tran | 2020 |
GPD1 Enhances the Anticancer Effects of Metformin by Synergistically Increasing Total Cellular Glycerol-3-Phosphate.
Topics: A549 Cells; Adenosine Triphosphate; Animals; Antineoplastic Agents; Cell Growth Processes; Cell Line | 2020 |
Metformin activates AMPK/SIRT1/NF-κB pathway and induces mitochondrial dysfunction to drive caspase3/GSDME-mediated cancer cell pyroptosis.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Caspase 3; Cell Proliferation; Cell Survival; | 2020 |
Starvation and antimetabolic therapy promote cytokine release and recruitment of immune cells.
Topics: Activating Transcription Factor 4; Antimetabolites; Cell Death; Deoxyglucose; Epithelial Cells; Gene | 2020 |
DPP4i, thiazolidinediones, or insulin and risks of cancer in patients with type 2 diabetes mellitus on metformin-sulfonylurea dual therapy with inadequate control.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Insulin; | 2020 |
Evaluating the impact of AMPK activation, a target of metformin, on risk of cardiovascular diseases and cancer in the UK Biobank: a Mendelian randomisation study.
Topics: AMP-Activated Protein Kinases; Cardiovascular Diseases; Female; Genome-Wide Association Study; Human | 2020 |
Metformin use reduced the overall risk of cancer in diabetic patients: A study based on the Korean NHIS-HEALS cohort.
Topics: Adult; Aged; Databases, Factual; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Incidence; | 2020 |
A CRISPR knockout negative screen reveals synergy between CDKs inhibitor and metformin in the treatment of human cancer in vitro and in vivo.
Topics: Animals; Aspartic Acid; CDC2 Protein Kinase; Citric Acid Cycle; CRISPR-Cas Systems; Cyclin-Dependent | 2020 |
Modulation of Tumor Hypoxia by pH-Responsive Liposomes to Inhibit Mitochondrial Respiration for Enhancing Sonodynamic Therapy.
Topics: Animals; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Cell Respiration; Humans; Hydrogen-Ion | 2020 |
Drug repurposing for cancer treatments: a well-intentioned, but misguided strategy.
Topics: Aspirin; Drug Repositioning; Humans; Metformin; Neoplasms; Vitamin D | 2020 |
Is There a Role for Statins and Metformin in Cancer Therapy?
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Atorvastatin; Humans; Hydroxymethylglutaryl | 2020 |
Use of metformin and aspirin is associated with delayed cancer incidence.
Topics: Aged; Aged, 80 and over; Aspirin; Delayed Diagnosis; Female; Humans; Incidence; Male; Metformin; Mid | 2020 |
'Doctor, will this medicine give me cancer?': Lessons from nitrosamines and extended-release metformin.
Topics: Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Industry; Drug-Related Side Effects and | 2021 |
Metformin and proliferation of cancer cell lines.
Topics: Antineoplastic Agents; Cell Line; Cell Proliferation; Diabetes Mellitus, Type 2; Humans; Metformin; | 2020 |
Metformin induced lactic acidosis impaired response of cancer cells towards paclitaxel and doxorubicin: Role of monocarboxylate transporter.
Topics: A549 Cells; Acidosis, Lactic; Animals; Antineoplastic Agents; Breast Neoplasms; Diabetes Mellitus, T | 2021 |
Circumventing Myeloid-Derived Suppressor Cell-Mediated Immunosuppression Using an Oxygen-Generated and -Economized Nanoplatform.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Cerium; Female; Hydrogen Peroxide; | 2020 |
The design of cyclometalated iridium(iii)-metformin complexes for hypoxic cancer treatment.
Topics: Antineoplastic Agents; Cell Line; Cisplatin; Coordination Complexes; Humans; Iridium; Metformin; Neo | 2021 |
Boosting anti-PD-1 therapy with metformin-loaded macrophage-derived microparticles.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell-Derived Microparticl | 2021 |
Asparagine couples mitochondrial respiration to ATF4 activity and tumor growth.
Topics: Activating Transcription Factor 4; Animals; Asparagine; Aspartic Acid; Cell Line, Tumor; Cell Prolif | 2021 |
Metformin use in cancer survivors with diabetes reduces all-cause mortality, based on the Korean National Health Insurance Service between 2002 and 2015.
Topics: Adult; Aged; Cancer Survivors; Cause of Death; Diabetes Mellitus; Female; Follow-Up Studies; Humans; | 2021 |
Metformin therapy and risk of cancer in patients after heart transplantation.
Topics: Heart Transplantation; Humans; Hypoglycemic Agents; Metformin; Neoplasms; Retrospective Studies | 2021 |
Metformin alters therapeutic effects in the BALB/c tumor therapy model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; BALB 3T3 Cells; Carcinogens; Cell Survival; | 2021 |
Multidimensional mechanisms of metformin in cancer treatment.
Topics: Antineoplastic Agents; Humans; Metformin; MicroRNAs; Neoplasms; Reactive Oxygen Species | 2022 |
Metformin generates profound alterations in systemic and tumor immunity with associated antitumor effects.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Disease Models, Animal; Female; Humans; Hypoglycem | 2021 |
Harnessing the soil: reshaping the tumor microenvironment towards an antitumor immune state by low-dose metformin.
Topics: Antineoplastic Agents; Humans; Metformin; Neoplasms; Soil; Tumor Microenvironment | 2021 |
Identification of a Small-Molecule Glucose Transporter Inhibitor, Glutipyran, That Inhibits Cancer Cell Growth.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitum | 2021 |
Dual inhibiting OCT4 and AKT potently suppresses the propagation of human cancer cells.
Topics: Animals; Apoptosis; Carcinogenesis; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Epigenesis, | 2017 |
Metformin inhibits RANKL and sensitizes cancer stem cells to denosumab.
Topics: BRCA1 Protein; Breast; Cell Line, Tumor; Denosumab; Drug Resistance, Neoplasm; Drug Synergism; Epith | 2017 |
Metformin and the incidence of viral associated cancers in patients with type 2 diabetes.
Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Metformi | 2017 |
Modulatory effects of metformin on mutagenicity and epithelial tumor incidence in doxorubicin-treated Drosophila melanogaster.
Topics: Animals; Carcinogenesis; Disease Models, Animal; DNA Damage; Doxorubicin; Drosophila melanogaster; F | 2017 |
Metformin use associated with lower risk of cancer in patients with diabetes mellitus type 2.
Topics: Adult; Aged; Carcinoma; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglyc | 2017 |
Metformin: Adjunct Therapy in Cancer Treatment.
Topics: Female; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Neoplasms; Off-Label Use | 2017 |
Metformin therapy reduces the risk of malignancy after heart transplantation.
Topics: Adult; Female; Follow-Up Studies; Forecasting; Heart Transplantation; Humans; Hypoglycemic Agents; I | 2017 |
Risk of Cause-Specific Death in Individuals with Cancer-Modifying Role Diabetes, Statins and Metformin.
Topics: Adult; Aged; Cause of Death; Diabetes Mellitus, Type 2; Female; Finland; Humans; Hydroxymethylglutar | 2017 |
Patient- and Cell Type-Specific Heterogeneity of Metformin Response.
Topics: Antineoplastic Agents; Cell Differentiation; Cell Line, Tumor; Cell Lineage; Cell Survival; Dose-Res | 2018 |
Use of metformin is associated with lower incidence of cancer in patients with type 2 diabetes.
Topics: Aged; Breast Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Metfor | 2017 |
Attenuation of CD4
Topics: AMP-Activated Protein Kinase Kinases; Antigens, CD; Cell Differentiation; CTLA-4 Antigen; Forkhead T | 2017 |
Synergistic Chemopreventive and Therapeutic Effects of Co-drug UA-Met: Implication in Tumor Metastasis.
Topics: Animals; Cadherins; Cell Line, Tumor; Drug Synergism; Female; Humans; Metformin; Mice; Neoplasm Meta | 2017 |
Effects of metformin on insulin resistance and metabolic disorders in tumor-bearing rats with advanced cachexia.
Topics: Animals; Cachexia; Insulin; Insulin Resistance; Male; Metformin; Neoplasms; Proto-Oncogene Proteins | 2018 |
A complex systems approach to cancer prevention.
Topics: beta-Glucans; Decision Support Techniques; Diet; Drug Synergism; Energy Metabolism; Exercise; Glucos | 2018 |
Metformin reduces the risk of cancer in patients with type 2 diabetes: An analysis based on the Korean National Diabetes Program Cohort.
Topics: Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Incidence; Kaplan-Meier Estimate; Ma | 2018 |
Anti-cancer Effects of Metformin: Recent Evidences for its Role in Prevention and Treatment of Cancer.
Topics: Antineoplastic Agents; Humans; Metformin; Neoplasms | 2018 |
Metabolic switching in the hypoglycemic and antitumor effects of metformin on high glucose induced HepG2 cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Diabetes Mellitus, Type 2; Energy Metabolism; | 2018 |
High dose targeted delivery on cancer sites and the importance of short-chain fatty acids for metformin's action: Two crucial aspects of the wonder drug.
Topics: Antineoplastic Agents; Cell Proliferation; Gastrointestinal Microbiome; Humans; Hypoglycemic Agents; | 2018 |
Aspartate is an endogenous metabolic limitation for tumour growth.
Topics: Animals; Antineoplastic Agents; Asparaginase; Aspartic Acid; Cell Proliferation; Drug Resistance, Ne | 2018 |
Glucose-regulated phosphorylation of TET2 by AMPK reveals a pathway linking diabetes to cancer.
Topics: 5-Methylcytosine; Adenylate Kinase; Animals; Diabetes Mellitus; Dioxygenases; DNA; DNA Methylation; | 2018 |
Bifurcation analysis of insulin regulated mTOR signalling pathway in cancer cells.
Topics: Apoptosis; Feedback, Physiological; Insulin; Kinetics; Metformin; Models, Biological; Neoplasms; Pho | 2018 |
Metformin reveals a mitochondrial copper addiction of mesenchymal cancer cells.
Topics: Antineoplastic Agents; Cell Death; Cell Line; Cell Survival; Click Chemistry; Copper; Epithelial-Mes | 2018 |
[Reappraisal of metformin : less restrictions and more potential indications].
Topics: Contraindications, Drug; Diabetes Mellitus, Type 2; Heart Diseases; Humans; Hypoglycemic Agents; Met | 2018 |
Dual Inhibition of the Lactate Transporters MCT1 and MCT4 Is Synthetic Lethal with Metformin due to NAD+ Depletion in Cancer Cells.
Topics: Acids; Animals; Cell Line, Tumor; Energy Metabolism; Humans; Intracellular Space; Lactic Acid; Male; | 2018 |
Pan-cancer analysis of transcriptional metabolic dysregulation using The Cancer Genome Atlas.
Topics: Cell Line; Cell Survival; Cellular Reprogramming; Citric Acid Cycle; Computational Biology; Drug Eva | 2018 |
Metformin-dependent metabolic reprogramming contributes to efficient anti-tumor immunity.
Topics: Humans; Immunologic Memory; Metformin; Neoplasms | 2017 |
Inhibiting neddylation modification alters mitochondrial morphology and reprograms energy metabolism in cancer cells.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclopentanes; Energy Metab | 2019 |
Metformin use and risk of cancer in patients with type 2 diabetes: a cohort study of primary care records using inverse probability weighting of marginal structural models.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Diabetes Mellitus, Type 2; Electronic Health Records | 2019 |
Respiratory Capacity and Reserve Predict Cell Sensitivity to Mitochondria Inhibitors: Mechanism-Based Markers to Identify Metformin-Responsive Cancers.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Electron Transport; Heterografts; Humans; Metformin; | 2019 |
Integrin β1-Mediated Cell⁻Cell Adhesion Augments Metformin-Induced Anoikis.
Topics: Anoikis; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Cell Survival; Gene Expression Regulat | 2019 |
Metformin and Reduced Risk of Cancer in the Hong Kong Diabetes Registry: Real Effect or Immortal Time Bias?
Topics: Cohort Studies; Diabetes Mellitus, Type 2; Hong Kong; Humans; Hypoglycemic Agents; Metformin; Neopla | 2019 |
Metformin and Docosahexaenoic Acid Hybrid Micelles for Premetastatic Niche Modulation and Tumor Metastasis Suppression.
Topics: Animals; Anti-Inflammatory Agents; Docosahexaenoic Acids; Lung; Metformin; Mice; Micelles; Neoplasm | 2019 |
Combination of Hypoglycemia and Metformin Impairs Tumor Metabolic Plasticity and Growth by Modulating the PP2A-GSK3β-MCL-1 Axis.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Fasting; Gene Expression Regulation, N | 2019 |
Metformin Treatment and Cancer Risk: Cox Regression Analysis, With Time-Dependent Covariates, of 320,000 Persons With Incident Diabetes Mellitus.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Inci | 2019 |
Metformin: a case of divide and conquer.
Topics: Cell Division; Humans; Hypoglycemic Agents; Metformin; Neoplasms; Neoplastic Stem Cells; Signal Tran | 2013 |
One-carbon metabolism: an aging-cancer crossroad for the gerosuppressant metformin.
Topics: Aging; AMP-Activated Protein Kinases; Animals; Anticarcinogenic Agents; Carbon; Cell Transformation, | 2012 |
Metformin, aging and cancer.
Topics: Aging; Animals; Antineoplastic Agents; Cellular Senescence; Hypoglycemic Agents; I-kappa B Kinase; M | 2013 |
Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patients.
Topics: Adult; Aged; Cardiovascular Diseases; Cause of Death; Cohort Studies; Confounding Factors, Epidemiol | 2013 |
Metformin inhibits heme oxygenase-1 expression in cancer cells through inactivation of Raf-ERK-Nrf2 signaling and AMPK-independent pathways.
Topics: Blotting, Western; Cell Line, Tumor; Cell Nucleus; Cell Survival; Cytosol; Galactosidases; Heme Oxyg | 2013 |
Metformin and rapamycin are master-keys for understanding the relationship between cell senescent, aging and cancer.
Topics: Aging; Animals; Cellular Senescence; Gene Expression Regulation; Humans; Hypoglycemic Agents; Immuno | 2013 |
Contributions of AMPK and p53 dependent signaling to radiation response in the presence of metformin.
Topics: AMP-Activated Protein Kinases; Animals; Cell Line, Tumor; Cell Proliferation; Humans; Metformin; Mic | 2013 |
Type 2 diabetes mellitus, glycemic control, and cancer risk.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Ag | 2014 |
Type 2 diabetes mellitus, glycemic control, and cancer risk.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Ag | 2014 |
Type 2 diabetes mellitus, glycemic control, and cancer risk.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Ag | 2014 |
Type 2 diabetes mellitus, glycemic control, and cancer risk.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Ag | 2014 |
Type 2 diabetes mellitus, glycemic control, and cancer risk.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Ag | 2014 |
Type 2 diabetes mellitus, glycemic control, and cancer risk.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Ag | 2014 |
Type 2 diabetes mellitus, glycemic control, and cancer risk.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Ag | 2014 |
Type 2 diabetes mellitus, glycemic control, and cancer risk.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Ag | 2014 |
Type 2 diabetes mellitus, glycemic control, and cancer risk.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Ag | 2014 |
Metformin and the incidence of cancer in patients with diabetes: a nested case-control study.
Topics: Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Metformin; Neoplasms | 2013 |
Genetic polymorphisms potentially associated with response to metformin in postmenopausal diabetics suffering and not suffering with cancer.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Diabetes Mellitus, Type 2; Estradiol; Female; Genotype; Hum | 2013 |
Metformin: are potential benefits on cancer risk extended to cancer survival?
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Neoplasms | 2013 |
Paradoxic effects of metformin on endothelial cells and angiogenesis.
Topics: Adipose Tissue; AMP-Activated Protein Kinases; Angiogenesis Inhibitors; Animals; Antineoplastic Agen | 2014 |
Incidence of bladder cancer in patients with type 2 diabetes treated with metformin or sulfonylureas.
Topics: Aged; Cohort Studies; Databases, Factual; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Huma | 2014 |
[Genetic testing of constitutive sensitivity to metformin in cancer patients with and without diabetes].
Topics: Adult; Aged; Aged, 80 and over; AMP-Activated Protein Kinase Kinases; Antineoplastic Agents; Diabete | 2013 |
[Potential sensitivity to metformin of the diabetics suffering and not suffering with cancer: a pharmacogenetic study].
Topics: Adult; Aged; Aged, 80 and over; Biotransformation; Diabetes Mellitus, Type 2; Female; Genome-Wide As | 2013 |
Diabetes drug may activate molecule that triggers cancer growth.
Topics: AMP-Activated Protein Kinases; Animals; Clinical Trials as Topic; Humans; Hypoglycemic Agents; Insul | 2014 |
Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis.
Topics: Carcinogenesis; Cell Line, Tumor; Electron Transport Complex I; Humans; Metformin; Neoplasms | 2014 |
Additive effects of blood glucose lowering drugs, statins and renin-angiotensin system blockers on all-site cancer risk in patients with type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucose; Hemoglobin A; Humans; Hydroxymethylglutar | 2014 |
Metformin does not affect cancer risk: a cohort study in the U.K. Clinical Practice Research Datalink analyzed like an intention-to-treat trial.
Topics: Adult; Aged; Aged, 80 and over; Databases, Factual; Diabetes Mellitus, Type 2; Female; Follow-Up Stu | 2014 |
Overcoming Drug Development Bottlenecks With Repurposing: Repurposing biguanides to target energy metabolism for cancer treatment.
Topics: Clinical Trials as Topic; Drug Repositioning; Energy Metabolism; Guanidines; Humans; Metformin; Neop | 2014 |
Overcoming Drug Development Bottlenecks With Repurposing: Old drugs learn new tricks.
Topics: Clinical Trials as Topic; Drug Discovery; Drug Repositioning; Humans; Metformin; Neoplasms | 2014 |
Oncobiguanides: Paracelsus' law and nonconventional routes for administering diabetobiguanides for cancer treatment.
Topics: Antineoplastic Agents; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Neoplasms | 2014 |
Metformin associated with photodynamic therapy--a novel oncological direction.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cyclooxygenase 2; Glutathione; Hypoglycemic Agents; Male; Malo | 2014 |
Metformin induces microRNA-34a to downregulate the Sirt1/Pgc-1α/Nrf2 pathway, leading to increased susceptibility of wild-type p53 cancer cells to oxidative stress and therapeutic agents.
Topics: Antineoplastic Agents; Apoptosis; Down-Regulation; HCT116 Cells; Humans; MCF-7 Cells; Metformin; Mic | 2014 |
Validating drug repurposing signals using electronic health records: a case study of metformin associated with reduced cancer mortality.
Topics: Administration, Oral; Adult; Diabetes Mellitus, Type 2; Drug Repositioning; Electronic Health Record | 2015 |
Metformin may be associated with false-negative cancer detection in the gastrointestinal tract on PET/CT.
Topics: Diabetes Mellitus, Type 2; False Negative Reactions; Fluorodeoxyglucose F18; Humans; Metformin; Neop | 2014 |
Use of crowdsourcing for cancer clinical trial development.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Crowdsourcing; Feasibility Studies; Humans; Interne | 2014 |
Diabetic oncopathy--one more yet another deadly diabetic complication!
Topics: Diabetes Complications; Glucose; Humans; Hyperinsulinism; Hypoglycemic Agents; India; Metformin; Mod | 2014 |
Differential effects of AMPK agonists on cell growth and metabolism.
Topics: Adenylate Kinase; Aminoimidazole Carboxamide; Animals; Biphenyl Compounds; Cell Cycle; Cell Line, Tu | 2015 |
Mechanisms by which low glucose enhances the cytotoxicity of metformin to cancer cells both in vitro and in vivo.
Topics: Adenosine Triphosphate; AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Blood Glucose | 2014 |
Are sulfonylurea and insulin therapies associated with a larger risk of cancer than metformin therapy? A retrospective database analysis.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Germany; Humans; Hypoglycemic Agents; In | 2015 |
Four key questions about metformin and cancer.
Topics: Animals; Antineoplastic Agents; Humans; Metformin; Mice; Neoplasms | 2014 |
Serine deprivation enhances antineoplastic activity of biguanides.
Topics: Animals; Biguanides; Cell Line, Tumor; Glycolysis; Humans; Metformin; Mice; Neoplasms; Oxidative Pho | 2014 |
Using Boolean Logic Modeling of Gene Regulatory Networks to Exploit the Links Between Cancer and Metabolism for Therapeutic Purposes.
Topics: Antineoplastic Agents; Computational Biology; Diabetes Mellitus, Type 2; Gene Regulatory Networks; H | 2016 |
Protective effect of metformin against walker 256 tumor growth is not dependent on metabolism improvement.
Topics: Animals; Blood Glucose; Carcinoma 256, Walker; Cell Proliferation; Diabetes Mellitus, Experimental; | 2014 |
Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug | 2015 |
Starvation of cancer via induced ketogenesis and severe hypoglycemia.
Topics: Adaptation, Physiological; Blood Glucose; Diet, Ketogenic; Gluconeogenesis; Humans; Hypoglycemic Age | 2015 |
Immune-mediated antitumor effect by type 2 diabetes drug, metformin.
Topics: Adoptive Transfer; AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Apoptosis; CD8-Pos | 2015 |
Cancer risk in HBV patients with statin and metformin use: a population-based cohort study.
Topics: Adult; Cohort Studies; Drug Synergism; Female; Hepatitis B, Chronic; Humans; Hydroxymethylglutaryl-C | 2015 |
A pharmacist's perspective on metformin use and cancer outcomes.
Topics: Diabetes Mellitus; Humans; Hypoglycemic Agents; Metformin; Neoplasms; Pharmacists | 2015 |
Should pharmacokinetic safety challenges prevent metformin use in patients with cancer?
Topics: Humans; Hypoglycemic Agents; Metformin; Neoplasms | 2015 |
Potential and real 'antineoplastic' and metabolic effect of metformin in diabetic and nondiabetic postmenopausal females.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Diabetes Mellitus, Type 2; Female; | 2015 |
Early treatment with metformin induces resistance against tumor growth in adult rats.
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Heterogra | 2015 |
Deciphering Signaling Pathway Networks to Understand the Molecular Mechanisms of Metformin Action.
Topics: Animals; Antineoplastic Agents; Computational Biology; Diabetes Mellitus, Type 2; Gene Expression Pr | 2015 |
Anti-ageing pill pushed as bona fide drug.
Topics: Aging; Animals; Caloric Restriction; Clinical Trials as Topic; Cognition Disorders; Diabetes Mellitu | 2015 |
Effect of metformin and adriamycin on transplantable tumor model.
Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Disease Models, Animal; Doxorubicin; Hypoglycemic A | 2015 |
A Trial for the ages.
Topics: Aging; Humans; Hypoglycemic Agents; Liver; Metformin; Mitochondria; Neoplasms | 2015 |
Pilot study of oral metformin in cancer-bearing cats.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Cat Diseases; Cats; Female; Insulin-Like Growt | 2017 |
Metformin for cancer and aging prevention: is it a time to make the long story short?
Topics: Animals; Anticarcinogenic Agents; Cricetinae; Disease Models, Animal; Drug Administration Routes; Dr | 2015 |
Diabetes, metformin and incidence of and death from invasive cancer in postmenopausal women: Results from the women's health initiative.
Topics: Aged; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Incidence; Metformin; Middle Aged; Neo | 2016 |
Metformin Antagonizes Cancer Cell Proliferation by Suppressing Mitochondrial-Dependent Biosynthesis.
Topics: Adaptor Proteins, Signal Transducing; AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; | 2015 |
Metformin Protects Kidney Cells From Insulin-Mediated Genotoxicity In Vitro and in Male Zucker Diabetic Fatty Rats.
Topics: Animals; Antioxidants; Cells, Cultured; Cytoprotection; Diabetes Mellitus, Experimental; DNA Damage; | 2016 |
Toward Repurposing Metformin as a Precision Anti-Cancer Therapy Using Structural Systems Pharmacology.
Topics: Antineoplastic Agents; Computational Biology; Drug Repositioning; Gene Regulatory Networks; Genomics | 2016 |
Metformin for cancer prevention: a reason for optimism.
Topics: Diabetes Mellitus, Type 2; Humans; Metformin; Neoplasms | 2016 |
Metformin Pharmacokinetics in Mouse Tumors: Implications for Human Therapy.
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Humans; Hypoglycemic Agents; Metformin; Mice | 2016 |
Are Metformin Doses Used in Murine Cancer Models Clinically Relevant?
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Hy | 2016 |
[Metformin - an anti-carcinogenesis drug?].
Topics: Carcinogenesis; Diabetes Complications; Humans; Metformin; Neoplasms; Octamer Transcription Factor-1 | 2016 |
[The risk is higher, but why?].
Topics: Carcinoma, Hepatocellular; Diabetes Complications; Humans; Liver Neoplasms; Metformin; Neoplasms; Pa | 2016 |
[Anti-oncogenic effect of metformin].
Topics: Antineoplastic Agents; Diabetes Mellitus; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Metfo | 2016 |
Metformin and cancer: Quo vadis et cui bono?
Topics: Animals; Antineoplastic Agents; Humans; Hypoglycemic Agents; Metformin; Mice; Neoplasms | 2016 |
Study about the Efficacy of Metformin to Immune Function in Cancer Patients.
Topics: CD8-Positive T-Lymphocytes; Clinical Protocols; Cytokines; Humans; Hypoglycemic Agents; Metformin; N | 2016 |
Environment Dictates Dependence on Mitochondrial Complex I for NAD+ and Aspartate Production and Determines Cancer Cell Sensitivity to Metformin.
Topics: Animals; Aspartic Acid; Cell Line, Tumor; Cell Proliferation; Electron Transport Complex I; Homeosta | 2016 |
Metformin targets histone acetylation in cancer-prone epithelial cells.
Topics: Acetyl Coenzyme A; Acetylation; BRCA1 Protein; Carcinogenesis; Epigenesis, Genetic; Epithelial Cells | 2016 |
The need for differentiating diabetes-specific mortality from total mortality when comparing metformin with insulin regarding cancer survival.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Metformin; Neoplasms | 2017 |
Metformin: Restraining Nucleocytoplasmic Shuttling to Fight Cancer and Aging.
Topics: Active Transport, Cell Nucleus; Aging; Animals; Caenorhabditis elegans; Humans; Metformin; Neoplasms | 2016 |
An Ancient, Unified Mechanism for Metformin Growth Inhibition in C. elegans and Cancer.
Topics: Acyl-CoA Dehydrogenase; Aging; Animals; Body Size; Caenorhabditis elegans; Caenorhabditis elegans Pr | 2016 |
Metformin: a metabolic modulator.
Topics: Acyl-CoA Dehydrogenase; Animals; Antineoplastic Agents; Caenorhabditis elegans; Caenorhabditis elega | 2017 |
Metformin to Treat Cancer: Misstep in Translational Research from Observational Studies.
Topics: Humans; Hypoglycemic Agents; Metformin; Neoplasms; Translational Research, Biomedical | 2017 |
Differential effects of metformin on age related comorbidities in older men with type 2 diabetes.
Topics: Aged; Aged, 80 and over; Aging; Cardiovascular Diseases; Cohort Studies; Comorbidity; Dementia; Depr | 2017 |
Cancer and aging: more puzzles, more promises?
Topics: Aging; Animals; Female; Humans; Hypoglycemic Agents; Longevity; Metformin; Mice; Neoplasms; Phosphat | 2008 |
Metformin slows down aging and extends life span of female SHR mice.
Topics: Aging; Animals; Body Temperature; Body Weight; Drinking Behavior; Estrous Cycle; Feeding Behavior; F | 2008 |
Sulphonylureas and cancer: a case-control study.
Topics: Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Gliclazide; Glybur | 2009 |
New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglyce | 2009 |
New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglyce | 2009 |
New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglyce | 2009 |
New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglyce | 2009 |
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Blood Pressure; Cohort Studies; Diabetes Melli | 2009 |
Metformin, cancer, alphabet soup, and the role of epidemiology in etiologic research.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglyce | 2009 |
AMPK: Evidence for an energy-sensing cytokinetic tumor suppressor.
Topics: AMP-Activated Protein Kinases; Animals; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Energy M | 2009 |
Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16.
Topics: Aged; Blood Pressure; Body Mass Index; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopath | 2010 |
Mysterious metformin.
Topics: Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Humans; Hypoglycemic Agents; Metformin; | 2009 |
Diabetes therapy and cancer risk: causal effects and other plausible explanations.
Topics: Diabetes Mellitus; Humans; Hypoglycemic Agents; Insulin; Metformin; Neoplasms | 2010 |
Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure.
Topics: Databases, Factual; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agent | 2010 |
The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Diabetes Mellitus, Type 2; Drug Resi | 2011 |
Glucose-lowering therapies and cancer risk: the trials and tribulations of trials and observations.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Neoplas | 2010 |
Metformin and cancer: licence to heal?
Topics: AMP-Activated Protein Kinase Kinases; Animals; Cell Line, Tumor; Diabetes Mellitus, Type 2; Female; | 2010 |
Low HDL cholesterol, metformin use, and cancer risk in type 2 diabetes: the Hong Kong Diabetes Registry.
Topics: Adult; Aged; Cholesterol, HDL; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Hong Kong; Huma | 2011 |
Metformin and cancer occurrence in insulin-treated type 2 diabetic patients.
Topics: Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; | 2011 |
Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort.
Topics: Aged; Cohort Studies; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Germany; Humans; H | 2011 |
Gender differences in metformin effect on aging, life span and spontaneous tumorigenesis in 129/Sv mice.
Topics: Age Factors; Aging; Animals; Blood Glucose; Body Temperature; Body Weight; Cholesterol; Chromosome A | 2010 |
Metformin and sex: Why suppression of aging may be harmful to young male mice.
Topics: Age Factors; Aging; Animals; Female; Hypoglycemic Agents; Longevity; Male; Metformin; Mice; Mice, 12 | 2010 |
Familial diabetes is associated with reduced risk of cancer in diabetic patients: a possible role for metformin.
Topics: Aged; Case-Control Studies; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Follow-Up Stu | 2012 |
Thailand Diabetic Registry cohort: predicting death in Thai diabetic patients and causes of death.
Topics: Aged; Asian People; Cardiovascular Diseases; Cause of Death; Diabetes Complications; Diabetes Mellit | 2010 |
Genomics: Drugs, diabetes and cancer.
Topics: Adenylate Kinase; AMP-Activated Protein Kinase Kinases; Animals; Ataxia Telangiectasia Mutated Prote | 2011 |
If started early in life, metformin treatment increases life span and postpones tumors in female SHR mice.
Topics: Age Factors; Animals; Body Temperature; Body Weight; Drinking; Eating; Estrous Cycle; Female; Humans | 2011 |
Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Car | 2011 |
The complete control of glucose level utilizing the composition of ketogenic diet with the gluconeogenesis inhibitor, the anti-diabetic drug metformin, as a potential anti-cancer therapy.
Topics: Blood Glucose; Cachexia; Diet, Ketogenic; Gluconeogenesis; Humans; Hypoglycemic Agents; Metformin; N | 2011 |
Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth.
Topics: AMP-Activated Protein Kinases; Animals; Antimetabolites; Antineoplastic Agents; Cell Cycle; Cell Lin | 2011 |
Metformin for cancer prevention.
Topics: Antineoplastic Agents; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin-Like Growth F | 2011 |
Cancer mortality reduction and metformin: a retrospective cohort study in type 2 diabetic patients.
Topics: Aged; Cohort Studies; Confounding Factors, Epidemiologic; Diabetes Mellitus, Type 2; Female; Follow- | 2012 |
mTORC1 activity as a determinant of cancer risk--rationalizing the cancer-preventive effects of adiponectin, metformin, rapamycin, and low-protein vegan diets.
Topics: Adiponectin; Diet, Vegetarian; Dietary Proteins; Down-Regulation; Humans; Mechanistic Target of Rapa | 2011 |
Targeting AMPK in the treatment of malignancies.
Topics: Adenylate Kinase; Animals; Antineoplastic Agents; Humans; Metformin; Molecular Targeted Therapy; Neo | 2012 |
Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models.
Topics: Animals; Deoxyglucose; Down-Regulation; Drug Evaluation, Preclinical; Energy Metabolism; Female; Hum | 2011 |
Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study.
Topics: Databases, Factual; Diabetes Mellitus, Type 2; Follow-Up Studies; Humans; Hypoglycemic Agents; Metfo | 2012 |
Metformin may antagonize Lin28 and/or Lin28B activity, thereby boosting let-7 levels and antagonizing cancer progression.
Topics: Animals; DNA-Binding Proteins; Histone Deacetylase Inhibitors; Humans; Metformin; Mice; MicroRNAs; N | 2012 |
Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cohort Studies; Databases, Factual; Diabetes Mellitus, T | 2012 |
Cancer research. Cancer prevention with a diabetes pill?
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Animals; Anticarcinogenic Agent | 2012 |
Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival.
Topics: Aged; Aged, 80 and over; Breast Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic A | 2012 |
Relation between diabetes, metformin treatment and the occurrence of malignancies in a Belgian primary care setting.
Topics: Belgium; Cohort Studies; Diabetes Mellitus, Type 2; Diet; Female; Humans; Hypoglycemic Agents; Life | 2012 |
Metformin and hepatic carcinogenesis.
Topics: AMP-Activated Protein Kinases; Animals; Humans; Hypoglycemic Agents; Liver; Male; Metformin; Neoplas | 2012 |
Metformin prevents liver tumorigenesis by inhibiting pathways driving hepatic lipogenesis.
Topics: AMP-Activated Protein Kinases; Animals; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; | 2012 |
Links among type 2 diabetes, cancer and metformin use: what have we learned?
Topics: Diabetes Mellitus, Type 2; Diet; Female; Humans; Hypoglycemic Agents; Male; Metformin; Neoplasms; Pr | 2012 |
Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells.
Topics: Adenylate Kinase; Animals; Antineoplastic Agents; Humans; Metformin; Mice; Mice, Inbred C3H; Neoplas | 2012 |
Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells.
Topics: Adenylate Kinase; Animals; Antineoplastic Agents; Humans; Metformin; Mice; Mice, Inbred C3H; Neoplas | 2012 |
Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells.
Topics: Adenylate Kinase; Animals; Antineoplastic Agents; Humans; Metformin; Mice; Mice, Inbred C3H; Neoplas | 2012 |
Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells.
Topics: Adenylate Kinase; Animals; Antineoplastic Agents; Humans; Metformin; Mice; Mice, Inbred C3H; Neoplas | 2012 |
Use of thiazolidinedione and cancer risk in Type 2 diabetes: the Hong Kong diabetes registry.
Topics: Aged; Asian People; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Follow-Up S | 2012 |
Cancer risk in type 2 diabetes.
Topics: Acyl Coenzyme A; AMP-Activated Protein Kinase Kinases; Diabetes Mellitus, Type 2; Female; Humans; Hy | 2012 |
Metformin: a diabetes drug for cancer, or a cancer drug for diabetics?
Topics: AMP-Activated Protein Kinase Kinases; Antineoplastic Agents; Body Mass Index; Breast Neoplasms; Chem | 2012 |
Cracking open window of opportunity trials.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Diabetes Mellitus; Female; Humans; Hypo | 2012 |
Distinct perturbation of the translatome by the antidiabetic drug metformin.
Topics: Analysis of Variance; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Humans; Indoles; | 2012 |
The influence of type 2 diabetes and glucose-lowering therapies on cancer risk in the Taiwanese.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Insulin; Male; Metformin; Middle Aged; Neopl | 2012 |
Untuning the tumor metabolic machine: Targeting cancer metabolism: a bedside lesson.
Topics: Adenylate Kinase; Antineoplastic Agents; Diabetes Mellitus; Humans; Metformin; Neoplasms; Oxidative | 2012 |
Illuminating the diabetes-cancer link.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blood Glucose; Breast Neoplasms; Clinical Trials as Topic | 2012 |
A report of the James Watson lecture at Yale University.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Cell Proliferation; Congresses as Topic; Connecticut; | 2012 |
Initial metformin or sulphonylurea exposure and cancer occurrence among patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Breast Neoplasms; Cohort Studies; Colorectal Neoplasms; | 2013 |
Metformin--an adjunct antineoplastic therapy--divergently modulates tumor metabolism and proliferation, interfering with early response prediction by 18F-FDG PET imaging.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tum | 2013 |
Metformin and mortality.
Topics: Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Male; Metformin; Neoplasms | 2013 |
Metformin and mortality. Reply to Lund SS [letter].
Topics: Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Male; Metformin; Neoplasms | 2013 |
Metformin and reduced risk of cancer in diabetic patients.
Topics: Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Me | 2005 |
Metformin and reduced risk of cancer in diabetic patients.
Topics: Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Me | 2005 |
Metformin and reduced risk of cancer in diabetic patients.
Topics: Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Me | 2005 |
Metformin and reduced risk of cancer in diabetic patients.
Topics: Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Me | 2005 |
Metformin and reduced risk of cancer in diabetic patients.
Topics: Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Me | 2005 |
Metformin and reduced risk of cancer in diabetic patients.
Topics: Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Me | 2005 |
Metformin and reduced risk of cancer in diabetic patients.
Topics: Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Me | 2005 |
Metformin and reduced risk of cancer in diabetic patients.
Topics: Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Me | 2005 |
Metformin and reduced risk of cancer in diabetic patients.
Topics: Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Me | 2005 |
Metformin and reduced risk of cancer in diabetic patients.
Topics: Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Me | 2005 |
Metformin and reduced risk of cancer in diabetic patients.
Topics: Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Me | 2005 |
Metformin and reduced risk of cancer in diabetic patients.
Topics: Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Me | 2005 |
Metformin and reduced risk of cancer in diabetic patients.
Topics: Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Me | 2005 |
Metformin and reduced risk of cancer in diabetic patients.
Topics: Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Me | 2005 |
Metformin and reduced risk of cancer in diabetic patients.
Topics: Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Me | 2005 |
Metformin and reduced risk of cancer in diabetic patients.
Topics: Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Me | 2005 |
Cancer protection.
Topics: AMP-Activated Protein Kinase Kinases; Diabetes Mellitus, Type 2; Enzyme Activation; Humans; Hypoglyc | 2005 |
Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin.
Topics: Aged; Cohort Studies; Comorbidity; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Fol | 2006 |
[From cancer to diabetes treatment : the tumor suppressor LKB1 as a new pharmacological target].
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Animals; Cyclic AMP Response El | 2006 |
Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth.
Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Fibroblasts | 2007 |
A central role for neuronal adenosine 5'-monophosphate-activated protein kinase in cancer-induced anorexia.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Anorexia; Deoxyglucose; Drug Adm | 2007 |